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ABSTRACT
Pulmonary fibrosis is characterised by excessive deposition of extracellular matrix 
proteins within the lung parenchyma. Activation of the coagulation cascade occurs in 
this condition and thrombin levels are increased in bronchoalveolar lavage fluid 
(BALF) from patients with this disorder. In addition to its role in blood coagulation, 
thrombin exerts cellular effects, including promoting fibroblast proliferation, 
procollagen production and expression of connective tissue growth factor (CTGF) via 
activation of protease activated receptor-1 (PAR-1). This thesis examined the 
hypothesis that thrombin plays a role in promoting lung collagen accumulation in 
pulmonary fibrosis, via activation of PAR-1. To address this hypothesis, the effect of 
a direct thrombin inhibitor, UK-156406 on bleomycin-induced pulmonary fibrosis 
was examined in rats. In addition, the effect of bleomycin-induced pulmonary fibrosis 
in PAR-1 knockout (PAR-1 7') and wild-type (WT) mice was evaluated. In rats, 
immunohistochemical expression of thrombin and PAR-1 were dramatically increased 
in the lung following bleomycin instillation, compared with saline-treated animals. 
Following bleomycin instillation, lung collagen doubled and was preceded by 
significant elevations in ai(I) procollagen and CTGF mRNA levels. In bleomycin- 
treated animals receiving an anticoagulant dose of UK-156046, lung collagen 
accumulation, oci(I) procollagen and CTGF mRNA levels were all significantly 
reduced. In WT mice given bleomycin, total lung collagen was increased but in 
bleomycin-instilled PAR-1 _/' mice, lung collagen accumulation was significantly 
reduced biochemically and histologically. Furthermore, BALF total inflammatory cell 
number, total protein and CTGF mRNA levels were also significantly reduced in 
bleomycin-instilled PAR-1 "A mice compared with WT mice receiving bleomycin. In 
summary, this thesis shows that direct thrombin inhibition attenuates lung collagen
accumulation in bleomycin-induced pulmonary fibrosis and also that PAR-17' mice 
are protected from bleomycin-induced lung injury. These data support the hypothesis 
that thrombin and PAR-1 play a critical role in experimental pulmonary fibrosis and 
that the pro-fibrotic effects of thrombin in this model, may be mediated, at least in 
part, via a CTGF-dependent mechanism.
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Chapter 1
Introduction
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1.1 Pulmonary Fibrosis
Pulmonary fibrosis is a debilitating condition, which is classically 
characterised by chronic inflammation and the excessive deposition of extracellular 
matrix proteins within the pulmonary interstitium. The pulmonary interstitium is 
defined as the alveolar walls (including epithelial cells and capillaries), septae and the 
perivascular, perilymphatic and peribronchilar connective tissues. Pulmonary fibrosis 
is a progressive disorder that leads to terminal loss of lung function and severe 
respiratory insufficiency. Current therapeutic strategies for this condition remain 
disappointingly inadequate.
The interstitial lung diseases (ILD’s) are a heterogeneous group of over two 
hundred disorders, which are complicated by pulmonary fibrosis. There are a number 
of known aetiologies for ILD’s, which are diverse, including physical (e.g. radiation), 
drug-related (e.g. bleomycin) and infective causes (e.g. tuberculosis) (see Table 1.1). 
However, a great proportion of the disease burden remains of unknown aetiology and 
there has been much controversy over the subsequent classification of these 
conditions.
Until recently, when the aetiology of an interstitial lung disease was unknown, 
patients were diagnosed as having cryptogenic fibrosing alveolitis (CFA), or 
idiopathic pulmonary fibrosis (IPF). This is now widely accepted as incorrect and 
these ILD’s are now referred to as the idiopathic interstitial pneumonias (HP’s).
The nomenclature and dogma surrounding the classification of HP’s has been 
extremely confusing for scientist and clinician alike. Since commencing this thesis, an 
expert committee has reclassified the HP’s in an attempt to make understanding of 
these conditions clearer (American Thoracic Society/European Thoracic Society
28
Consensus Classification, 2002). The forthcoming paragraphs briefly review this new 
classification which is subsequently used throughout this thesis.
Table 1.1: Examples of Aetiological Factors for Interstitial Lung Diseases
Aetiology Conditions
Infective
Circulatory/Haemodynamic
Genetic 
Physical 
Drug-related 
Organic/Inorganic dust inhalation 
Autoimmune
Granulomatous
Metabolic
Neoplastic
Bacteria: Tuberculosis 
Fungi: Histoplasmosis 
Viral: Epstein Barr Virus
Acute Respiratory Distress Syndrome 
(ARDS)
Familial CFA
Radiation
Bleomycin, Amiodarone
Bird Fanciers Lung, Silicosis, Asbestosis
Rheumatoid Arthritis, Systemic 
Sclerosis
Sarcoidosis, Eosinophillic Granuloma 
Uraemia 
Alveolar Cell Carcinoma
Modified from Marshall et al, 1997.
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1.2 The Idiopathic Interstitial Pneumonias
The concept of interstitial pneumonia is not new and has been recognised as a 
chronic progressive lung disease for more than a century. In 1892, it was described by 
Osier as ‘cirrhosis of the lung’, and was characterised by fibrinoid change of the lung 
parenchyma. In 1944, Hamman and Rich described four cases of acute interstitial 
fibrosis in which ‘the alveolar walls were thickened and crowded with fibroblasts’. 
For some time, Hamman-Rich syndrome was used to describe all diffuse idiopathic 
fibrotic lung diseases. By the 1960’s, it was recognised that not all cases were 
idiopathic as collagen vascular diseases and occupational exposure to certain injurious 
agents were shown to cause interstitial pneumonia.
In terms of classification of idiopathic interstitial pneumoniae, in 1969, Liebow 
and Carrington described five separate types, which were re-classified in 1998 by 
Katzenstein and Myers. However, the American Thoracic Society/European Thoracic 
Society has now revised this schema to emphasise the importance of an integrated 
clinical and pathological approach to the diagnosis of idiopathic interstitial pneumonia 
(see Table 1.2). The full description of each separate histological entity will not be 
discussed here (for extensive recent reviews, see Nicholson et al, 2002, Collard and 
King, 2003). However, the major differences in the various idiopathic interstitial 
pneumoniae will now be elaborated upon.
Seven idiopathic interstitial pneumoniae have now been characterised as separate 
disease entities. The most important of these conditions is called idiopathic pulmonary 
fibrosis or cryptogenic fibrosing alveolitis (IPF/CFA). Whereas this diagnosis was 
previously ascribed to all cases of pulmonary fibrosis of unknown aetiology, it is now 
a very specific condition where the histological pattern seen on lung biopsy is termed 
usual interstitial pneumonia (UIP). It is now realised that it is very important to
distinguish this condition from the six other IIP’s since the clinical course of UIP is 
very different. Median survival for EPF/CFA is only 2.9 years following diagnosis, 
which is considerably worse than any of the other IIP’s. In addition, EPF/CFA appears 
to be far more resistant to conventional anti-inflammatory therapies, which are the 
main therapeutic approach available for the treatment of this disease (reviewed in 
NHLBI Workshop, 2002).
Table 1.2: Histologic and Clinical Classification of Idiopathic Interstitial Pneumonias
Histological Pattern Clinicopathological Diagnosis
Usual Interstitial Pneumonia (UIP) Cryptogenic Fibrosing Alveolitis (CFA/ 
Idiopathic Pulmonary Fibrosis (EPF)
Non-specific Interstitial Pneumonia 
(NSIP)
Non-specific Interstitial Pneumonia
Organising Pneumonia (OP) Cryptogenic Organising Pneumonia/ 
Bronchiolitis Obliterans-Organising 
Pneumonia (BOOP)
Diffuse Alveolar Damage (DAD) Acute Interstitial Pneumonia (AEP)
Desquamative Interstitial Pneumonia 
(DIP)
Desquamative Interstitial Pneumonia
Respiratory Bronchiolitis (RB) Respiratory Bronchiolitis-Associated 
Interstitial Lung Disease (RBILD)
Lymphocytic Interstitial Pneumonia 
(LIP)
Lymphocytic Interstitial Pneumonia
Adapted from ATS/ERS Consensus 
Classification o f IIP’s, 2002
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Epidemiological data on pulmonary fibrosis is scant and conflicting but it is 
known that UIP is the most common histological pattern seen in cases of IIP. In the 
most recent large epidemiological study, the prevalence of all interstitial lung disease 
was found to be 80/100,00 of the general population for men and 60/100,00 for 
women. Of these cases, the prevalence of IPF/CFA, was found to be 20/100,000 and 
in particular, affected the older population and men (Coultas et al, 1994). Although 
this study is the most widely quoted in the literature and perhaps provides the most 
robust data on this topic, it is unclear if all the patients labeled as IPF/CFA in this 
study had genuine UIP since very few had open surgical biopsy. Despite this 
limitation, what was clear from this study was that the prevalence and incidence of 
pulmonary fibrosis were five to ten times higher than any previous published figures.
In the United Kingdom, it is thought that over 3000 people die each year from 
pulmonary fibrosis alone, and 1000 of these deaths are thought to be from IPF/CFA 
(Hubbard et al, 1996). This figure also appears to be rapidly rising suggesting that the 
incidence of the disease may have been previously underestimated.
In summary, pulmonary fibrosis is a devastating condition that represents a very 
significant clinical problem. A better understanding of the pathogenic mechanisms 
underlying disease progression is urgently required in order to develop new therapies 
for the numerous disorders associated with pulmonary fibrosis.
1.3 Pathogenesis of Pulmonary Fibrosis
Although much time has recently been spent on the classification of ILD’s, 
rapid advances have also been made, in elucidating the pathogenesis of pulmonary 
fibrosis. As described above, a wide range of ILD’s, of known and unknown 
aetiology, are complicated by pulmonary fibrosis. However, these disorders have been
found to share a number of biological mechanisms, resulting in similar 
clinicopathological features (McAnulty and Laurent, 1995, Green, 2002) (please see 
Table 1.3).
Table 1.3: Clinico-pathological Features of Pulmonary Fibrosis
Clinical Pathological
Progressive dyspnoea on exertion
Non-productive cough
Abnormal breath sounds on auscultation
Abnormal chest Xray or HRCT scan
Restrictive pattern and reduced capacity of 
the lung for carbon monoxide (DLCO) on 
lung function tests
Fibrosis of the interstitium involving 
collagen, smooth muscle and elastic 
elements
Architectural remodeling of the 
interstitium
Chronic inflammation of the interstitium
Hyperplasia of Type II cells
Hyperplasia of endothelial cells
Many of these observations have been documented for some time, but further 
understanding of the pathogenesis of this condition has been particularly aided by the 
generation of a number of animal models of the disease and rapid advances in in vitro 
cell biological techniques. The commonest animal model used in this context is the 
bleomycin model of pulmonary fibrosis, where experimental lung fibrosis is induced 
by intratracheal (Laurent et al, 1983), intraperitoneal (Adamson et al 1974), 
subcutaneous (Adamson et al, 1974) or intravenous (Adamson et al, 1977) 
administration of this anti-neoplastic agent. The following paragraphs describe this 
animal model in greater detail, paying particular attention to the intratracheal route of 
administration, since this method was used extensively in this thesis.
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1.3.1 The Bleomycin Model of Pulmonary Fibrosis
Following intratracheal instillation of bleomycin, the initial insult damages 
both alveolar epithelial and endothelial cells. Within hours, this is characterised 
histologically by patchy areas of denuded alveolar epithelium, necrosis of alveolar 
capillary endothelium with associated intra-alveolar haemorrhage and peri-vascular 
and peri-bronchiolar oedema. Concurrently, a rapid influx of inflammatory cells and 
plasma proteins into the alveolar wall and air spaces occurs, which reaches a peak 
approximately seven days after initial lung injury. These events are also accompanied 
by the release of a plethora of pro-inflammatory and pro-fibrotic cytokines from 
resident and recruited lung cells. As the acute inflammatory response resolves, a 
fibroproliferative process predominates, in which fibroblasts lay down extracellular 
matrix proteins including collagen. Excessive deposition of matrix components 
continues, such that fourteen days after initial intratracheal insult, total lung collagen 
doubles, manifested histologically by mature areas of fibrosis, which are 
predominantly peri-bronchial and sub-pleural in their distribution (Mutsaers et al, 
1998, reviewed in Hay et al, 1991).
1.3.2 Mechanism of Bleomycin-Induced Pulmonary Toxicity
The precise nature of how bleomycin exerts pulmonary toxicity and leads to 
pulmonary fibrosis is still debated but a number of proposed mechanisms have been 
postulated. The major mechanism by which bleomycin is thought to exert its 
cytotoxic effects following administration is via cleavage of DNA in a process 
dependant on both oxygen and a divalent metal ion. Following intratracheal 
instillation bleomycin binds to the plasma membrane of cells, is endocytosed and 
rapidly penetrates the nucleus. Bleomycin binds a number of metal ions in vivo but
the iron (Fe)-bleomycin complex is thought to be the most important. It has been 
shown that bleomycin simultaneously binds DNA and Fe (II) in the presence of 
molecular oxygen, which leads to the release of reactive oxygen species, including 
highly potent hydroxyl radicals. This initial complex is then reduced to form a ferric 
or ‘activated bleomycin complex’, which releases further reactive oxygen species in 
close proximity to polynucleotide chains of DNA (Hay et al, 1991).
Whereas pyrimidine and imidazole moieties of the bleomycin molecule are 
important for binding Fe and oxygen, studies have revealed that the interaction of the 
positively charged bithiazole moiety at the end of the bleomycin molecule interacts 
with the negatively charged polynucleotide chain of DNA to deliver the ‘activated 
oxygen-Fe-bleomycin complex’ to the DNA. Subsequent DNA damage includes 
deoxyribose modification and the release of free bases without scission and also 
single and double strand scission at the C3’-C4’ bond of the sugar residue. Until 
recently, it was generally assumed that intracellular oxidative stress caused the 
majority of pulmonary toxicity following bleomycin instillation. However, a recent 
study has shown that extracellular oxidative stress may also be important in the 
pathogenesis of this animal model since mice which overexpress the antioxidant 
extracellular superoxide dismutase are protected following bleomycin instillation 
(Bowler et al, 2002).
Another mechanism by which bleomycin is proposed that to mediate lung 
damage other than by DNA degradation, is to initiate decomposition of long chain 
fatty acids present in cell membranes, releasing powerful oxidising agents. Fe (III) 
and Fe (IT)-bleomycin complexes have both been shown to enhance lipid 
peroxidation, which may be particularly important in causing alveolar cell damage. 
Finally, bleomycin has been shown to interact with specific cellular receptors which
may also contribute to the pulmonary toxicity of the molecule although less is known 
about this mechanism of action (Ekimoto et al, 1985, reviewed in Hay et al, 1991).
1.3.3 Hypotheses for the Pathogenesis of Pulmonary Fibrosis
On the basis of historical clinico-pathological studies and findings concluded 
from in vitro and in vivo experiments, a ‘classical* hypothesis for the pathogenesis of 
pulmonary fibrosis was postulated. This hypothesis proposed that following injury to 
the lung from an identified or unidentified agent, an acute inflammatory response was 
triggered, resulting in an inflammatory infiltrate, together with a number of blood 
borne proteins accumulating in the pulmonary interstitium. It was then proposed that 
soluble mediators within the inflammatory infiltrate and also those released from 
activated inflammatory cells and injured resident lung cells, stimulate key effector 
cells, such as fibroblasts and other collagen producing cells, to migrate, proliferate or 
produce excess collagen. A cycle of chronic inflammation is then initiated, eventually 
leading to established parenchymal fibrosis (please see Diagram 1.1).
Based on the classical hypothesis for the pathogenesis of pulmonary fibrosis, a 
number of anti-inflammatory drugs have been used in clinical trials (reviewed in 
Mason et al, 1999, NHLBI Workshop, 2002). However, the lack of efficacy of agents 
used to date, particularly in cases of IPF/CFA with biopsy-proven UIP, has led to the 
evolution of further novel hypotheses for the pathogenesis of this condition. Although 
the lion’s share of attention in this area has focused on IPF/CFA, it is likely that 
newer concepts regarding disease pathogenesis will also be directly relevant to the 
other HP’s and pulmonary fibrosis in general. The next section reviews some of these 
alternative hypotheses.
The most controversial concept of recent years, which remains unresolved, is 
the role of inflammation in the pathogenesis of IPF/CFA. Whereas it has been 
proposed that chronic inflammation is central to IPF/CFA, more recently, this 
hypothesis has been challenged (for recent reviews, see Pardo and Selman 2002, 
Gauldie 2002, Green, 2002). Part of the reason for this scepticism stems from studies 
which have looked at the histopathological features of IPF/CFA in great detail. It is 
now recognised that the histopathological features of UIP are distinct from other 
HP’s, the key difference being the temporal heterogeneity of the histologic changes. 
In the same lung biopsy specimen of UIP, areas of interstitial collagen formation are 
interspersed with end-stage honeycomb lung and early active areas of fibroblast 
proliferation, called fibroblastic foci. In UIP, fibroblastic foci are situated within the 
interstitial space, directly beneath the alveolar epithelium. It has therefore been 
proposed that fibroblastic foci represent the ‘leading edge’ of the progressive fibrotic 
process. In contrast, histologic features in other HP’s, are more homogeneous with 
relative paucity of fibroblastic foci.
These observations have led to the generation of a novel hypothesis for the 
pathogenesis of IPF/CFA (reviewed in Pardo and Selman, 2002). It is proposed that 
following initial lung injury, alveolar epithelial cells are activated and induce an 
aberrant wound healing response. Activated epithelial cells then interact with 
fibroblasts causing them to proliferate, migrate and differentiate into myofibroblasts, 
within fibroblastic foci. Within these areas, myofibroblast apoptosis is reduced 
causing increased release of, and responsiveness to, archetypal fibrogenic cytokines 
such as transforming growth factor beta (TGF/3), platelet-derived growth factor 
(PDGF) and endothelin-1 (ET-1). Furthermore, myofibroblasts induce epithelial cell 
apoptosis, such that there is inappropriate re-epithelisation, basement membrane
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disruption and impaired remodelling of the extracellular matrix. Fibrogenic growth 
factors are sequestered within the remodeled matrix and angiogenesis is affected in 
these areas. Finally, it is thought that this pattern of events is an ongoing process in 
UIP, such that fibroblastic foci represent microenvironments of alveolar-epithelial 
injury and fibroblast activation, which coalesce, ultimately resulting in excessive 
deposition of extracellular matrix and destruction of alveolar-capillary units, the 
hallmark features of established pulmonary fibrosis (please see Diagram 1.2).
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Further evidence supporting the hypothesis that fibrogenesis in IPF/CFA may occur 
independently of inflammation has been provided by studies using an adenoviral 
vector system to express and deliver individual cytokine and growth factor genes to 
the lung epithelium, in experimental animals. The most compelling study to date 
using this approach showed that when an adenovirus encoding active TGF/3 was over­
expressed in the lung, fibrosis and remodeling occurred without apparent 
inflammation (Sime et al, 1997).
Although this novel mechanism for the pathogenesis of IPF/CFA is highly 
plausible, some of the studies that have led to the generation of this hypothesis could 
be interpreted differently. Firstly, the histopathological studies of UIP which advocate 
the fibroblastic foci to be so important, ignore the fact that these studies only provide 
a ‘snapshot’ of the disease process and may not reflect the natural history of the 
disease. Secondly, it could be argued that the adenoviral vector studies performed in 
animal models described above, which claim that fibrogenesis is independent of 
inflammation, are invalid, as the cytokines and growth factors used were 
overexpressed at super-physiologic concentrations (Strieter, 2002).
In addition, experimental evidence continues to emerge which still advocates 
inflammation as a key mechanism in the progression of IPF/CFA. A prospective study 
on the histopathologic variability of surgical lung biopsies in patients with IIP 
(Flaherty et al, 2001) demonstrated that chronic inflammation and established fibrosis 
often co-existed in the same lung biopsy specimen. This raised the notion that the 
natural history of UIP may actually begin as predominantly inflammatory non­
specific interstitial pneumonia (NSIP), and progress to relatively fibrogenic UIP.
Other studies have also shown that the lungs of patients with IPF/CFA exhibit 
a Th-2-immune pattern inflammatory response, characterised by the presence of
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eosinophils, mast cells and cytokines such as IL-4 and IL-13 (Martinez et al, 1997, 
Hancock et al 1998). In addition, studies in animal models have revealed that a 
predominantly Th-1 phenotype appears protective in this condition (Wallace et al, 
1995, Kunkel et al, 1996). Interestingly, following the most promising clinical trial in 
IPF/CFA to date, of the immunomodulating agent interferon gamma (IFN-7 ), one of 
the mechanisms proposed to explain the improved clinical parameters, was the 
conversion of the immune response from a Th-2 to a Th-1 pattern (Ziesche et al, 
1999).
Another interpretation of the current literature, which may be the most 
accurate, is that the chronic process of fibrosis is distinct from the acute process of 
inflammation, but inflammation is necessary, but not sufficient to explain the 
pathophysiology of IPF/UIP (Sheppard, 2001). Evidence supporting this theory was 
provided from studies by Kolb and colleagues, where the inflammatory cytokine IL- 
10 was over-expressed by the adenoviral delivery system described above. In this 
study, following delivery of IL-10, fibrosis occurred subsequently to an acute 
inflammatory response (Kolb et al, 2001). One interpretation of this result is that IL- 
1 0  may reprogram lung cells to continuously produce pro-fibrotic cytokines, such as 
TGF0. In addition, IL-10 may have exerted potent effects on acute inflammation, 
therefore inducing defective cross-talk between mesenchymal cells, epithelial cells 
and components of the extracellular matrix. This loss of cellular communication may 
have lead to an abnormal pattern of wound healing, with enhanced collagen 
deposition and the development of progressive fibrosis.
Other ‘background’ factors have also been proposed to play an important role 
in the pathogenesis of pulmonary fibrosis, in particular genetic influences and 
environmental agents (reviewed in Gross and Hunninghake, 2001). Genetic influences
may play an important role in this condition since up to 3% of cases of CFA appear to 
cluster in families (reviewed in Marshall et al, 1997). Furthermore, a number of recent 
studies have identified polymorphisms in fibrogenic candidate genes, thought to be 
important in this disease. In particular, it has been shown that individuals appear to 
have an increased risk of IPF/CFA with polymorphisms in the interleukin-1 receptor 
antagonist and tumour necrosis factor-a genes (Whyte et al, 2000). Another study, 
showed that IPF/CFA was associated with inherited abnormalities in surfactant 
proteins (Amin et al, 2001). Furthermore, cases of IPF/CFA and NSIP have been 
found in a single family that were associated with surfactant protein C gene (Thomas 
et al, 2002). The cases of NSIP predominated in the younger family members, which 
again raised the question of whether NSIP may be a precursor to UIP. Finally, 
environmental agents such as dust exposure, smoking (Schwartz et al, 1991) and 
latent viral infections (Egan et al, 1996) have also been linked to the progression of 
this condition.
It is clear that many questions remained unanswered regarding the exact 
pattern of pathogenic events occurring in the fibrotic lung disease. Numerous different 
biological mechanisms contribute to the disease and a complex interplay exists 
between these processes. However, the final end point of these events is the 
deposition of collagen and other extracellular matrix proteins in the pulmonary 
interstitium. The following section elaborates on the distribution and metabolism of 
collagen in the normal and fibrotic lung.
1.4 Collagen Distribution and Metabolism in the Normal and Fibrotic Lung
1.4.1 Collagens in the Lung
The collagens are a family of at least 26 closely related extracellular matrix 
proteins, which are the products of 40 individual collagen genes (reviewed in Pace et 
al, 2003). To date, 11 different collagen subtypes are known to be present in the lung. 
Collagens consist of three polypeptide a-chains of similar or different amino acid 
composition and collagen subtypes exist as homotrimers (e.g.) collagen HI or 
heterotrimers (e.g.) collagen I and VI. The three a-chains are held together by 
interchain hydrogen bonding to form one or more right-handed triple helical domains. 
Individual a-chains contain a large proportion of glycine residues and have regions 
with the generalized structure Gly-X-Y, where approximately one third of the X 
positions are occupied by proline and one third of the Y positions are occupied by 
hydroxyproline (Miller et al, 1995). This particular structure is necessary for stable 
helix formation, posttranslational modifications, fibril formation and cross linking.
In the adult human lung, both fibril and non-fibril forming collagens are 
abundant. The primary role of fibril-forming collagens is to provide the lung with 
tensile strength and approximately 90% of lung collagen is comprised of the 
interstitial fibrillar collagen Types I and III in a ratio of 2:1 (Kirk et al, 1984). Types I 
and III collagens are co-distributed in the interstitium, large bronchi and blood vessels 
and it is thought that fibroblasts are the major producer of these collagens. However, 
they can also be synthesised by other cell types, such as endothelial cells, epithelial 
cells, alveolar type II cells and smooth muscle cells. The commonest non-fibril 
forming collagen in the lung is Type IV collagen, which constitutes the major 
component of the alveolar and capillary basement membranes (Paulsson, 1992). Other 
important collagen subtypes that are also present in the adult lung, but in smaller
amounts include, Type V (a fibrillar collagen found in basement membranes and the 
interstitium), Type VI (a non-fibrillar collagen which forms fine filaments associated 
with Type I and III collagens), Type II (a fibrillar collagen exclusive to cartilage and 
distributed in large airways) and Type IX and XI collagens, which are co-distributed 
with Type II collagen in the trachea and large bronchi (reviewed in Chambers and 
Laurent, 1997).
1.4.2 Collagen Deposition in the Normal and Fibrotic Lung
In the normal lung, collagens exist in a dynamic equilibrium involving a 
balance between synthesis and degradation. Studies have revealed that in the lungs of 
young adult mammals, an amount of collagen equivalent to one tenth of the total 
collagen content, is synthesised and degraded each day (McAnulty and Laurent, 
1987). Although the relative rates may decline with age, collagens continue to be 
synthesised and degraded throughout adult life. It is therefore proposed that these 
processes could be altered in pulmonary fibrosis leading to increased deposition of 
collagen in the lung (McAnulty and Laurent, 1987).
Whereas in the normal lung, the alveolar wall is thin and contains small 
amounts of collagen, in pulmonary fibrosis it is thickened, and collagen is deposited 
in a progressive and disorganised fashion. Eventually, the alveolar structure is 
replaced by dense fibrotic tissue leading to a reduction in gas transfer and progressive 
hypoxia. In early fibrosis, there is an increased ratio of type III to type I collagen, 
whereas this pattern is reversed in established fibrosis (Kirk et al, 1984, Bateman et 
al, 1981). However, it is thought that the increase in total collagen mass is more 
important in the pathogenesis of this disease than the ratio of collagen types per se 
(Chambers and Laurent, 1997). There is also indirect evidence that collagen synthesis
rates are altered in humans. In situ hybridisation experiments showed that Type I 
collagen gene expression is increased in the fibrotic lung (Broekelmann et al, 1991). 
In addition, procollagen peptides, which are cleaved extracellularly from fibrillar 
collagens by procollagen proteases (procollagen N- and C- proteinase), are elevated in 
the serum and bronchoalveolar lavage fluid (BALF) from patients with pulmonary 
fibrosis (Harrison et al, 1990). Procollagen peptides are also elevated in serum and 
BALF from patients with ALI/ARDS (Acute Lung Injury/Adult Respiratory Distress 
Syndrome), (Clark et al, 1995), a condition in which rapid fibroproliferation and 
matrix synthesis can lead to the development of extensive fibrotic lesions (reviewed in 
Marshall et al, 1998).
A number of animal models of pulmonary fibrosis have also provided direct 
evidence that collagen synthesis rates are altered. For example, following 
administration of intratracheal bleomycin, lung collagen synthesis rates are increased 
(Laurent et al, 1983) and this observation also correlates with increased expression of 
the COL1A1, COL1A2 and COL3A1 genes, encoding the a l and 02 chains of type I 
collagen and the a l chains of type III collagen respectively, when examined by 
Northern analysis and in situ hybridization (Zhang et al, 1994, Shahzeidi et al 1993).
1.4.3 Regulation of Collagen Synthesis and Degradation in the Fibrotic Lung
In pulmonary fibrosis, in addition to collagen, a number of extracellular 
components such as elastin, fibronectin, laminin and nidogen are upregulated. 
However, regulation of the basic mechanisms that alter the synthetic and degradative 
processes responsible for increased deposition of collagen by fibroblasts, are the most 
important determinants of disease progression in the fibrotic lung. These processes 
include chemotactic attraction to increase the number of fibroblasts at the site of lung
injury (migration), local mitogenesis of fibroblasts (proliferation) and selection of 
subpopulations of fibroblasts with a specific phenotype favouring fibrogenesis 
(differentiation). In addition, there are a number of ways by which the amount of 
collagen synthesised and degraded per cell can be altered (extracellular matrix 
synthesis) (reviewed in Chambers and Laurent 1997). Although a detailed account of 
collagen metabolism is not provided here, briefly, collagen synthesis by fibroblasts 
can be regulated at the transcriptional, translational and post-translational level. 
Collagen degradation can be modulated in two major ways, first by altering the 
amount of procollagen secreted from the cell by intracellular degradation and second 
by affecting the amount of collagen deposited in the extracellular matrix by 
collagenolysis.
The consequences of increased lung collagen synthesis in humans and animal 
models have been described above but less is known about the importance of collagen 
degradation in the pathogenesis of pulmonary fibrosis. There is some evidence in 
animal models that collagen secretion in the lung is potentiated by decreasing the 
proportion of procollagen degraded intracellularly (Laurent and McAnulty 1983). 
Studies examining whether extracellular collagenolysis is affected in pulmonary 
fibrosis have been conflicting since increased levels of collagenase have been 
reported in BALF of patients with CFA (Gadek et al, 1979), whereas other studies 
have suggested that the increase in collagen content in CFA was related to a decrease 
in collagenolytic activity (Selman et al, 1986).
More recently, the role of extracellular collagenolysis in pulmonary fibrosis 
has been aided by an increased understanding of the expression of matrix 
metalloproteinases (MMPs) and their endogenous inhibitors, the tissue inhibitors of 
metalloproteinases (TIMPs), in the lung. MMP’s are capable of degrading
extracellular matrix components, and the expression of the collagenase subfamily 
(MMP-1, 9 and 13), the gelatinase subfamily (MMP’s 2 and 9) and all four members 
of the TIMPs, have been evaluated in patients with IPF/CFA (Selman et al, 2000). 
This study showed that TIMPs were more widely distributed than MMPs in the 
fibrotic lung. Furthermore MMP-2 and 9 expression by subepithelial myofibroblasts 
was increased in the area of denuded alveolar basement membranes in the fibrotic 
lung, suggesting that they might play a role in basement membrane disruption, aiding 
fibroblast invasion into the alveolar spaces. Overall, this study suggests that there is a 
prevailing non-degradative microenvironment in the lungs of patients with IPF/CFA.
1.5 Mediators of Pulmonary Fibrosis
The preceding paragraphs have described the diverse role of the fibroblast and 
other matrix producing cells in synthetic and degradative processes occurring in the 
fibrotic lung. The function of the fibroblast in these various processes is known to be 
affected by a host of stimulatory and inhibitory soluble polypeptide growth factors 
and cytokines, that may act via autocrine and paracrine mechanisms (reviewed in 
Coker et al, 1995, also see Table 1.4). Many of these mediators are released 
following fibroblast activation but studies have also shown that other cells such as 
recruited inflammatory cells, endothelial cells, smooth muscle cells and platelets also 
secrete and respond to pro-fibrotic growth factors in the fibrotic lung (for a review see 
Allen et al, 2002). In addition, it is increasingly recognised that mediators released 
from activated alveolar epithelial cells may play a particularly important role in 
IPF/CFA as elaborated upon in Introduction Section 1.3.
A classic example of a pro-fibrotic mediator is TGFp, the most potent 
stimulator of collagen production characterised to date. TGFp mRNA and protein
levels are increased in patients with pulmonary fibrosis (Broekelmann et al, 1991, 
Khalil et al, 1989) and in animal models of this disease (Hoyt et al, 1988, 1989). 
TGFp maximises the amount of collagen produced in the lung by acting at different 
points in the pathway of collagen synthesis and degradation. TGFp stimulates 
procollagen gene transcription (Raghow et al, 1987, Ignotz et al, 1987), increases 
mRNA stability (Raghow et al, 1987), decreases intracellular degradation of 
procollagen (McAnulty et al, 1991) and decreases extracellular degradation of 
collagen by inhibiting MMP production and promoting TIMP production (Edwards et 
al, 1987, Overall et al, 1989). Futhermore, TGFp has also been shown to induce the 
transformation of fibroblasts into a-actin-expressing contractile myofibroblasts, the 
major fibroblast phenotype in the fibrotic lung (Serini et al, 1999).
Other pro-fibrotic growth factors and cytokines implicated in pulmonary 
fibrosis include platelet-derived growth factor (PDGF), connective tissue growth 
factor (CTGF), insulin-like growth factor-1 (IGF-1) and endothelin-1 (ET-1). A 
relative paucity of inhibitory mediators, such as prostaglandin E2 , have also been 
shown to be important in the pathogenesis of this condition (reviewed in McAnulty 
and Laurent, 1995). However, more recently, compelling evidence has arisen 
suggesting that activation of the coagulation cascade with the resultant generation of 
coagulation proteases, in particular, the serine protease thrombin, may also play an 
important role in this condition.
This thesis will specifically focus on the role of thrombin in the pathogenesis 
of pulmonary fibrosis and the next section(s) will describe the function of thrombin in 
pathophysiology in greater detail.
Table 1.4: Major Mediators of Fibroblast Proliferation and Procollagen Synthesis
Mediator Effect on Fibroblast 
Proliferation
Effect on Collagen 
Production
Reference
TGFP + + Varga and Jimenez, 1985 
Raghow et al, 1987
IL-1 + +/- Postlethwaite et al, 1984, 
1988; Singh et al, 1988
IL-4 + + Wallace et al, 1995 
G illeryefa/, 1992
TNF-a + - Vilcek et al, 1986, 
Mauviel et al, 1991
IGF-1 + + Phillips et al, 1987, 
Goldstein et al, 1989
PDGF + + O liv e r s  al, 1989, 
Butt e ta l  1995
IFN-y +/- - Hunninghake et al, 1986, 
Elias et al, 1990, 
Rosenbloom eta l ,  1984
p g e 2 - - Oliver et al, 1989, 
Saltzman et al, 1982
Factor Xa + n/k Blanc-Brude et al, 2001
Endothelin-1 + + Cambrey et al, 1994 
Peacock etal,  1996
CTGF + + Frazier etal,  1996
Thrombin + + Gray et al, 1990 
Chambers etal,  1998
+ — stimulatory
=  inhibitory 
n/k = not known
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1.6 The Coagulation Cascade
1.6.1 The Role of The Coagulation Cascade in Haemostasis
The coagulation cascade is a complex and highly regulated proteolytic system, 
whose prime function is to generate insoluble, cross-linked fibrin strands which bind 
and stabilise the weak platelet haemostatic plug, formed at sites of vascular injury. 
The formation of this provisional clot, which comprises aggregated platelets 
enmeshed by fibrin, is critically dependent on the action of the major effector of the 
coagulation cascade, thrombin, and is generated following the stepwise activation of 
coagulation proteases via two pathways, called the extrinsic and intrinsic systems 
(see Diagram 1.3 below). The generation of fibrin at the end of these pathways is 
localised to the area where the original platelet plug was formed and this is achieved 
in two ways. First, the chain of reactions that lead to fibrin production are 
programmed and occur most efficiently when restricted to a surface, such as platelet 
phospholipid. Second, a series of endogenous inhibitors restrict these reactions to the 
site of initial injury (see Section 1.6.2). The following paragraphs describe this 
process in more detail (reviewed in Ruf and Riewald 2003, Walker and Royston, 
2002, Brummel et al, 2002, Carmeliet, 2001 and specific references also added in 
text).
The coagulation proteases of the intrinsic and extrinsic pathways circulate in 
the plasma as inactive zymogens and are also referred to as coagulation factors. The 
majority of zymogens are activated by limited proteolysis and it was previously 
thought this only occurred in a stepwise fashion, such that upstream coagulation 
proteases activated subsequent downstream zymogens. However, it is now realised 
that multiple amplifying feedback loops exist in the coagulation cascade and active 
proteases from each separate pathway influence one another directly.
The extrinsic (or tissue factor) pathway is the principle trigger mechanism for 
intravascular blood coagulation in vivo. Tissue factor (TF) is a glycoprotein receptor, 
not observed free in the circulation that is normally only expressed at sites physically 
separated from circulating blood. Examples of cells that express tissue factor include, 
smooth muscle cells of the sub-endothelium of blood vessels, activated endothelial 
cells that line blood vessels and cells of epithelial surfaces. At sites of vascular 
endothelial damage, extravascular exposed/expressed TF comes into contact with 
factor VII. TF allosterically activates and converts factor VII to factor Vila. The 
resulting TF-factor Vila complex, in association with cell surface phospholipids and 
calcium ions, bind factor X via multiple interactions to form the vitamin-K dependent 
extrinsic tenase complex (TF-factor Vlla-factor X). Calcium ions in the complex 
serve as a buffer to ensure that the negatively-charged coagulation proteases can 
successfully interact with the similarly negatively-charged phospholipid membrane. 
At this point, the extrinsic pathway converges with the intrinsic pathway and the 
extrinsic tenase complex activates a limited amount of Factor IX, which contributes to 
the intrinsic tenase complex (see below). In addition, within the extrinsic tenase 
complex, factor X is converted to factor Xa, generating a transient ternary complex 
(TF-factor Vlla-factor Xa). A small amount of Factor Xa released from the TF-factor- 
Vlla-factor Xa complex activates prothrombin, leading to the initiation stage of 
thrombin generation. The subnanomolar amounts of thrombin generated begin the 
processes of platelet activation, fibrinogen cleavage and activation of Factor V, Factor 
VIII and Factor XIII which cross-links the provisional fibrin clot, entrapping platelets, 
resulting in the formation of a stable haemostatic plug.
The propagation phase of thrombin generation is a function of the intrinsic 
pathway, which is triggered when blood comes into contact with negatively-charged
extravascular components of sub-endothelial connective tissue, such as collagen. This 
pathway begins with the sequential activation of Factor XII, Factor XI and Factor IX 
and it is thought that the initial activation step is mediated via the autoactivation of 
factor XII on negatively-charged surfaces (Rojkaer and Schousboe, 1997). Factor 
Xlla converts factor XI into factor XIa and also the kallikrein-kinin system on 
endothelial cells (Wiggins et al, 1977). Factor XIa then activates IX into IXa which 
together with Factor Villa, phospholipids and calcium ions form the intrinsic tenase 
complex (Lenting et al, 1996) which activates Factor X at the point of pathway 
convergence, termed the common pathway. Factor Xa triggers the common pathway 
by binding to a cell surface receptor with high affinity called effector protease 
receptor-1 (EPR-1) on the surface of platelets (Bouchard et al, 1997). This interaction 
can also occur on other cells such as monocytes (Altieri and Edgington, 1989), 
endothelial cells (Bono et al, 1997), fibroblasts (Kumar et al, 1995) and smooth 
muscle cells (Nicholson et al, 1996). Factor Xa bound to EPR-1 in association with 
factor Va, phospholipids and calcium form the prothrombinase complex which 
vigorously converts prothrombin to thrombin.
In summary, the role of the extrinsic pathway is to initiate the coagulation 
cascade immediately after vascular injury and generate trace amounts of thrombin and 
factor Xa. These factors then feed back into the intrinsic cascade, via factors XI and 
IX, to induce the kinetically-efficient intrinsic tenase complex to generate increased 
amounts of factor Xa. This leads to prolonged generation of the components of the 
prothrombinase complex, and a major burst in thrombin activity, thereby sustaining 
blood coagulation via dramatic amplification of the original signal (reviewed in 
Brummel et al, 2002, and see Diagram 1.3).
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Diagram 1.3: The Coagulation Cascade
1.6.2 Regulation of Coagulation Cascade Activity
The coagulation cascade and subsequent production of fibrin is tightly 
regulated by a number of endogenous initiators and inhibitors. The major protease 
inhibitor responsible for the early shut-down of the extrinsic pathway is tissue factor 
pathway inhibitor (TFPI). TFPI is synthesised and released from the endothelium and 
contains three Kunitz-type serine protease domains (Kl, K2 and K3). TFPI acts by 
targeting the TF-factor-VTIa-factor Xa transient ternary complex. The K2 domain 
forms an inactive binary complex by binding reversibly to factor Xa. Subsequently, 
the K l domain of the resultant TFPI/Factor Xa complex combines with TF-factor 
Vila to form a quaternary complex, which promotes the scavenging of factors IXa and 
Xa, and dampens tissue factor-mediated procoagulant activity (Broze, 1995, 
Hamamoto et al, 1993). Individuals with TFPI deficiency have not been identified and 
mice homozygous for the deletion of Kl in the TFPI gene die in utero, implying that 
such a deficiency is not compatible with life (reviewed in Walker and Royston, 2002).
The main physiological inhibitor of the intrinsic pathway is antithrombin El 
(AT-III). AT-III is a single-chain glycoprotein that is synthesised in the liver and is 
not vitamin K-dependent. It acts by irreversibly neutralising thrombin and factors 
Xlla, XIa, IXa and Xa, in the presence of heparin. In addition to its role in 
coagulation, AT-III has anti-inflammatory properties. Some of these may be due to 
inhibiting the pro-inflammatory effects of thrombin and factor Xa, mechanisms of 
which will be elaborated in Section 1.9. However, more recently AT-III has also been 
found to exert coagulation- independent anti-inflammatory effects. AT-EI binds a 
cellular receptor, syndecan-4 which interferes with intracellular signals induced by 
inflammatory mediators such as lipopolysaccharide (Roemisch et al, 2002).
Other inhibitors of the coagulation cascade include, heparin co-factor 1, 
protease nexin-1, ai-antitrypsin which are all serine protease inhibitors (serpins), and 
a 2-macroglobulin. These molecules inhibit the proteases of the coagulation cascade 
with varying degrees of specificity although all inhibit thrombin.
Finally, the coagulation cascade can be modulated when thrombin, at low 
concentrations, binds to an endothelial cell surface receptor, called thrombomodulin. 
The conformation of the resultant stoichiometric complex exposes the active site of 
thrombin in such a fashion, that the protease is converted from a pro- into an anti­
coagulant factor. Once thrombin is bound by thrombomodulin, rather then cleave 
fibrinogen, the complex converts inactive zymogen protein C to activated protein C 
(APC) (reviewed in Walker and Royston, 2002). This reaction is highly dependent on 
zymogen protein C binding to the endothelial protein C receptor (EPCR) (Taylor et al, 
2001). APC then complexes with its cofactor, protein S on the surface of endothelial 
cells or platelets to catalyse the proteolytic cleavage of factors Va and Villa, causing 
their inactivation (Esmon et al, 1989). Loss of factor Va and Villa prevents further 
thrombin generation by preventing the appropriate participation of these proteases in 
the prothrombinase and intrinsic tenase complexes respectively, such that the 
extrinsic pathway trigger mechanism for coagulation and positive feedback 
mechanisms in the intrinsic pathway are blocked.
1.6.3 Evidence for the Role of The Coagulation Cascade in Pulmonary Fibrosis
There have been rapid advances in understanding the pathogenesis of 
pulmonary fibrosis and a number of studies have been performed which support an 
pivotal role for activation of the coagulation cascade in this condition. Extravascular 
intra-alveolar accumulation of fibrin has been described for patients with pulmonary
fibrosis (Chapman et al, 1986, Ikeda et al, 1989, Kotani et al, 1995), organising 
pneumonia, (one of idiopathic interstitial pneumoniae) (Peyrol et al, 1990), acute lung 
injury (ALI) and the acute respiratory distress syndrome (ARDS) (Bachofen et al, 
1982, Idell et al, 1987). Studies proposing that thrombin may play an important role 
in fibrotic lung disease have revealed that levels of the protease are increased in 
BALF obtained from patients with pulmonary fibrosis associated with systemic 
sclerosis (Hemadez-Rodriguez et al, 1995, Ohba et al, 1994). Furthermore, thrombin 
levels in BALF are elevated following experimental radiation-pneumonitis (Huang et 
al, 2001) and bleomycin-induced lung injury in rats (Tani et al, 1991).
Excessive procoagulant activity in the lung observed in these diseases is 
thought to arise from an imbalance between pro- and anti-coagulant factors. For 
example, BALF from patients with ARDS, has been shown to contain tissue 
factor/factor VH/VIIa complexes (Idell et al, 1987), which can activate factor X, and 
trigger activation of coagulation cascade (for further discussion please refer to 
Section 1.6.1). In addition, increased tissue factor expression on alveolar 
macrophages and type II pneumocytes, in close association with fibrin deposits, has 
been described in the fibrotic lung (Imokawa et al, 1997).
The prevailing balance between the pro- and anti-coagulant state in the lung 
following injury, is also affected by regulatory mechanisms which control the 
clearance of deposited fibrin (fibrinolysis). This process, which occurs at all sites of 
wound healing, is initiated when plasminogen is converted to plasmin by the 
proteases, urokinase-type plasminogen activator (u-PA) or tissue-type plasminogen 
activator (t-PA). Plasmin subsequently cleaves fibrin into a range of fibrin 
degradation products (FDP’s). Fibrinolytic activity in the vasculature is largely under 
the control of t-PA; whereas extravascular fibrinolysis in the lung is controlled by u-
PA. The conversion of plasminogen to plasmin by t-PA and u-PA, is regulated by an 
endogenous inhibitor called plasminogen activator inhibitor-1 (PAI-1) and a number 
of human and animal studies have shown that there is increased expression of PAI-1 
in pulmonary fibrosis, thus favouring fibrin persistence (Kotani et al, 1995, Olman et 
al, 1995). The fibrinolytic system is also influenced by a plasma glycoprotein called 
thrombin-activatable fibrinolysis inhibitor (TAFI). During fibrin degradation, plasmin 
exposes C-terminal lysine residues on the fibrin molecule to potentiate its clearance. 
TAFI cleaves these residues, which therefore favours fibrin persistence and it is 
noteworthy that a recent study has shown that levels of TAFI are increased in BALF 
from patients with interstitial lung disease (Fujimoto et al, 2003) (please see Diagram
1.4).
In terms of a deficiency of anticoagulant factors, levels of AT-III are reduced 
in patients with ARDS (Kirschstein et al, 1985). In addition, it has been shown that 
conversion of zymogen protein C into the anticoagulant APC is reduced in the intra- 
alveolar space of patients with interstitial lung disease and is associated with 
abnormal lung collagen turnover (Yasui et al, 2000). Futhermore, although levels of 
the major endogenous inhibitor of the extrinsic coagulation cascade, TFPI are 
detectable in plasma and BALF from patients with ARDS, they are insufficient to 
block fibrin deposition (Sabharwal et al, 1995), (for further details of the mechanism 
of action of these endogenous anticoagulants, please refer to Section 1.6.2).
A number of reports have examined the effects of modulating the coagulation 
cascade in ALI. For example, exogenous delivery of the highly specific direct thrombin 
inhibitor hirudin or AT-III, have been shown to be protective in animal models of ALI 
(Hoffmann et al, 1990, Schmidt et al, 1996, Uchiba et al, 1997). In addition, heparin, 
which inhibits coagulation proteases by potentiating the formation of AT-HI/serine
protease complexes, but also has anti-inflammatory properties, lead to improved gas 
exchange in an animal model of ALI (Abubakar et al, 1998). Heparin has also been 
shown to attenuate bleomycin-induced pulmonary fibrosis in mice (Piguet et al,
1996), although in this study, it was uncertain whether heparin was delivered at an 
anticoagulant dose and whether the protective effects were due to its direct anti­
proliferative effects, or due to blocking the coagulation cascade.
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1.7 The Structure of Thrombin
Thrombin is a 39 kD ellipsoid molecule whose biological functions are 
dependent on specific structural regions of the protease. It consists of an A- and a B- 
chain, which are covalently linked by four disulphide bridges. Thrombin possesses a 
number of distinct binding sites for various substrates, inhibitors, cofactors and 
sodium ions (Na+). The Na+ site seems to help determine whether thrombin acts as a 
procoagulant and recognises fibrinogen as a substrate (in the presence of Na+ ions) or 
whether it acts as an anticoagulant, by recognising protein C as a substrate, (in the 
absence of Na+ ions). The active site of thrombin or ‘catalytic triad’, comprises Ser- 
195-His57-Aspl02 and is located between the t-barrel domains of the B-chain, within 
a deep cleft. The disulphide-linked A-chain forms an integral structural part of the 
enzyme, but is not involved in catalysis. Thrombin is classically described as ‘trypsin­
like’. However, the active site of thrombin is much narrower and deeper than that of 
trypsin, since the B-chain has a number of insertion loops. These insertion loops block 
the access of many macromolecular substrates and inhibitors to the catalytic residues, 
conferring a much narrower substrate specificity on the molecule (Bode et al, 1989). 
The cleft itself is hydrophobic, exhibiting a preference for apolar amino acids 
preceding arginine at a thrombin susceptible bond. Within the cleft lie the unique 
thrombin anion-binding exosites. As rapid developments in our knowledge of the 
structure-function relationships of thrombin have evolved, it has also been recognised 
that fibrinogen is not thrombin’s only important substrate. Anion binding exosite-1 
(ABE-1), previously referred to as the fibrinogen recognition exosite, is a positively 
charged region to the ‘east’ of the active site (Stubbs and Bode 1993). ABE-1 is 
involved in the binding of fibrinogen, fibrin, the major thrombin receptor - protease 
activated receptor-1, heparin co-factor II, and the highly specific leech-derived
thrombin inhibitor, hirudin. A second positively charged region to the northwest of 
the active site is called ABE-II or the heparin-binding site (Stubbs and Bode, 1993). 
ABE-II is principally involved in the binding of the glycosaminoglycan bound serpins 
antithrombin III, heparin co-factor-II and protease nexin-I. Both exosites have been 
implicated in the binding of coagulation factors V and VIII (Esmon et al, 1996). In 
addition, the B-chain of thrombin also contains the RGD triplet sequence (Arg 187- 
Gly 188- Asp 189), which may play a role in cell adhesion. Finally, residues 54-116 
on one of the insertion loops of the B-chain are thought to represent the chemotactic 
domain, in particular for macrophage-like cells (Bar-Shavit et al, 1984).
1.8 Thrombin Receptors
1.8.1 Overview
After it was first recognised that thrombin was a potent aggregator of platelets 
in the absence of other proteases of the coagulation cascade (Davey and Luscher, 
1967), it became apparent that thrombin could exert cellular effects in addition to its 
critical role in fibrinogen cleavage and clot formation. Thrombin is now known to 
exert a wide range of cellular responses that play important roles in subsequent 
inflammatory and tissue repair processes. These will be discussed further in Section 
1.9. Cellular effects of thrombin are mediated by a unique family of ubiquitously 
expressed cell-surface receptors called protease-activated receptors (PARs). PARs are 
a novel family of seven transmembrane G-protein coupled receptors that exhibit a 
unique mechanism of activation involving the unmasking of a tethered ligand by 
limited proteolysis of specific amino acid sequences from its N-terminus of the 
receptor (Vu et al, 1991). Following proteolytic cleavage of PARs, the newly 
generated tethered ligand binds intramolecularly to the second extracellular loop of
the receptor inducing a conformational shape change, allowing it to interact with 
heterotrimeric G-proteins and initiate downstream signalling responses (please see 
Diagram 1.5). To date, four PARs have been characterised, of which three, (PAR-1, - 
3, and -4), are activated by thrombin. All four PAR genes share a similar structure. 
They are comprised of two exons, exon 1 encoding a signal peptide and exon 2, the 
mature receptor protein (Kahn et al, 1998). The PAR-1, 2 and 3 genes are clustered 
within the same locus on 5ql3, whereas the PAR-4 gene is located on 19pl2 (Xu et 
al, 1998). Synthetic peptides corresponding to the tethered ligands of PAR-1, 2 and 4 
are capable of mimicking a number of cellular responses elicited by their respective 
endogenous ligands. The first PAR to be cloned and characterised was PAR-1 (Vu et 
al, 1991), which has subsequently been shown to be the major receptor involved in 
mediating thrombin's cellular effects, in particular on fibroblast responses (Trejo et al, 
1996, Chambers et al, 1998, Chambers et al, 2000; please see Section 1.9.5). PAR-1 
has a wide tissue distribution and is present on a number of cell types including 
platelets, endothelial cells, epithelial cells, fibroblasts, smooth muscle cells, 
monocytes, lymphocytes, mast cells and certain tumour cell lines (reviewed in Dery et 
al, 1998). Less is known about the distribution of PAR-3 and PAR-4 but their 
expression appears to be lower than that of PAR-1 (Xu et al, 1998). They have both 
been identified on the surface of mouse and human platelets and until recently it was 
thought that their major role was in platelet activation (also see Section 1.9.1). 
However, PAR-3 and PAR-4 have also been identified on human bronchial epithelial 
cells (Asokananthan et al, 2002), and selective PAR-4 agonist peptides induce 
functional responses in leucocytes, endothelial cells and smooth muscle cells 
(Vergnolle et al, 2002), suggesting that these receptors may play a more diverse role 
in pathobiology than previously thought. Finally, thrombin has been reported to
activate certain cells including fibroblasts, via a non-proteolytic mechanism, but the 
exact nature of the receptor involved is currently unknown (Sower et al, 1999).
Since PAR-1 is the major thrombin receptor shown to mediate cellular 
responses of the protease to date, the forthcoming sections describe the physiological 
consequences of PAR-1 activation by thrombin in more detail.
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Diagram 1.5: Activation of Protease Activated Receptors by Thrombin
Following proteolytic cleavage of PARs, the newly generated tethered ligand binds to the second extracellular loop of the receptor 
inducing a conformational shape change in the receptor, allowing it to interact with heterotrimeric G-proteins and initiate 
downstream signalling responses
1.8.2 PAR-1 Signalling Pathways
Following receptor activation by thrombin, PAR-1 couples to several different 
heterotrimeric G proteins, including the a-subunits of Gq, G0, Gi and G12/13 families. 
This causes downstream activation of mitogen activated protein kinase, phospholipase 
C/protein kinase C and nuclear factor-K/3 signalling pathways in number of different 
cell types, including fibroblasts, platelets and endothelial cells (see Dery et al, 1998 
and MacFarlane et al, 2001 for reviews). It is thought that PAR-1 couples to the 
various a-subunits of G proteins via its second cytoplasmic loop (Verrall et al, 1997). 
This pluripotent pattern of signalling is in keeping with the broad range of cellular 
effects exerted by thrombin.
A major thrombin signalling mechanism following PAR-1 activation is 
through Gc ,^ proteins (please see Diagram 1.6). This signalling pathway is thought to 
be particularly important in certain fibroblast lines, endothelial cells and platelets and 
is typified by studies performed in CCL-39 fibroblasts (Hung et al, 1992). In these 
experiments where blocking antibodies to Gc^, were used, which confirmed that 
coupling of PAR-1 to Gc^ results in the activation of phospholipase C/3, which in turn 
triggers phosphoinositide hydrolysis, generating inositol triphosphate (IP3) and 
diaclyglcerol (DAG). This results in activation of calcium channels on the 
endoplasmic reticulum membrane, increased cytosolic calcium concentration and 
protein kinase C activation. Subsequently, the mitogen activated protein kinase 
(MAPK) cascade is initiated, and p42MAPK or p44MAPK are translocated to the 
nucleus where they phosphorylate a number of transcription factors to effect gene 
transcription to influences cellular effects such as fibroblast proliferation. The same 
pathway has also been shown to be important in platelet aggregation and granule 
secretion (reviewed in Dery et al, 1998).
Another major PAR-1 signalling pathway is initiated via receptor coupling to 
Gaj proteins, which is also thought to be important in fibroblast and platelet 
responses. This pathway involves activation of Src, which then forms a complex with 
the adaptor proteins She and Grb2 and the Ras activator SOS. This complex then 
stimulates Ras, Raf and the MAPK cascade, which leads to fibroblast proliferation 
(Luttrell et al, 1997, Della Rocca et al, 1999). In addition, coupling of PAR-1 to Gaj 
causes the inhibition of adenyl cyclase and reduces cyclic AMP generation. This 
results in potentiation of calcium ion mobilisation in response to thrombin (Hung et 
al, 1992), which may also play a role in platelet aggregation and fibroblast 
proliferation. Furthermore, studies in Chinese hamster ovary cells have suggested that 
GjO! proteins also couple PAR-1 to cytoplasmic phospholipase A2 resulting in PGE2 
production (Winitz et al, 1994).
Less is known about the effects of PAR-1 coupling to Goto following thrombin 
stimulation (Hung et al, 1992). However, it is proposed that this may activate the Ras 
and the MAPK pathway in a similar fashion to Gai proteins and a recent study has 
shown that Gc^ proteins regulate cell shape changes in endothelial cells (Vanhauwe et 
al, 2002). Finally, immunoprecipitation studies have revealed that PAR-1 also 
transduces important signals via the a  subunits of G12 and G13 (Offermanns et al, 
1994). Following interaction of G12 and G13 with PAR-1, guanine-nucleotide 
exchange factors are bound resulting in activation of small G proteins such as Rho. 
This provides a pathway for Rho-dependent cytoskeletal responses likely to be 
involved in shape changes in platelets and migration in endothelial cells. Furthermore, 
a recent study has suggested that this signalling pathway may be involved in 
thrombin-induced myofibroblast differentiation (Bogatkevich et al, 2003).
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1.8.3 PAR-1 Inactivation, Desensitisation, Trafficking and Resensitisation
The process of PAR-1 cleavage by thrombin is an irreversible phenomenon 
rendering the activated receptor inactive and resistant to further proteolytic cleavage 
by its activator. The cell therefore remains unresponsive to thrombin until new 
receptors are replenished at the cell surface (see below). Other proteases including 
trypsin, tryptase, chymase, elastase and the neutrophil protease, cathepsin G, also 
cleave PAR-1, but do so at non-activating sites. However, these proteases can take 
part in extracellular inactivation of PAR-1, since they remove the tethered ligand by 
limited proteolysis, terminating thrombin signalling via PAR-1 (reviewed in Dery et 
al, 1998).
PAR-1 signalling can also be rapidly attenuated by intracellular 
desensitisation, a mechanism by which the receptor is uncoupled from the signalling 
cascade and internalised. In this process, PAR-1 is phosphorylated at specific residues 
so that further coupling to G proteins is prevented (reviewed in Dery et a l  1998). This 
is thought to be due to the action of two classes of protein kinases. Homologous 
receptor desensitisation (where there is agonist-dependent activation of the same 
receptor) is mediated via the G-Protein receptor kinases (GRKs), which use arrestins 
as co-factors (reviewed in Bunemann and Hosey, 1999). Heterologous receptor 
desensitisation (where desensitisation is caused by agonist-independent activation of a 
separate receptor) is mediated via second messenger dependent-protein kinases A and 
C (Yan etal, 1998).
After the receptor is internalised, it is recruited to clathrin-coated pits and 
endocytosed within minutes. The internalised receptors are taken up into endosomes 
and in an extremely efficient process, approximately 75% of receptors are trafficked 
to lysosomes for degradation (downregulation) within 30-60 minutes (Hoxie et a l
1993). It has been shown that the process of lysosomal sorting is regulated by the 
cytoplasmic tail of PAR-1 (Brass et al, 1994) and by a membrane-associated protein 
called sorting nexin-1 (SN-1) (Wang et al, 2002). A portion of cleaved PAR-1 avoid 
the process of lysosomal sorting and are recycled to the cell surface. However, they 
are re-expressed with the tethered ligand in an inactive state and are therefore unable 
to respond to thrombin (Hoxie et al, 1993). Thus, following initial receptor cleavage, 
PAR-1 is only capable of mediating downstream effects of the protease once.
Resensitisation is maintained by two processes and in fibroblasts and 
endothelial cells, the predominant mechanism is via delivery of new PAR-1 receptors 
to the cell surface from pre-formed intracellular pools stored in the Golgi apparatus 
and vesicles and the second is via de novo synthesis of new receptors (see Dery et al, 
1998 for a review). The rapid mobilisation of these intracellular pools of PAR-1 
means that most cells can quickly recover cellular responsiveness to thrombin. In 
contrast, in human megakarocytes, recovery of PAR-1 signalling is a slow process 
requiring new protein synthesis, since these cells do not possess large intracellular 
stores of PAR-1. This is consistent with the notion that there is no need for a special 
resensitisation mechanism in platelets (reviewed in Coughlin et al, 2000).
1.9 Protease Activated Receptor-Mediated Cellular Effects of Thrombin
As introduced above, thrombin influences multiple cellular responses 
following PAR activation, which play critical roles in normal physiological 
homeostasis. However, a number of these effects may also be pertinent to tissue 
injury and fibrogenesis and are discussed in more detail below.
1.9.1 Platelet Aggregation
Numerous studies have confirmed that thrombin is a major agonist for 
platelets, initiating a number of events leading to platelet aggregation in vitro and in 
vivo (Eidt et al, 1988). In addition to aggregating in response to thrombin, platelets 
undergo shape change, release thromboxane A2, platelet factor 4, 5-HT (serotonin), 
ATP and fibrogenic mediators, such as TGF/3 and PDGF. Thrombin also mediates the 
translocation of P-selectin and CD40 ligand to the plasma membrane o f platelets, 
facilitating binding to endothelial cells (Stenberg et al, 1985, Henn et al, 1998). Many 
of these effects can be mimicked with PAR-1 selective agonists and blocked with 
PAR-1 neutralising antibodies, suggesting a critical role for PAR-1 in mediating these 
responses.
Human platelets express PAR-1 and PAR-4, and both receptors mediate 
thrombin signalling independent of each other (Kahn et al, 1999). Sustained inhibition 
of thrombin signalling in human platelets can be achieved by blocking PAR-1, but in 
the absence of PAR-1, PAR-4 can mediate platelet activation in response to high 
concentrations of thrombin (Kahn et al, 1999). This has raised the question as to the 
exact biological function of PAR-4 in human platelets. It has been suggested that 
PAR-4 may act as a back-up system for platelet activation. However, it is also thought 
that this receptor may mediate responses in platelets to proteases, other then thrombin.
Consistent with this hypothesis, platelet activation by cathepsin G has been shown to 
be a PAR-4-dependent process (Sambrano et al, 2000).
Interestingly, platelets derived from PAR-1 knockout mice (PAR-1'7"), 
homozygous for receptor deficiency, respond normally to thrombin, due to a dual 
system of activation utilising PAR-3 and PAR-4 (Kahn et al, 1998). In this system, 
mouse PAR-3 does not mediate signalling by itself, but exists as a cofactor for 
cleavage and activation of mouse PAR-4 at low concentrations of thrombin 
(Nakanishi-Matsui et al, 2000). Furthermore, these mechanisms are likely to be 
important in disease, since recent studies have shown that mice deficient in either 
PAR-3 or PAR-4 are protected from experimentally-induced vascular thrombosis 
(Weiss et al, 2002, Sambrano et al, 2001).
From these observations, it is clear that PARs play a critical role in thrombin- 
induced platelet aggregation during normal haemostasis and following vascular 
injury. However, the role of platelet responses in the pathogenesis of fibrotic lung 
disease is less clear. Dramatic activation of the coagulation cascade, with resultant 
intra- and extra-vascular thrombin generation occurs in this condition (please see 
Section 1.6.3). Thrombin stimulates platelets to release fibrogenic mediators and also 
induces platelets to participate in endothelial responses following vascular injury, via 
PAR-mediated effects, which may be important mechanisms following initial lung 
injury in pulmonary fibrosis.
1.9.2 Vascular Tone and Permeability
In addition to its potent effects on platelet function, thrombin modulates 
vascular tone by an endothelial-dependent mechanism involving both the release of 
nitric oxide and a direct vasoconstrictive effect on vascular smooth muscle (Magazine
et al, 1996). Thrombin is also mitogenic for endothelial cells (Herbert et al, 1994), 
and thrombin and PAR-1 activating peptides have been shown to increase vascular 
permeability in vitro (Lum et al, 1993). Consistent with this observation, direct 
systemic infusion of thrombin increases pulmonary microvascular permeability in the 
lungs of experimental animals (Lo et al, 1985). Furthermore, the potential importance 
of thrombin-induced PAR-1-mediated responses in this observation has been 
demonstrated, since microvascular permeability was abrogated in lungs isolated from 
PAR-1 '/_ mice, following systemic perfusion with thrombin (Vogel et al, 2000). 
Importantly, increased microvascular permeability with the resultant leakage of 
plasma components into the interstitial and alveolar space is a prominent feature of 
acute and chronic forms of fibrotic lung disease.
Thrombin and PAR-1 activating peptides increase vascular permeability via a 
number of mechanisms. In terms of direct effects, thrombin causes cultured 
endothelial cell shape change and disrupts endothelial cell-cell junctions (Lum et al, 
1993, Rabiet et al, 1996). Thrombin influences microvascular permeability indirectly, 
predominantly through the production of pro-inflammatory secondary mediators (also 
see Section 1.9.4). For example, thrombin increases the production of IL-6 and IL-8 
by endothelial cells (Johnson et al, 1998). More recently, thrombin has also been 
shown to upregulate prostacyclin and cyclooxygenase-2 expression in human 
endothelium, via a PAR-1-dependent mechanism (Houliston et al, 2002). Thrombin 
also affects endothelial permeability by releasing serotonin from platelets as described 
in Section 1.9.1, histamine from mast cells (Cirino et al, 1996) and platelet activating 
factor, which is also a neutrophil activator.
1.9.3 Angiogenesis and Vascular Injury
Thrombin is also known to play a critical role in angiogenesis via a number of 
PAR-1-dependent mechanisms. An early event in angiogenesis is local dissolution of 
the basement membrane and thrombin has been shown to induce endothelial cells to 
decrease their attachment to basement membrane components, by increasing the local 
production of MMP-2 (Maragoudakis et al, 2001). Thrombin increases endothelial 
cell proliferation by production of vascular endothelial growth factor (VEGF) and 
also its receptors, kinase inserting domain-containing receptor (KDR) and Fms-like 
tyrosine kinase (flt-1), and these findings can be mimicked with PAR-1 agonists 
(Tsopanoglou et al, 1999). Thrombin increases endothelial production of the pro- 
angiogenic cytokines IL- 6  and IL-8 , via activation of PAR-1 as described above and 
also increases the production of the c^ jS3 integrin, (a marker of angiogenic phenotype 
of endothelial cells), (Tsapanoglou et al, 2 0 0 2 ), but it is yet to be established whether 
this is a PAR-1-dependent effect. Finally, the importance of thrombin and PAR-1 in 
angiogenesis in utero has recently been elucidated, since re-expression of the PAR-1 
gene in endothelial cells of PAR-1'7' embryos, reverses the fetal vessel fragility that 
causes premature death of these animals (Griffin et al, 2001). Although angiogenesis 
is a normal physiologic process that occurs during wound repair, it can also occur in 
pathological situations. It has been recognised for a number of years that 
neovascularisation occurs in the lungs of patients with pulmonary fibrosis (Tumer- 
Warwick et al, 1963) and it is conceivable that thrombin and PAR-1 may play a role 
in this process.
Thrombin is also mitogenic for smooth muscle cells (Bydlowski et al, 1998) 
and thrombin’s receptor-mediated effects on smooth muscle cell proliferation have 
been extensively studied in the field of vascular biology. It is proposed that thrombin
plays a role in normal wound healing by promoting vessel wall repair after injury and 
also in pathological conditions associated with hyperproliferation of smooth muscle 
cells, such as atherosclerosis and restenosis. Consistent with this hypothesis, a number 
of studies have shown that administration of PAR-1 antagonists attenuate vascular 
restenosis in animal models (Sarembock et al, 1991, Takada et al, 1998, Andrade- 
Gordon et al, 2001, Derian et al, 2003).
1.9.4 Inflammatory Cell Trafficking
Thrombin also exerts dramatic effect on inflammation and some of thrombin’s 
effects in this process have already been introduced, since it is so intimately linked to 
endothelial cell permeability. Thrombin is a potent chemoattractant and mitogen for 
inflammatory cells (Bar-Shavit et al, 1983, Bizios et al, 1986, reviewed in Grand et 
al, 1996). Thrombin also induces the expression of the T cell chemokine, RANTES, 
in fibroblasts, via a PAR-1-dependent mechanism (Hirano et al, 2002). In addition, 
thrombin stimulates the production of a number of other chemoattractants and pro- 
inflammatory cytokines from a variety of cell types including, monocyte chemotactic 
factor (MCP-1), IL-1/3, IL-2, IL6 and IL-8 (Marin et al 2001, Mari et al, 1994, Sower 
et al, 1995, Ueno et al, 1996 and Naldini et al, 1998, 2000; please see Table 1.5). 
Thrombin also plays an important role in inflammatory cell trafficking by inducing 
the expression of endothelial cell surface adhesion molecules, including P-selectin, E- 
selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) via PAR-1-dependent mechanisms (Sugama et al, 1992, 
Shankar et al, 1994 and Kaplanski et al, 1997,1998).
The exact role of inflammatory mechanisms in the pathogenesis of fibrotic 
lung disease is controversial (see Section 1.3), but it is possible that thrombin-induced
PAR-1 inflammatory responses are involved. In support of this hypothesis, PAR-17" 
mice are protected from experimentally-induced glomerulonephritis (Cunningham et 
al, 2000), an inflammatory disease affecting the kidney, which can progress to end- 
stage renal fibrosis. Furthermore, a recent study has shown that PAR-1 and PAR-4 
agonists stimulate IL-6 and IL-8 production by human bronchial epithelial cells, 
suggesting that PARs may play a role in lung inflammation (Asokananthan et al, 
2002).
1.9.5 Fibroblast Function and Extracellular Matrix Production
There is unequivocal evidence that mesenchymal cells, in particular 
fibroblasts, play a critical role in the pathogenesis of fibrotic lung disease (see Section
1.4). Of particular relevance to this observation, thrombin is a potent lung fibroblast 
mitogen in vitro (Dawes et al, 1993, Chen et al, 1975, Carney et al, 1978) and also 
promotes fibroblast chemotaxis (Dawes et al, 1993). These effects can be mimicked 
with PAR-1 agonists and PAR-17' fibroblasts are unresponsive to thrombin in terms 
of MAP kinase signalling and proliferation (Trejo et al, 1996). Furthermore, thrombin 
has also been shown to be a major fibroblast mitogen in BALF fluid from patients 
with pulmonary fibrosis (Hemadez-Rodriguez et al, 1995, Ohba et al, 1994).
In addition to mitogenesis and chemotaxis, thrombin exerts stimulatory effects 
on connective tissue protein production by mesenchymal cells. Thrombin promotes 
procollagen production by fibroblasts (Chambers et al, 1998) and smooth muscle cells 
in vitro (Dabbagh et al, 1998), via PAR-1 dependent mechanisms. Thrombin has also 
been shown to promote a role in lung myofibroblast differentiation via activation of 
PAR-1 (Bogatkevich et al, 2001, 2003), a process hypothesised to be critical in the 
pathogenesis of pulmonary fibrosis (please see Section 1.3). Consistent with this
observation, PAR-1 expression has been shown to correlate with liver stellate cell 
transformation into myofibroblasts, following thrombin stimulation (Gaca et al, 
2002). After changing phenotype, stellate cells proliferate, produce collagen and 
cause liver fibrosis.
Further evidence that thrombin may be important in promoting extracellular 
protein synthesis has been provided by studies showing that the protease can increase 
basolateral secretion of collagen and proteoglycan synthesis by endothelial cells in 
vitro (Peracchia et al, 1994) and stimulate collagen lattice formation and contraction 
by fibroblasts (Michel et al, 1990, Bogatkevich et al, 2001). Thrombin has also been 
shown to promote the production of fibronectin by fibroblasts and epithelial cells 
(Kang et al 1991) and also stimulates mast cells to adhere to fibronectin (Vliagoftis, 
2002). In addition, thrombin increases the production of matrix metalloproteinases 
including progelatinase A (Zucker et al, 1995) and MMP’s-1, -2, and -3 , which are 
thought to be important in regulating connective tissue synthesis and degradation (see 
Section 1.4.3).
Taken together, the observations described in the previous paragraphs 
demonstrate that thrombin and PAR-1 play a major role in normal tissue repair 
following injury, involving mechanisms such as inflammatory cell recruitment, 
mesenchymal cell migration, proliferation and connective tissue deposition. It is 
feasible that the unopposed action of thrombin on these cellular processes at sites of 
injury, may lead to excessive connective tissue deposition, leading to the development 
of fibrosis. The aim of this thesis is to examine this hypothesis in more detail, in the 
context of fibrotic lung disease.
1.10 Release of Secondary Mediators Following Thrombin Receptor Activation
The preceding section (1.9) elaborated upon some of the functional receptor- 
mediated effects exerted by thrombin. It is clear that the majority of these effects are 
mediated via the induction and release of a host of secondary mediators (for a review 
see Dery et al, 1998). Many of these secondary mediators are pro-fibrotic and pro- 
inflammatory and are of particular pertinence to the studies of this thesis, since they 
may potentially play an important role in the pathogenesis of pulmonary fibrosis. The 
following paragraphs will elaborate on a number of secondary mediators that exert 
potent effects on lung fibroblast function. A full list of mediators is shown in Table 
1.5.
An example of such a mediator is PDGF, which comprises of two polypeptide 
chains, A and B, and is active as a homo- or heterodimer. Two PDGF receptors (a and 
p) exist which exhibit different affinities for the A and B isoforms. Proteolytic 
activation of PAR-1 has been shown to be necessary and sufficient for the mitogenic 
effects of thrombin on fibroblasts (Trejo et al, 1996). However, following receptor 
cleavage it is thought that fibroblast proliferation is mediated, at least in part, via the 
autocrine production of PDGF-AA and upregulation of the PDGF-a receptor (Ohba et 
al, 1994, 1996), ensuring that the target cell is capable of responding to the autocrine 
mediator induced. Experiments have also been performed to examine the effect of the 
culture supernatant of thrombin-stimulated alveolar macrophages on fibroblast 
proliferation in vitro. Such culture supernatants promote fibroblast proliferation and 
this effect is blocked with antibodies to PDGF-AA, suggesting that this growth factor 
may also act in a paracrine fashion on fibroblasts in the fibrotic lung (Tani et al,
1997).
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Thrombin also stimulates the release of the archetypal pro-fibrotic mediator 
TGF/3 by platelets (Soslau et al, 1997) and vascular smooth muscle cells following 
PAR-1 activation (Bachhuber et al, 1997) and in addition, TGF/3 from the pericellular 
matrix (Taipale et al, 1992). These processes may be important in the fibrotic lung 
where TGF/3 may act as a paracrine mediator for fibroblasts. However, since thrombin 
does not directly increase TGF/3 production by fibroblasts (Chambers et al, 2000), the 
effects of the protease on procollagen production by these cells in vitro cannot be 
explained by increased production of this mediator.
A potential mechanism for this observation has recently been elucidated by Dr 
Chambers. It was initially noted that the stimulatory effects of thrombin on 
procollagen mRNA levels by fibroblasts in vitro were delayed and could be abolished 
with cycloheximide (Chambers et al, 1998), suggesting the involvement of a newly 
synthesised protein product. It has now been shown that thrombin is a potent inducer 
of CTGF production by human lung fibroblasts via direct proteolytic activation of 
PAR-1 (Chambers et al, 2000). Furthermore, this effect was independent of TGF/3, 
since it was not blocked with a pan-specific TGF/3 neutralising antibody. This has lead 
to the proposal that some of the pro-fibrotic effects of thrombin, in particular on 
procollagen production, may be mediated, at least in part, via increased production of 
CTGF in an autocrine fashion. A number of the experiments conducted in this thesis 
examine this hypothesis further, and a more detailed review of the role of CTGF in 
normal biological processes and disease follows.
Table 1.5: Secondary Mediators Produced or Released
Following PAR-1 Activation by Thrombin
Pro-Inflammatory Mediators Cell Type Reference
IL-IP Macrophages/Monocytes Naldini e ta l, 1998
IL-2 T Lymphocytes Mari e ta l, 1994
IL-6 Lung Fibroblasts 
Endothelial Cells 
Lung Epithelial Cells 
Macrophages/Monocytes 
Mast Cells 
Smooth Muscle Cells
Sower et al, 1995 
Johnson et al, 1998 
Sower et al, 1995 
Naldini et al, 1998 
Cirino e ta l, 1996 
Kranzhofer et al, 1996
IL-8 Lung Fibroblasts 
Bronchial Epithelial Cells 
Macrophages/Monocytes 
HUVEC
Ludwicka-Bradley et al, 
2000
Asokananthan et al, 2002 
Suk et al, 1999 
Ueno et al, 1996
MCP-1 HUVEC Marin e ta l, 2001
Prostacyclin HUVEC Wheeler-Jones et al, 1996
COX-2 HUVEC Houliston et al, 2002
RANTES Synovial Fibroblasts Hirano et al, 2002
ICAM-1 HUVEC Kaplanski et al, 1998
VCAM-1 HUVEC Kaplanski et al, 1998
Pro-Fibrotic Mediators Cell Type Reference
PDGF Lung Fibroblasts 
Synovial Fibroblasts 
Lung Epithelial Cells 
HUVEC 
Vascular Smooth Muscle Cells
Ohba e ta l, 1994 
Ohba e ta l, 1996 
Shimizu et al, 2000 
Shankar et al, 1994 
Stouffer et al, 1998
TGFP Vascular Smooth Muscle Cells 
Platelets
Bachhuber et al, 1997 
S oslaue/a/, 1997
b-FGF Vascular Smooth Muscle Cells Stouffer et al, 1998
Endothelin-1 Vascular Smooth Muscle Cells 
Endothelial Cells 
Monocytes/Macrophages
Lepailleur-Enouf et al, 2000 
Marsen e ta l, 1995 
Srivastava et al, 1998
IGF-1 Vascular Smooth Muscle Cells Du e ta l, 2001
CTGF Human Lung Fibroblasts 
HELA Cells
Chambers et al, 2000 
Riewald et al, 2001
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1.11 Connective Tissue Growth Factor (CTGF)
1.11.1 Introduction
CTGF is a novel 38 kDa cysteine-rich heparin-binding growth factor, which 
was first isolated from human endothelial cells in culture, when it was observed that a 
novel polypeptide growth factor secreted by these cells stimulated DNA synthesis and 
chemotaxis by fibroblasts (Bradham et al 1991). CTGF has emerged as one of six genes 
that have been classified as encoding a group of structurally-related molecules named 
the CCN family (acronym of Cyr61/CEF-10, CTGF/Fisp-12, Nov), which exert diverse 
functions in processes such as cell proliferation and differentiation. The primary 
translational products of the CCN family are characterised as mosaic proteins that 
comprise four structural modules, which determine the various biological functions of 
group members.
The CTGF gene is located on chromosome 6q23.1 and consists of 5 exons, 
which encode a signal peptide and the characteristic four modules. The first exon, 
encoding the signal peptide, is essential for the transport of CTGF from the 
endoplasmic reticulum to the Golgi (Chen et al 2001). Exon 2 encodes a low affinity 
IGF binding domain (module I) (reviewed in Moussad and Brigstock, 2000). Exon 3 
encodes a cysteine rich domain which displays high similarity to the von Willebrand 
factor type C (module II). It was previously thought to be involved in oligomerisation 
but a recent study has suggested that this region may also be important for CTGF 
signalling, which will be discussed further below (Abreu et al, 2002). Exon 4 encodes a 
thrombospondin type I domain which contains a cell attachment motif (module III). 
Finally, exon 5 encodes a C-terminal domain that contains a cystine knot, thought to be 
important in dimerisation and receptor binding (module IV) (reviewed in Moussad and 
Brigstock, 2000), (see Diagram 1.7 below).
BPutative
Function
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
Signal Peptide IG F-Binding I C R- vw c Cvs t ine  Knot
Module 1 Module II Module III Module IV
Export IGF Oligomerisation, Cell Dimerisation
ER-Golgi Binding Cell Signaling Attachment
P =  Promoter, I = Intron: Adapted from Moussad and Brigstock, (2000), Blom, (2002)
Diagram 1.7: Gene Organisation of CTGF
1.11.2 Role of CTGF in Pathophysiology and Tissue Fibrosis
CTGF is proposed to be involved in embryonic development and differentiation 
(Kireeva et al, 1997) but in adults, it is thought to have a more diverse role in a number 
of processes including cell proliferation, angiogenesis, cell attachment, cell survival, 
apoptosis and connective tissue formation after tissue injury (reviewed in Blom et al, 
2002). CTGF has been implicated in the pathogenesis of a number of conditions 
complicated by fibrosis and they are shown below in Table 1.6.
Of particular pertinence to tissue fibrosis, CTGF has been shown to promote 
fibroblast proliferation, chemotaxis and procollagen and fibronectin production in vitro 
(Frazier et al, 1996). In addition, CTGF mRNA levels are highly upregulated in skin 
wound healing models in vivo and subcutaneous injection of CTGF into newborn 
mice results in increased connective tissue deposition, producing similar histological 
features to mice injected with TGFBi (Frazier et al, 1996).
Evidence that CTGF may play a role in the pathogenesis of pulmonary fibrosis 
has been provided by a number of studies. Firstly, CTGF expression is dramatically 
increased in lung biopsy specimens from patients with IPF/CFA, compared with 
normal lung tissue, when examined by RT-PCR analysis (Pan et al, 2001). In this 
study, CTGF was predominantly localised to activated fibroblasts and type II alveolar 
epithelial cells in fibrotic lung tissue specimens, when assessed by 
immunohistochemistry and in situ hybridisation. Another study showed that CTGF 
expression was also increased in BALF inflammatory cells obtained from patients 
with IPF/CFA (Allen et al 1999). Finally, CTGF mRNA expression is upregulated in 
mice in the bleomycin model of pulmonary fibrosis (Lasky et al, 1998).
Table 1.6: Fibrotic Disorders in which CTGF is Implicated
Tissue Disease Reference
Lung IPF/CFA
FA-SSc
Sarcoidosis
Pan et al, 2001 
White et al, 2002 
Allen e ta l, 1999
Skin Systemic Sclerosis 
Keloid Scars 
Nodular Fasciitis 
Dupytrens Contracture
Denton et al, 2001 
Denton et al, 2001 
Igarashi et al, 1996 
Igarashi et al, 1996
Kidney Renal Fibrosis Crean et al, 2001
Liver Liver Fibrosis Hayashi et al, 2002
Pancreas Chronic Pancreatitis di Mola et al, 1999
Gastrointestinal Tract Inflammatory Bowel Disease 
Intra-Abdominal Adhesions
Dammeier et al, 1998 
Thaler et al, 2002
1.11.3 Biological Effects of CTGF
Although CTGF was first discovered in 1991, progress in elucidating the 
mechanisms by which this growth factor exerts its biological effects has been slow, for 
a number of reasons. Firstly, recombinant CTGF (rCTGF), which has been used to 
examine potential mechanisms of action, has not been commercially available. 
Consequently, a number of laboratories have produced rCTGF from different sources 
and by varied purification techniques, which have lead to conflicting experimental 
results. In additional to technical difficulties in producing the recombinant protein, an 
additional factor that might explain the disparity in results obtained may be related to 
the size of the recombinant protein used in experiments. A recent study examining the 
effect of rCTGF on porcine skin fibroblast gene expression showed that biological 
effects in these cells could only be induced when a full length 38 kDa rCTGF with an 
intact C-terminal domain was used and that a truncated 16-20 kDa form of rCTGF was 
non-functional (Wang et al, 2003). Furthermore, since CTGF has a complex modular 
structure, it is possible that various recombinant proteins produced to date may not
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reflect the true structure of the mature CTGF protein. Finally, a number of studies have 
provided evidence that CTGF may act as a modulator of biological events induced by 
other agents, rather than act as a significant individual stimulus on its own, which has 
questioned the exact pathophysiological role of this protein in normal homeostasis and 
disease (reviewed in Blom et al, 2002).
A number of putative receptor(s) and signalling pathways by which CTGF may 
exert its cellular effects have been described. CTGF binds to a number of integrins 
including 04,183, Onb/33, Ofc/3i (Chen et al, 2001, Jedsadayanmata et al, 1999, Kireeva et al,
1998), which may be important in processes such as chemotaxis, mitogenesis and 
matrix remodelling (Chen et al, 2001). In addition, the low-density lipoprotein receptor- 
related protein/alpha-2 macroglobulin receptor (LRP) has been proposed to act as a 
receptor for CTGF in fibroblasts (Segarini et al, 2001). However, to date, no direct cell 
signalling has been detected following CTGF binding to LRP and more recently, LRP 
was shown to be involved in the rapid internalisation of CTGF and its subsequent 
degradation by endosomes (Chen et al, 2001). It is therefore possible that LRP is 
primarily involved in clearance of CTGF, rather than propagating a downstream signal.
A recent study has shown that CTGF binds both TGF/3 and bone morphogenetic 
protein-4 (BMP-4), through its cystine-rich von Willebrand type c domain (Module II), 
in the extracellular space (Abreu et al, 2002). Binding of CTGF to TGF/3 and BMP-4, 
leads to activation of the TGF/3 signalling pathway and inhibition of BMP signalling, 
respectively. It has therefore been suggested that some of the functional effects exerted 
by TGF/3, may be propagated through a synergistic relationship with CTGF. This study 
has shown that the relationship between CTGF and TGF/3 is complex, since it had 
previously been proposed by a number of investigators, that CTGF was an autocrine 
mediator responsible for mediating some of the downstream cellular effects of TGFB.
Evidence in favour of this hypothesis has been provided by a number of studies. Firstly, 
TGFB induces CTGF expression by cultured fibroblasts, an effect not seen with several 
other mediators, including PDGF and IGF-1 (Ricupero, 1999). Evidence for a 
functional relationship between the activation of CTGF and TGFB was also provided by 
experiments in which the effects of TGFB were blocked using antagonists of CTGF. 
Examples include studies where CTGF antisense constructs and neutralising antibodies 
were shown to abrogate the effects of TGFB on fibroblast anchorage-independent 
growth and procollagen production (Kothapalli et al, 1997), although these findings 
were not universally reproducible (Ricupero et al, 1999, Duncan et al, 1999).
Further evidence that CTGF may play a role in mediating the downstream 
effects of TGFB was provided by experiments showing the presence of a TGFB 
response element (TGFBRE) exists in the CTGF promoter region (Grotendorst et al, 
1996). However, more recently, it has been shown that the TGFBRE appears to be 
responsible for basal expression of CTGF in skin and lung fibroblasts and has been 
renamed the basal control element (BCE-1). Furthermore, it has also been shown that 
the presence of a functional SMAD binding site in the CTGF promoter is necessary for 
the induction of CTGF by TGFB in normal skin fibroblasts. Interestingly, in skin 
fibroblasts cultured from patients with scleroderma, a mulisystem fibrotic condition, the 
constitutive expression of CTGF appears to be independent of SMAD-dependent TGFB 
signalling, and dependent on BCE-1 (Holmes et al, 2001).
In addition to the overwhelming evidence supporting a link between CTGF 
expression and TGFB in tissue fibrosis, there are a number of other growth factors, 
cytokines and stimuli, other than TGFB that have recently been shown to affect CTGF 
production by a variety of cell types (please see Table 1.7). Of particular relevance to 
the experiments of this thesis is the observation that thrombin induces CTGF production
in fibroblasts in vitro (Chambers et al, 2000). This has raised the possibility that CTGF 
may be a common downstream mediator or co-factor for both thrombin and TGFB. 
Furthermore, it raises the question whether CTGF may be responsible for mediating 
some of the pro-fibrotic effects of thrombin in the development of pulmonary fibrosis. 
This concept will be examined further in the experiments of this thesis, for which the 
specific hypothesis and aims are presented in the forthcoming and final section of this 
introduction.
Table 1.7: Factors Known to Induce CTGF Production
Stimulus Cell Type Reference
TGF-0 Human Lung, Skin and Dermal 
Fibroblasts
Ricupero e ta l, 1999 
Igarashi e ta l,  1993 
Frazier et al, 1996
Thrombin Human Lung Fibroblasts 
Hela Cells
Chambers et al, 2000 
Riewald et al, 2001
Factor Xa Human Lung Fibroblasts 
Hela Cells
Chambers et al, 2000 
Riewald et al, 2001
Factor V ila Human Lung Fibroblasts Pendurthi et al, 2000
TNF-a Hepatic Stellate Cells Liu et al, 2001
VEGF Retinal Vascular Endothelial Cells Suzuma et al, 2000
Advanced Glycosylation End 
Products
Human Dermal Fibroblasts Twigg e ta l, 1999
Activation of Heptahelical 
Receptors by Serotonin and 
Lysophosphatidic Acid
Renal Mesangial Cells Hahn et al, 2000
Hydrogen Peroxide Lens Epithelial Cells Park et al, 2001
a-tocopherol Human Smooth Muscle Cells Villacorta et al, 2003
Dexamethasone 3T3 Fibroblasts Dammeier et al, 1998
Mechanical Stimulation and 
Strain
Rat Osteocytes 
Human Lung Fibroblasts
Yamashiro et al, 2001 
Schild et al, 2002
Static Pressure Human Mesangial Cells Hishikawa et al, 2001
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1.12 Summary, Hypothesis and Specific Aims of This Thesis
Pulmonary fibrosis is the end stage of a heterogeneous group of disorders, 
characterised by excess deposition of extracellular matrix proteins within the 
pulmonary interstitium. The pathogenesis of this condition is still unknown, but it is 
known that dramatic activation of the coagulation cascade occurs in the lungs of 
patients with this disease.
In this chapter, the role of the serine protease thrombin in physiology and lung 
pathobiology has been reviewed. Thrombin plays a central role in blood coagulation, 
but also exerts a number of cellular effects including influencing fibroblast 
proliferation, connective tissue synthesis and inflammatory cell migration in vitro. It 
is proposed that many of these effects are mediated following limited proteolysis of 
the major thrombin receptor, PAR-1 and the subsequent release of secondary 
mediators such as PDGF and CTGF. Despite the indirect evidence that the 
procoagulant and cellular effects of thrombin may play an important role in the 
pathogenesis of pulmonary fibrosis, there have been no previous reports that have 
specifically addressed whether thrombin directly affects lung collagen accumulation 
in this disorder.
This thesis will therefore address the following hypothesis:
Persistent and Excessive Generation of Thrombin Plays a Role in Promoting
Lung Collagen Accumulation in Pulmonary Fibrosis, via Activation 
of its Major Cellular Receptor, PAR-1
The specific aims of this thesis are to:
(i) Examine the effect of a potent and highly selective direct thrombin 
inhibitor, UK-156406 (Pfizer Central Research, UK) on bleomycin- 
induced pulmonary fibrosis in rats.
(ii) Evaluate the role of PAR-1 in bleomycin-induced pulmonary fibrosis, by 
comparing the fibrotic response in PAR-1 deficient mice (PAR-1 "A) versus 
wild-type mice, (please see Diagram 1.8).
Diagram 1.8: Potential Role for Thrombin in Pathogenesis of Pulmonary Fibrosis
Thrombin
Fibrinogen
Procoagulant Cellular
Effects Effects
Pulmonary Fibrosis
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Chapter 2
Materials and Methods
Materials
2.1 Cell Culture and Major Reagents
All chemicals were of analytical grade or above and obtained from 
BDH/Merck (Lutterworth, Leicestershire, UK), unless otherwise indicated. All water 
used for the preparation of chemicals and buffers was distilled and de-ionised using a 
Millipore Water Purification System (Millipore R010 followed by Milli-Q Plus; 
Millipore, Watford, Hertfordshire, UK). Solvents for the preparation of high 
performance liquid chromatography (HPLC) buffers and solutions were of HPLC 
grade and obtained from BDH/Merck. 7-chloro-4-nitrobenzo-2-oxa-l,3-diazole 
(NBDC1) and methyl blue were obtained from Sigma Chemical Co. Ltd (Poole, 
Dorset, UK). Sterile tissue culture dishes, polypropylene centrifuge tubes and pipettes 
were obtained from Falcon (New Jersey, USA), unless otherwise stated. Other 
disposable plasticware was purchased from Sterilin (Ashford, Middlesex, UK). Sterile 
tissue culture medium, sterile tissue culture grade amino acids, trypsin/EDTA and 
antibiotics were obtained from GEBCO-BRL (Paisley, Renfrewshire, UK). New bom 
calf serum (NCS) (heat inactivated) was purchased from Imperial Laboratories 
(Andover, Hampshire, UK).
The direct thrombin inhibitor, UK-156406 was supplied as a dry powder and 
generous gift from Dr Andrew Gray (Pfizer Central Research, Sandwich, Kent, UK). 
Purified human a-thrombin (cat no.T4393) and recombinant hirudin were obtained 
from Sigma Chemical Co. Ltd, (Poole, Dorset, UK). [H]-Thr-Phe-Leu-Leu-Arg-[OH] 
(TFLLR - PAR-1 agonist peptide) was commercially supplied by Dr Robert Mecham, 
(Washington University, St Louis, USA). Hypnorm and Euthatal were obtained from 
Jansson (Saunderton, High Wycombe, Buckinghamshire, UK). Carbon Dioxide,
Oxygen and Nitrogen gases were purchased from BOC, London, UK). All filters for 
HPLC were obtained from Millipore (Millipore, Watford, Hertfordshire, UK). 
Bleomycin sulphate was obtained from Lundbeck (Caldecotte, Milton Keynes, UK).
2.2 Antibodies
Rat-specific PAR-1 antibodies were generated by immunising rabbits with the 
agonist sequence SFFLRNPSENTFELVPL-NH2 (abbreviated SFFL). Human specific 
PAR-1 antibodies were raised against the peptide SFLLRNPNDKYEPF-NH2 
(abbreviated SFLL), also in rabbits. Both antibodies were purified by affinity 
chromatography (Jenkins et al, 1993) and were a generous gift from Professor 
Eleanor Mackie (University of Melbourne, Australia). Purified rabbit anti-hirudin 
antibodies were obtained from American Diagnostica, (Greenwich, Connecticut, 
USA). All additional antibodies were obtained from DAKO, (High Wycombe, UK) 
unless otherwise stated.
2.3 cDNA Probes and PCR Primers
The cDNA probe for human CTGF was inserted into the EcoRl and Not 1 sites 
of pBluescript and was kindly provided by Dr Raj Beri (AstraZeneca R&D 
Chamwood, Loughborough, UK). The cDNA probe for FISP12 (the murine orthologue 
of CTGF), encompassing nucleotides 1663 to 2930 was generated from a plasmid 
(pBluescriptfispl2del) kindly provided by Dr Joseph A. Lasky (Tulane University, New 
Orleans, Louisiana, USA). The pBluescriptfispl2del plasmid was subcloned from a 
plasmid (A12/pMexNeo I) originally obtained from Dr. Rolf-Peter Ryseck (Bristol- 
Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA). The cDNA 
probe for cq(I) procollagen (probe Hf677) was kindly provided by Dr. M. L. Chu
(Thomas Jefferson University, Philadelphia, PA, USA). The cDNA probe for rat 
PAR-1 was obtained subcloned into the plasmid Bluescript KS (Niclou et al, 1994) 
and was a generous gift from Dr Professor Eleanor Mackie (University of Melbourne, 
Australia). The cDNA probe for human PAR-1 was a kind gift from Prof. Sean 
Coughlin (UCSF, USA) and was also subcloned into plasmid Bluescript KS. A 
representative description of the methodology used in preparing the different cDNA 
probes for Northern analysis is described in Section 2.7.2. Polymerase Chain 
Reaction (PCR) for murine PAR-1 was performed using commercially-available 
primers as suggested by The Jackson Laboratory. The full methodology and 
description of primers is described in Section 2.9.2 (details also available at 
www.aretha.iax.org/).
Methods
2.4 Fibroblast Cell Culture
2.4.1 Culture Conditions
Human foetal lung fibroblasts (HFL-1) were obtained from the American 
Type Culture Collection (ATCC- Rockville, Maryland USA). Primary cultures of rat 
lung fibroblasts were obtained by explant culture (please see Section 2.4.2). Cells 
were maintained in static culture on 75 cm culture flasks in Dulbecco's modification 
of Eagle's medium (DMEM), supplemented with penicillin (200 i.u/ml), streptomycin 
(200 i.u/ml), glutamine (4 mM) and 10% (v/v) newborn calf serum (NCS), (Imperial 
Laboratories, Andover, Hampshire, UK). Plates were incubated at 37°C in a 
humidified atmosphere of air containing 10% CO2 . Cells were routinely tested for
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mycoplasma contamination using a probe for mycoplasma ribosomal RNA (Gen- 
Probe, Mycoplasma, T.C.II. Laboratory Impex, Teddington, Middlesex, UK).
2.4.2 Isolation of Prim ary Rat Lung Fibroblasts
Primary cultures of rat lung fibroblasts were generated from lung tissue of 
male Lewis rats sacrificed with a lethal dose of Euthatal. Using sterile techniques, 
lungs were perfused with serum-free DMEM via the inferior vena cava until they 
were pale (also see Section 2.10.1). Lungs were removed from the thoracic cavity and 
dissected free of major airways using sterile instruments. Lungs were immediately 
placed in sterile DMEM supplemented with penicillin (200 i.u/ml), streptomycin (200 
i.u/ml), glutamine (4 mM) and 0.01% (v/v) fungizone. Lungs were transferred into a 
sterile tissue culture hood, diced into 2-4 mm pieces and placed into 10 mis sterile- 
filtered collagenase ( 1  mg/ml) for two hours at room temperature, with regular mixing 
every 15 minutes. After two hours, the supernatant was removed and separated from 
undigested tissue and debris by filtration through sterile gauze. The cell suspension 
was aspirated into a 50ml sterile polypropylene centrifuge tube (Falcon) and 
centrifuged (300 x g for 7 minutes at 4°C) using a bench centrifuge (MSE Mistral 
3000, Loughborough, Leicestershire, UK), prior to plating. The supernatant was 
discarded and the cell pellet was brought into a single cell suspension with 1 ml of 
DMEM or 1 ml of 10% NCS/DMEM by gentle mixing with a pipette. A further 9 mis 
of culture medium was then added and an aliquot of suspension was removed with a 
sterile pipette. Cells were then counted using an Improved Neubauer haemocytometer 
(British Drug House/Merck, Lutterworth, UK) and the cell suspension was diluted 
with either DMEM or DMEM-10% NCS, prior to cells being plated in tissue culture 
flasks and maintained as described in Section 2.4.1.
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2.4.3 Cell Subcultivation
Upon reaching near visual confluence (3-5 days for primary rat lung 
fibroblasts, 6-7 days for HFL-1), cells were subcultured (passaged) into new culture 
flasks. By passage 2, rat lung fibroblasts had formed homogeneous monolayers 
morphologically consistent with a fibroblast phenotype, when examined with an 
inverted phase contrast light microscope (Olympus TCK-2, Olympus Optical Co Ltd, 
London, UK). For both fibroblast lines, medium in tissue culture flasks was removed 
at near visual confluence using a sterile pipette and the residual cell layer was washed 
with 10 mis phosphate buffered saline (PBS) (Ca2+/Mg2+-free) to remove any 
remaining culture medium. Cells were brought into suspension by the addition of 2 
mis trypsin (0.05% w/v) / EDTA (0.02% w/v) solution and incubating the cells at 
37°C until complete cell detachment from the tissue culture plasticware had occurred, 
(approximately 2 minutes). To confirm that the cells had detached, they were 
observed under an inverted phase contrast light microscope. The effect of trypsin was 
then neutralised with 10 mis of DMEM containing 10% NCS. For subcultivation the 
cell suspensions were split in ratios 1:4. Cells used for in vitro experiments were 
usually between passages 14-23 for HFL-1 and between passages 2-6 for primary rat 
lung fibroblasts.
2.4.4 Preparation of UK-156406 and TFLLR
UK-156406 was supplied a dry powder and stored at 4° C in the presence of 
desiccant. For in vitro experiments, an aliquot of UK-156406 was weighed, dissolved 
in serum-free DMEM and a fresh stock solution generated (2.3 x 10’3 M). This was 
then diluted to a range of concentrations (10 nM - 1 pM). Prior to addition to cell 
cultures, UK-156406 was pre-incubated with human a-thrombin, for 60 minutes, in
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serum-free DMEM, at 37°C. To examine the effect of thrombin alone, the protease 
was similarly pre-incubated in serum-free DMEM under the same conditions. For 
details of preparation of UK-156406 for in vivo experiments, please see Section 2.9.4.
TFLLR was stored at -20 0 C in the presence of desiccant. For in vitro 
experiments, an aliquot of TFLLR. was weighed, dissolved in serum-free DMEM and 
DMSO (1%) and a fresh stock solution generated (10 x 10'3M). This was then diluted 
to a range of concentrations (10 -  200 /zM), prior to addition to cell cultures.
2.5 Fibroblast Proliferation Assay
2.5.1 Principle of the Assay
Fibroblast proliferation was assessed using a spectrophotometric assay based on 
the uptake and subsequent elution of the dye methylene blue according to the method 
described by Oliver et al (1989). Methylene blue is a base with a positive charge at pH
8.5 and binds electrostatically to negatively-charged groups, including phosphate 
moieties of nucleic acids and charged proteins, within the cell layer. The dye is eluted 
from the cell layer by lowering the pH to below 2 with hydrochloric acid (HC1). This 
results in the protonation of acidic groups and liberation of methylene blue into the 
eluent. Methylene blue forms dimers in aqueous solution at low pH. The formation of 
these dimers is suppressed by using hydrochloric acid/ethanol eluent, which results in a 
single absorption peak at 650 nm.
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2.5.2 Cell Culture Conditions
All proliferation experiments were performed on cells in sub-confluent culture in 
the absence of serum. Cells were brought into suspension as described in Section 2.4.3 
and seeded into 96 well plates at a concentration of 5 x 103 cells in lOOpl DMEM-5% 
NCS using a multi-channel pipette (Titertek, Rickmansworth, UK). In order to avoid 
edge effects, cells were only dispensed into the central 1 0x6  wells of the 96 well plate. 
The outer wells were filled with lOOpl of DMEM only. After 12-16 hours, the medium 
was removed by gentle aspiration and replaced with lOOpl of fresh, serum-free DMEM 
for a further 24 hours.
For in vitro experiments using HFL-1, cells were exposed to thrombin alone or 
thrombin previously pre-incubated with UK-156406 (10 nM - 1 pM), in fresh serum- 
free DMEM. For in vitro experiments using primary rat lung fibroblasts, cells were 
similarly exposed to thrombin alone or TFLLR (10 -  200 pM), in fresh serum-free 
DMEM (n=6 for each dose for all experiments). All cell culture plates were returned to 
the incubator and left to incubate at 37° C for 48 hours. In order to determine the 
absorbance of cultures at the onset of each experiment (to absorbance), a plate containing 
cells plated as described above and left to incubate for the initial 24 hours only, was 
processed as described in the following paragraph, Section 2.5.3.
2.5.3 Assay Procedure
At the end of the incubation period, the culture medium was removed by blotting 
the plate over absorbent paper and gently dipping the plate in a beaker of PBS. The plate 
was re-blotted and the cell layer fixed by addition of 1 0 0  pi formal saline (1 0 % vol/vol 
formalin in 0.15 M NaCl). After a minimum of 30 minutes, formal saline was flicked
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off, the plate blotted dry and 100 pi freshly filtered methylene blue (1% w/v in 0.01 M 
borate buffer, pH 8.5) was added for 30 minutes. Excess dye was flicked off the plate 
and the cell layer washed by serially dipping the plate in 4 reservoirs containing 0.01 M 
borate buffer (pH 8.5). After the last rinse, the plate was patted dry and bound dye was 
eluted from the cell layer by addition of 100 pi acidified alcohol (0.1M HC1 in 50% 
ethanol). The plate was gently shaken and the absorbance for each well measured at 650 
nm on a microplate photometer (Titertek Multiscan MCC/340 Mk II, Flow 
Laboratories, Rickmansworth, UK). The photometer was blanked on the first column of 
wells containing the elution solvent only and results were expressed as absorbance/well. 
The percent change in fibroblast replication, relative to media control cells, was 
calculated according to the equation:
% Change = Absorbance (treated)/ Absorbance (control) - 1 x 100
2.5.4 Cytometry
Any change in cell number was also confirmed using direct cell counting. 
Cells were seeded into 24 well plates at a density of 5 x 105 and treated as above. 
Following stimulation, the medium was removed and the cells re-suspended in 100 pi 
trypsin/EDTA at room temperature and counted using an Improved Neubauer 
haemocytometer by loading 10 pi of cell suspension. Six wells were counted for each 
condition. For cell counts, the percent change, relative to media control cells, was 
calculated according to the equation:
% Change = Cell No. (treated)/ Cell No. (untreated) - 1 x 10
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2.6 Determination of Fibroblast Procollagen Production in vitro
2.6.1 Introduction
Procollagen metabolism by cultured fibroblasts was assessed by measuring 
hydroxyproline in intact proteins in the cell layer and supernatant (ethanol-insoluble 
fraction), using a high-performance liquid chromatography method developed in the host 
laboratory (Campa et al 1990). Hydroxyproline represents approximately 12% of the 
primary sequence of procollagen, and is essential for the formation of the collagen triple 
helix. This amino acid, is not present in a significant level in most other proteins. 
Proteins that have been reported to contain Hydroxyproline are elastin, Clq component 
of complement, acetylcholinesterase, surfactant apolipoproteins A and D, ficollin a  and 
P and macrophage scavenger protein (Campa et al, 1990). These proteins have not been 
found in isolated fibroblasts in culture, and therefore hydroxyproline concentration from 
fibroblast cultures in vitro is a robust determinant of procollagen metabolism.
The following paragraphs describe the methodology for measuring 
procollagen in cultured HFL-1 fibroblasts by HPLC, in experiments where the effect 
of UK-156406 on thrombin-induced fibroblast procollagen production was assessed. 
In this thesis, this technique was also used to measure hydroxyproline content in lung 
tissue hydrolysates from in vivo experiments. Relevant differences in the procedure 
are highlighted in Section 2.10.4.
2.6.2 Cell Culture Conditions
Cells from confluent cultures were brought into suspension as described in 
Section 2.4.3 and seeded at a cell density of 1x10s cells/well in 1 ml DMEM-10% NCS 
into 12 well sterile culture dishes. Upon reaching visual confluence (after 5-6 days), the
100
culture medium was removed and replaced with 1 ml serum-free DMEM, supplemented 
with freshly added glutamine (4 mM), penicillin (200 units/ml), streptomycin (200 
units/ml), ascorbic acid (50 pg/ml), proline (0.2 mM) (pre-incubation media). Great care 
was taken to avoid disruption of the fragile cell monolayer during this procedure. After 
a further 24 hours, the medium was replaced with identical control medium or 
medium supplemented with thrombin or thrombin pre-incubated with various 
concentrations of UK-156406 (10 nM - 1 pM), in fresh serum-free DMEM (n=6 for 
each dose for all experiments). Identical cell cultures were treated in parallel to allow 
assessment of cell number by direct cell counting at the end of the incubation period. 
As there is a small amount of procollagen in the cell layer and culture serum, time zero 
samples (to) were included for all experiments performed, and consisted of freshly added 
incubation medium into which the cell layer had been scraped at the onset of the in­
cubation period.
2.6.3 Cell Harvesting
At the end of the incubation period (48 hours), tissue culture plates were 
frozen at -40° C to avoid proteolysis prior to analysis. Subsequently, plates were 
thawed and the cell layer scraped into the culture medium. Contents of each culture 
well were aspirated and transferred to polystyrene bijou tubes (Sterilin, UK). Culture 
wells were rinsed with 1 ml sterile PBS which was combined with the initial aspirate.
2.6.4 Separation of Ethanol-Insoluble and Ethanol-Soluble Fractions
Proteins were precipitated by addition of absolute ethanol to a final concentration 
of 67% (v/v) at 4° C overnight (16 hours). Ethanol-insoluble proteins (precipitated 
proteins) were separated from ethanol-soluble moieties (amino acids and small peptides)
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using filtration through an acid resistant 0.45 pm pore filter (type HV, Millipore Ltd, 
Watford, UK) using a vacuum filtration unit (Millipore Ltd, Watford, UK). Proteins 
adhering to the filters were washed twice with 2.5 ml 67% aqueous ethanol (v/v). Filters 
with adherent proteins were transferred to hydrolysis tubes, and the filters were re­
suspended and hydrolysed in 3 ml hydrochloric acid ( 6  M) at 110°C for 16 hours. 
Hydrolysates were decolourised with 30 mg activated charcoal (Hopkins and Williams, 
Chadwell Heath, Essex, UK) and filtered through an acid resistant 0.65pm pore filter 
(type DA, Millipore Ltd, Watford, UK).
2.6.5 Measurement of Hydroxyproline by Reverse-Phase HPLC in vitro 
Principle o f  the Assay
Hydroxyproline in sample hydrolysates was isolated and measured by reverse- 
phase-HPLC following derivatisation with 7-chloro-4-nitrobenzo-2-oxa-l,3-diazole 
(NBD-C1; Sigma Chemical Co. Ltd, Poole, UK) according to the method described by 
Campa et al (1990). The chemical reaction between NBD-C1 and Hyp is shown in 
Diagram 2.1. Under the conditions described below, secondary amino acids react with 
NBD-C1 to produce a chromophore exhibiting a strong light absorbance at 495 nm. 
NBD-C1 also reacts with primary amino acids but these amino acids only have limited 
absorbance at this wavelength. In addition, the reaction with hydroxyproline and proline 
occurs one order of magnitude faster than with primary amino acids (Ahnoff et al, 
1981). Interference from primary amino acids is therefore minimised by keeping the 
derivatisation time to 2 0  minutes, a time point at which the extent of hydroxyproline 
derivatisation with NBD-C1 at 37° C was previously shown to be maximal for up to 20 
nmol Hyp (Campa et al, 1990).
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OH Cl
Hydroxyproline NBD-C1
37°C,
NO
N
COOH
OH
Derivatised hydroxyproline 
Diagram 2.1: Hydroxyproline Derivitisation with NBD-C1
Pre-column Derivatisation
A 150 pi aliquot of each sample hydrolysate, prepared as described above, was 
transferred to a microfiige tube and evaporated to dryness under vacuum on a sample 
concentrator (Savant Speedvac Plus AR SCI 10 AR, Life Science International, 
Basingstoke, Hampshire, UK). In order to avoid contamination during the drying 
procedure, the mouth of the tube was covered with perforated parafilm. The residue 
obtained was re-dissolved in lOOpl HPLC grade water, buffered with lOOpl 0.4 M 
potassium tetraborate (pH 9.5) (Sigma Chemical Co. Ltd, Poole, Dorset, UK) and
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reacted with 100 pi 36 mM NBD-C1 (in methanol) to a final concentration of 12 mM 
NBD-C1. NBD-Cl-derivatised amino acids are light sensitive, so the samples were 
protected from light by wrapping the microfuge tube in aluminium foil. The samples 
were incubated in a water bath at 37° C for 20 minutes, after which time the reaction was 
stopped by lowering the pH with 50 pi hydrochloric acid (1.5 M). After adding 150 pi of 
a concentrated solution of HPLC running buffer A (167 mM sodium acetate in 26% 
aqueous acetonitrile, pH 6.4), samples were filtered using an HPLC low dead volume 
filter (pore size 0.22 pm, type GV; Millipore Ltd, Watford, UK). Finally, a 100 pi 
aliquot was injected onto the HPLC column and eluted with an acetonitrile gradient as 
described below (Table 2.1).
Instrumentation and Chromatographic Conditions
Derivatised samples were separated on a Beckman System Gold HPLC system 
(Beckman Coulter, High Wycombe, Buckinghamshire, UK), with a reverse-phase 
cartridge column (LiChroCART LiChrospher 250 mm length x 4 mm diameter, 5 pm 
particle size, 100 RP-18; BDH/Merck, Lutterworth, UK) protected by a directly coupled 
pre-column (LiChrosorb, 4 mm x 4 mm, 5 pm, 100 RP-18; BDH/Merck, Lutterworth, 
UK). The columns were continuously maintained at 40° C in a heated column oven.
At the beginning of each experiment, running buffers were degassed with helium 
(BOC, London, UK), and the HPLC system equilibrated in running buffer A for 40 
minutes. The first three samples derivatised at the start of each experiment were Hyp 
standard solutions (equivalent to 50 pmol), which were then used for calibration and 
quantitation. NBD-C1 derivatives in samples and standards were eluted with an 
acetonitrile gradient which was generated by gradually changing the relative proportions
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of the running buffers, thereby increasing the concentration of acetonitrile over time. The 
chromatographic conditions employed are summarised in Table 2.1. Post-column 
detection was achieved by monitoring absorbance at 495 nm using a flow-through 
variable wavelength monitor. The signal was processed on an on-line chromatography 
computing integrator (System Gold Integrator, Beckman Coulter, High Wycombe, 
Buckinghamshire, U K ) for quantitation.
Hydroxyproline elutes from the column as a well-defined peak, between 5 and 7 
minutes after injection, between glutamine (3.5 minutes) and serine (7 to 9 minutes) and 
just prior to the mobile phase becoming predominantly organic. Remaining amino acid 
derivatives in the sample were eluted as the hydrophobicity of the organic buffer 
(acetonitrile) was increased. The total running and column regeneration time was 25 
minutes.
Quantitation of Hydroxyproline Content
Quantitation of the hydroxyproline content in each 150 pi sample injected onto 
the column was determined by comparing peak areas of chromatograms obtained for 
each sample to those generated from the three standard solutions derivatised and 
separated under identical conditions at the beginning of each experiment. All values 
were corrected for the amount of Hyp in the ethanol-insoluble fraction of the to sample, 
representing protein-bound hydroxyproline measured in the cell layer and culture 
medium at the onset of the incubation period.
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Calculation of Pro-collagen Production
Hydroxyproline measured in the ethanol-insoluble fraction (after subtraction of 
the to value) was taken to represent procollagen produced by the cells over the incubation 
period. Data is expressed as procollagen production (nmoles Hyp/105 cells/48 hours).
Column LiChrosopher, 100 RP-18,250 x 4 mm, 5 n m
Mobile phase Buffer A - aqueous acetonitrile (8 %, v/v),
50 mM sodium acetate, pH 6.4
Buffer B - aqueous acetonitrile (75% v/v)
Column Flow rate 1 . 0 0  ml/min
Column Temperature 40° C
Wavelength for Detection 495 nm
Elution Gradient Time (min) % Buffer B
0 0
5 5
6 80
1 2 80
12.5 0
25 0
Table 2.1: Conditions and Buffers for the Separation of 
Hydroxyproline by Reverse-Phase HPLC
2.7 mRNA Studies
2.7.1 Preparation of cDNA Probes
A number of the cDNA probes described in Section 2.3 had to be prepared 
for use in in vitro and in vivo studies. As an example, the methodology involved in the 
preparation of the rat PAR-1 cDNA probe is described in detail. Rat PAR-1 cDNA 
was initially, obtained subcloned into the plasmid Bluescript KS (Niclou et al, 1994)
Bacterial Transformation
A 100 fil aliquot of Escherichia coli cells, DH5a-Subcloning Efficiency strain 
(Life Technologies Ltd, Paisley, UK) were thawed on ice. Subsequently, 50 ng of 
plasmid DNA (containing an ampicillin resistance gene) was gently mixed with 
bacterial cells and incubated for 30 minutes on ice. For transformation, the cells were 
heat-shocked for 45 seconds at 42° C in a waterbath and immediately put on ice for 2 
minutes. Subsequently, 3 mis of Luria-Bertani LB broth (BDH-Merck Ltd, 
Lutterworth, UK) was added to the cells, which were then shaken for 1 hour in a 
rotating incubator (Gallenkamp, Fisher Scientific, Loughborough, UK) at 37° C at 220 
rpm.
Bacterial Culture
Cells were then streaked onto LB-agar plates (30 ml of LB-agar mix from 
BDH-Merck Ltd, Lutterworth, UK, poured into 10 cm diameter Petri dishes) 
containing ampicillin (50 /xg/ml, Sigma Chemical Co. Ltd, Poole, Dorest, UK). The 
plates were then incubated overnight at 37° C. Two ampicillin resistant colonies were 
then picked off the plates and starter cultures generated by seeding colonies into 2  ml
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LB broth (BDH-Merck Ltd, Lutterworth, UK) containing ampicillin in 14 ml snap- 
cap tubes (Vials 2059, Falcon Inc, Marathon Lab Supplies, London, UK). Cultures 
were grown for 8  hours at 37° C in an orbital-shaking incubator at 220 rpm. 
Subsequently, the cloudy 2 ml cultures were inoculated into 250 ml of LB broth 
containing ampicillin (50 /xg/ml) in a 1 litre conical flask and grown overnight in LB 
broth at 37° C in an orbital shaking-incubator at 220 rpm.
Plasmid Extraction
Initially, the bacterial culture was decanted into a 500 ml container and 
centrifuged at 6000 x g for 15 minutes at 4° C (Sorvall, UK). The supernatant was 
discarded and the DNA from the bacterial pellet was purified using a Qiagen 
Maxiprep kit following the manufacturer’s protocol (Qiagen Ltd, Crawley, UK). The 
pellet was re-suspended in 10 mis of buffer (50 mM Tris.HCl, pH 8 ; 10 mM EDTA; 
100 jLtg/ml RNAase A). The bacterial cell suspension was placed in 30 ml tubes 
(BDH/Merck, Lutterworth, UK) and plasmid DNA was liberated from cells by adding 
lysis buffer (0.2 M sodium hydroxide (NaOH), 1% sodium dodecyl sulphate (SDS)). 
SDS solubilises the cell membrane surface whereas NaOH lyses bacteria and also 
denatures chromosomal and plasmid DNA. The lysate was mixed gently and 
neutralised by addition of 10 mis potassium acetate (3 M, pH 5.5). The high salt 
concentration causes SDS to precipitate, and denatured proteins and chromosomal 
DNA become trapped in salt/SDS complexes. Since plasmid DNA is smaller, it 
renatures in solution. The lysate was loaded on a Qiagen filter cartridge, the filtrate 
collected and incubated with endotoxin removal buffer for 30 minutes. Subsequently, 
a DNA-binding column was equilibrated with buffer (750 mM sodium chloride 
(NaCl), 50 mM 3-N-morpholino propanesulfonic acid (MOPS), pH 7; 15%
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isopropanol; 0.15% Triton X-100) and the endotoxin-free lysate was added to the 
column and filtered by gravity flow. The resin containing DNA was washed and DNA 
eluted with 15 mis of a high salt buffer (1.6M NaCl; 50 mM MOPS pH 7; 15% 
isopropanol). To precipitate DNA, 10.5 mis of isopropanol was added at room 
temperature, mixed and centrifuged at 15000 x g (GS-15R Centrifuge, Beckman 
Coulter, High Wycombe, Buckinghamshire, UK). The resultant pellet was washed 
twice in 70% ethanol and re-centrifuged. The final pellet was air-dried and re­
suspended in endotoxin-free water. The concentration of plasmid in the final 
preparation was determined by ultraviolet (UV) spectrophotometry at 260 nm ( 1  
optical density unit at 260 nm = 50 /ig/ml of DNA), (Ultraspec 3000, Pharmacia 
Biotech, Buckinghamshire, UK).
Restriction Enzyme Digest o f Plasmid DNA
1 fig of plasmid DNA was digested with 1 jLtl each of the restriction enzymes 
EcoRI and Hind III for one hour at 37° C, in compatible lx  restriction enzyme buffer 
containing bovine serum albumin (all from Promega Life Science Ltd, Southampton, 
UK). The digestion products (pBluescript vector and the PAR-1 insert) were mixed 
with DNA loading buffer and separated by electrophoresis in 1 % low melting point 
agarose gel (45 V for 4 hours) containing ethidium bromide. Digestion products were 
visualised by fluorescent scanning of the gel (Fuji, FLA 3000) (see Diagram 2.2). 
Once it had been confirmed that digestion products were of the correct molecular 
weight, a larger volume digest was performed and loaded on a bigger agarose gel.
The PAR-1-encoding insert was then cut out of the agarose gel with a sterile 
scalpel. Each piece of gel containing the PAR-1 insert was melted in three times 
volume of double distilled water in a pre-weighed eppendorf tube. After analysis by
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spectrophotometry of the DNA concentration, it was adjusted to 25 ng//d. The PAR-1 
insert was then stored at -20° C and used as a template for the random primer DNA 
labelling kit (see Section 2.7.2 for further details).
Linearised
pBluescript
Vector
PAR-1 Insert
Lad Uncut Cut Uncut Cut
Diagram 2.2: Restriction Enzyme Digest of pBluescript Vector and 
Rat PAR-1 Insert with Hind III and ECOR1
(Lad = molecular weight ladder, Uncut = reaction mixture running as a 
supercoil, Cut = restriction enzyme digest)
2.7.2 Northern Blot Analysis
In the experiments of this thesis, Northern analysis was performed on 
fibroblasts cultures in vitro, lung tissue from rats and mice and human lung biopsy 
material. As a representative example, the following paragraphs describe the 
methodology of Northern analysis on fibroblast cultures in vitro, using experiments 
where the effect of UK-156406 on thrombin-induced CTGF mRNA levels in HFL-1 
was assessed. Relevant differences in methodology for samples collected from rats, 
mice and humans are highlighted in Section 2.10.3.
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Precautions taken to Prevent RNAse Activity
For all experiments involving RNA isolation, deionised water was pre-treated 
with 0.1 % (v/v) diethyl pyrocarbonate (DEPC) overnight at 37° C. The treated water 
was then autoclaved to cause breakdown and inactivation of the DEPC. All 
subsequent reagents were made using molecular biology grade chemicals (Sigma 
Chemical Co. Ltd, Poole, Dorset, UK, unless otherwise stated) with DEPC-treated 
deionised water.
RNA Isolation and Quantitation
For Northern analysis of CTGF mRNA levels in vitro, HFL-1 fibroblasts were 
seeded at 2 x 105 cells/ml in 6  cm diameter dishes in DMEM-5%NCS. Upon reaching 
visual confluence, cells were quiesced in serum-free DMEM for 16 hours and 
exposed to thrombin alone, or thrombin pre-incubated with various concentrations of 
UK-156406, (10 nM - 100 nM). After 90 minutes, the media was removed and the 
cell layer was scraped into 1 ml of TRIzol, a phenol-based reagent for single-step 
isolation of RNA from cells and tissues. Total RNA was isolated according to the 
manufacturers instructions (Gibco BRL, Paisley, UK). The homogenate was 
incubated at room temperature for 1 0  minutes, followed by the addition of 2 0 0  /d 
chloroform and centrifugation at 12,000 g for 15 minutes at 4° C. The aqueous phase 
was aspirated into a new tube and 500 [il isopropanol was added to each sample. 
Following 10 minutes of incubation at room temperature, the samples were 
centrifuged at 12,000 g for 10 minutes at 4° C. Supernatants were then discarded and 
the pellets washed with 1 ml 75% ethanol. Samples were centrifuged at 7,500 g for 5 
minutes at 4° C and the supernatants aspirated. Pellets were partially air-dried until a
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clear gel obtained and re-suspended in 50 /xl DEPC-treated water. RNA samples were 
stored at -70°C until used.
For RNA quantification, 2 /xl of each RNA sample was diluted in 500 /xl 
double distilled water. The absorbance of each sample was sequentially measured at a 
wavelength of 260 nM and 280 nM using a UV spectrophotometer (Ultraspec 3000, 
Pharmacia Biotech, Buckinghamshire, UK). The ratio of the optical density units at 
260 nM and 280 nm, was used as a gross indicator of the purity of the RNA sample. 
Ratios between 1.6 and 1.9 were considered acceptable. RNA concentration was 
calculated based on the assumption that 40 /xg of total RNA in 1 ml water gives an 
absorbance reading of 1 optical density unit at 260 nm. The volume of the RNA 
sample containing 5 /xg total RNA from fibroblast cultures was calculated and made 
up to a total volume of 10 /xl with DEPC-treated water. The samples were mixed with 
RNA loading buffer containing ethidium bromide (3 /xl) and heated to 65° C for 10 
minutes, prior to loading onto an agarose gel.
Electrophoresis and Transfer to Nylon Hybridisation Filters
To prepare a 1% agarose gel, 2 g of agarose were added to 162 ml DEPC- 
treated water and heated in a microwave. After cooling the agarose solution down to 
about 65° C, formaldehyde to 9% (v/v; about 18 ml) and 20X MOPS (0.4 M 3-N- 
morpholino-propane sulphonic acid, 32 mM sodium acetate and 4 mM EDTA; about 
20 ml, to generate a final concentration of IX MOPS), were added. The gel was then 
cast into a gel tray, containing a loading comb and left to set for 60 minutes at room 
temperature. The gel was finally submerged in running buffer (IX  MOPS).
RNA samples were loaded into the wells of the agarose gel and separated by 
electrophoresis in an electrophoresis chamber (International Biotechnologies Inc., CT,
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USA) at a constant voltage of 70 V for 2-3 hours. RNA loading and integrity was 
confirmed by the presence of the ethidium bromide stained 18S and 28S ribosomal 
RNA bands, which were visualised and quantitated by fluorescent scanning of the gel 
(Fuji, FLA 3000).
The gel was subsequently washed in DEPC-treated water for 20 minutes and 
RNA transferred to a nylon filter, (Hybond N, Amersham International, High 
Wycombe, UK) prewetted with running buffer, by overnight Northern blotting in 20X 
SSC (sodium chloride/sodium citrate solution: 175.3 g/1 NaCl, 88.4 g/1 sodium 
citrate), following established protocols (Maniatis et al, 1989). The RNA transferred 
to the filter was cross-linked using a Stratalink ultraviolet cross-linker (120,000 jJ) 
(Stratagene Europe Ltd, Cambridge, UK).
Hybridisation and Quantitation o f  Autoradiographic Signal
Nylon filters were pre-hybridised in 5X Denhardt’s solution (10 g/1 Ficoll, 10 
g/1 polyvinylpyrolidone and 10 g/1 bovine serum albumin), 5X SSC, 0.1% SDS and 
100 jitg/ml denatured salmon sperm DNA (Life Technologies Ltd, Paisley, UK) for at 
least one hour at 65° C in a rotating hybridisation oven (Bachofer, Germany). During 
this time, the CTGF cDNA probe was radiolabelled with 32P-dCTP using the 
Megaprime random priming DNA labelling kit (Pharmacia Biotech, Piscataway, NJ, 
USA) according to the manufacturers instructions. Pre-hybridisation solution was 
discarded and replaced with hybridisation solution (identical to pre-hybridisation 
solution, without salmon sperm DNA). The radiolabelled CTGF cDNA probe was 
added to the hybridisation solution and the filter incubated overnight at 65° C.
At the end of the incubation period, the filter was rinsed at low stringency (2 x 
SSC, 0.1% SDS, for 5 minutes at room temperature), at medium stringency (0.5 x
SSC, 0.1% SDS, for 25 minutes at 65° C) and at high stringency (0.1 x SSC, 0.1% 
SDS, for 5 minutes at 65° C). Filters were wrapped in clingfilm, and exposed to a 
phosphorimage storage screen (Fuji) for 2-4 hours. *
CTGF mRNA levels were quantitated using a phosphorimager (Fuji FLA 
3000) linked to Aida v2.00 image-analysis software (Raytest Isotopenmessgarate 
GmbH, Germany). Phosphorescence values of the signal representing the bands for 
the mRNAs were normalised relative to the loading of total RNA in the same sample. 
This was determined by comparing the signal to the scanned ethidium bromide 
stained 18S or 28S ribosomal RNA bands in the agarose gel.
* In experiments assessing PAR-1 mRNA levels in cultured primary rat lung 
fibroblasts, filters were washed four times in 4X SSC. 0.1% SDS, for 25 minutes at 
55° C and exposed to phosphorimage storage screen for 12 hours, prior to 
quantitation.
2.8 Immunocvtochemistry
Primary cultures of rat lung fibroblasts were assessed for the presence of PAR- 
1 receptors by immunocytochemistry. Subconfluent cells were plated into 8-well 
tissue culture chamber slides (Nunc, Life Technologies, Paisley, Scotland, UK), (5000 
cells in 300pl of DMEM containing 5% NCS. Cells were allowed to attach for 24 
hours and then quiesced in serum-free media for a further 24 hours. The media was 
removed and the cell layer washed three times with PBS. Cells were fixed in 4% 
paraformaldehyde for 30 minutes. Following fixation, the cell layer was washed again 
with PBS and then incubated with non-antigenic swine serum (4%) diluted in PBS,
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for 30 minutes at room temperature. This was subsequently removed and cells were 
incubated with a rabbit-anti-rat PAR-1 primary antibody (SFFL) at room temperature 
for three hours.
Conditions for primary antibody incubation were varied to optimise specificity 
of staining. Antibodies were used at the following concentrations: neat antibody, 1:25, 
1:50, 1:75, 1:100, 1:200, 1:500 and 1:1000, diluted in PBS. For final experiments, a 
concentration of 1:25 proved to be optimal. Sub-type specific rabbit IgG at an equal 
concentration (Sigma Chemical Company Ltd, Poole, Dorset, UK) served as a control 
primary antibody. Cells were washed a further three times in PBS and then incubated 
with a FITC-conjugated swine-anti rabbit secondary antibody (Sigma, UK) at a 1:50 
dilution in PBS, for 1 hour at room temperature. Cells were washed again in PBS, the 
wells removed and glass cover slips mounted using citiflour/glycerol mounting 
medium. Cells were viewed via immunoflourescent microscopy (Zeiss).
2.9 The Bleomycin Model of Pulmonary Fibrosis
2.9.1 Animals
Rats and mice were both used in the experiments of this thesis. All animals 
were kept at the Central Biological Services Facility, University College London. 
Animals were housed in cages (4 per cage for rats, 6 per cage for mice after weaning), 
on wood shavings, with free access to food and tap water (12 h light/dark cycle, 
normal sodium dry fishmeal diet, temperature 18-20° C). All studies were performed 
in accordance with The Home Office Animals (Scientific Procedures) Act (HMSO,
1986). Animals were weighed prior to investigation and then daily, for the duration of
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experiments. Many of the procedures and techniques carried out in rats and mice were 
similar and are described together in the following methods.
Male Lewis rats
Male Lewis rats aged 6-8 weeks and weighing 150-200 g were purchased from 
Harlan (UK). Rats were purchased at least one week prior to the start of experiments 
and housed in the Central Facility, in order for animals to acclimatise.
PAR-1 v' and Wild-Type Mice
PAR-1 _/* mice (strain C57BL/6-129/Sv) were originally generated in Prof S 
Coughlin's laboratory, UCSF (Connolly et al, 1996). Murine PAR-1 has a two-exon 
genomic structure in which the first exon encodes 5'-untranslated sequence and signal 
peptide, and the second exon encodes the mature receptor protein and 3'-untranslated 
sequence. Connolly and colleagues constructed a targeting vector for the PAR-1 gene 
containing the phosphoglycerate kinase (PGK)-Neo cassette (neomycin resistance 
gene), from the plasmid pPNT. The PAR-1 gene was disrupted by insertion of the 
PGK-Neo cassette between two restriction enzyme sites in exon 2, thus replacing the 
segment of the gene encoding transmembrane domains 1-7 of the receptor.
The DNA construct containing the disrupted gene was electroporated into RF8 
embryonic stem cells, which were cultured. Following homologous recombination, 
targeted embryonic stem cell clones were selected for neomycin resistance and 
microinjected into mouse blastocysts. The resultant chimeras were bred with 
C57BL/6-129/Sv mice to establish germline transmission. These mice were 
extensively backcrossed (>97%) onto the C57BL/6 background (Cunningham et al, 
2000) and homozygous-breeding pairs of this strain of PAR-1 'A mice were provided
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as a result of a collaboration initiated with Dr Peter Tipping (Monash, Australia) and 
used in the experiments of this thesis. Mice were initially bred in filter cages until 
infection control screening had been completed. Selected weaned offspring from 
initial litters were subsequently inter-bred, such that 6 healthy breeding pairs of PAR- 
1 ''' mice were eventually generated. Breeding pairs of C57BL/6J wild-type control 
mice were bred in the same conditions as PAR-1 v' mice. Weaned offspring from 
PAR-1 ''' and wild-type mice that were not used for inter-breeding, were used in 
experiments once they were 6-8 weeks old.
2.9.2 Genotyping of P A R - 1 a n d  Wild-Type Mice 
Extraction and Purification of DNA
PAR-1 transgenic breeding pairs that were shipped from Monash, Australia 
were documented as homozygote for the deficient receptor. However, to confirm that 
there had been no unforeseen mixing of mice prior to transfer, experiments were 
conducted on the progeny to verify the genotype of these animals. Genotype of PAR- 
1 ''' and wild-type mice was assessed, by performing polymerase chain reaction (PCR) 
analysis on double-stranded DNA (ds DNA) extracted from liver tissue.
Liver tissue, kept frozen in liquid nitrogen, was crushed to a fine powder using 
a pestle and mortar. 2-3 mg of tissue was placed in a 1.5 ml eppendorf tube and 
immediately mixed with 500 /xl lysis buffer (1 M Tris 5% v/v, 5 M NaCl 4% v/v, 0.5 
EDTA 20%, 1% SDS in H2O), before adding 10 /xl of fresh proteinase K (50 mg/ml in 
water). The lysis reaction mixture was incubated at 55°C in a rotating waterbath 
overnight. Samples were centrifuged at 12000 x g for five minutes, the supernatant 
removed and placed in an eppendorf. A further 500 /xl lysis buffer was added to the 
pellet, which was re-suspended prior to re-centrifugation at 12000 x g for five
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minutes. The supernatant was combined with that removed after initial centrifugation 
and DNA precipitated by addition of 750 fi\ of isopropanol. The resultant pellet was 
washed in ethanol (70%) and allowed to air-dry. Once dry, pellets were re-suspended 
in water and allowed to stand at room temperature overnight. DNA was quantified as 
described in Section 2.7.1 and diluted to a concentration of 10 ng/ml, prior to 
genotyping.
For PCR analysis of PAR-1 ''' and wild-type mice, two primers to the inserted 
PGK-Neo cassette (oIMR013, oIMR014) and two to genomic sequence outside the 
2.0-kb 5’ flanking sequence in the targeting vector (oIMR578, oIMR579) were used. 
The cycling protocol is shown in Table 2.2 which gave rise to PCR reaction products, 
which were loaded onto a 1.5% agarose gel containing ethidium bromide. The gel was 
run for 30 minutes at 150 volts. Fluorescent scanning of the gel (Fuji, FLA 3000) 
showed bands corresponding to a 545 base pair (bp) product for wild-type mice and a 
smaller 280 bp product for PAR-1'/_ mice (please see Figure 3.4.2).
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Reaction Mix Vol. per rxn [working] Cycling
h2o 3.03 QS to 12 ^l 1) 94C 3min
10 X PE Bufferll 0.96 0.8 X 2) 94C 35sec
25mM MgCI2 0.96 2mM 3) 64C 45sec
2.5 mM dNTP 0.96 0.2 mM * - 0.5C per cycle
20 jjM olMR 013 0.45 0.75 jj,M 4) 72C 45sec
20 jjM olMR 014 0.45 0.75pM 5) Goto 2,12 times
20 j^ M olMR 578 0.75 0.8 ^M 6) 94C 35sec
20 jjM olMR 579 0.75 o 00 T 7) 58C 30sec
DNA loading dye 1.66 . 138|j,l/jj,ITV 8) 72C 45sec
5 U/^l Taq Pol. 0.03 0.0125 U/yl 9) Goto 6, 25 times
DNA (2 jJ per Rxn)
10
2
10) 72C
11)10C
2min
12
OIMR578 5 ’-gAT TgT gTT CAT TgT CAg CCT TCC-3’ Cf2r (JR2862) wild type primer 
OIMR579 5’-ACg TgT AgC AgA CCg Tgg AAA C -3’ Cf2r (JR2862) wild type primer 
OIMR013 5'- CTT GGG TGG AGA GGC TAT TC -3' N eo l generic neo primer 
OIMR014 5'- AGG TGA GAT GAC AGG AGA TC -3' N eo2 generic neo primer
Table 2.2: PCR Protocol for PAR-1"/_ and Wild-Type Mice
Individual samples of DNA (2 fil) from PAR-1 'A and wild-type mice were mixed 
with water and covered with mineral oil, prior to additon of the PCR reaction 
mixture in the working concentrations shown above. On completion of the 
reaction (cycling), the reaction products were analysed on a 1.5% agarose gel 
containing ethidium bromide.
PE = Perkins Elmer Buffer (Applied Biosystems, California, USA), rxn = 
reaction, MgCl2 = magnesium chloride.
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2.9.3 Bleomycin Instillation
Bleomycin is an antineoplastic antibiotic isolated from a strain of the bacteria 
Streptomyces verticillus. Bleomycin is thought to induce lung injury by a number of 
mechanisms since it binds iron and DNA in the presence of molecular oxygen. This 
complex is then reduced by a number of compounds including superoxide to a ferric 
or activated bleomycin complex, which damages DNA (Hay et al, 1991). It is also 
proposed that bleomycin may cause lung damage by affecting lipid peroxidation and 
interacting with specific cellular receptors (Ekimoto et al, 1985).
Bleomycin is inactivated by the enzyme bleomycin hydrolase, which is 
primarily located in the liver and kidneys. There is a paucity of the enzyme in the 
lungs, which may explain the toxic effects of bleomycin in pulmonary tissue. 
Bleomycin has been used to induce the rapid onset of acute lung injury and 
subsequent fibrosis in a variety of animal species, including the rat and mouse 
(Mutsaers et al, 1998, Shahzeidi et al 1991). It has been delivered in a number of 
ways including via the intratracheal (Laurent et al, 1983), intraperitoneal (Adamson et 
al 1974), subcutaneous (Adamson et al, 1974) and intravenous (Adamson et al, 1977) 
routes.
In the experiments of this thesis, bleomycin was delivered by intratracheal 
instillation to ensure adequate delivery to the lung under direct visualisation. In 
addition, this method of delivery rapidly induces pulmonary fibrosis with a clear 
initiation time of lung injury. Finally, considerable expertise had been demonstrated 
for this method in the host laboratory (Mutsaers et al, 1998). Bleomycin sulphate is a 
lyophilised photosensitive powder and was therefore stored in the dark at 4°C prior to 
use. A fresh vial of bleomycin was reconstituted in 0.9% saline, according to the dose 
required (see paragraph below) for each experiment.
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Male Lewis rats were anaesthetised by intramuscular injection of 0.75-1.0 
ml/kg Hypnorm (fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml; Janssen Phar­
maceutical, High Wycombe, UK). PAR-1 'A and wild-type mice were anaesthetised in 
halothane (3.5 1/min) and oxygen (2 1/min). For both species, the neck area was 
shaved, cleaned and the trachea exposed by ventral incision and cannulated. For rats, 
bleomycin was administered by a single intra-tracheal injection via a 24-gauge 
venflon (1.5 mg/kg body weight in 0.3 ml sterile saline), whereas control animals 
received 0.3 ml saline alone. For mice, bleomycin (1 mg/kg body weight in 45 ji\ 
saline) was administered by a single intra-tracheal injection via a standard insulin 
syringe. Control mice received a similar volume of saline.
Immediately after instillation, rats and mice were positioned ‘head-up’ to 
minimise reflux into the upper airways. The dermal incision was closed with Michel 
clips and animals were placed prone in a heated cage and allowed to recover, prior to 
return to their cages. Animals were subsequently allowed free access to food and 
water for the duration of experiments.
2.9.4 Administration of UK-156406 in Male Lewis Rats
UK-156406 was administered continuously via osmotic minipumps (Alzet, 
Palo Alto, California, USA) implanted subcutaneously, 24 hours prior to bleomycin 
instillation. This parenteral route of administration was chosen as UK-156406 only 
has a half-life of one hour.
UK-156406 was delivered at a range of doses (0.33-1.5 mg/kg/hour). Each 
osmotic minipump delivers 2 mis of reconstituted drug or saline over a 14 day time 
period (2ML2, Alzet, Palo Alto, California, USA). The following calculation was
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used to determine the amount of UK-156406 (mg) required per minipump for each 14 
day experiment:
Drug dose (mg/kg) x ra t weight (kg) x 24 (hours in day) x 14 (days)
UK-1560406 was reconstituted in 2 mis 0.9% sterile saline and the drug was 
slowly introduced into the minipump via an 18-gauge needle. Minipumps containing 
2 mis sterile saline were prepared for control rats receiving drug vehicle alone.
To insert minipumps, rats were anaesthetised as above, the flank shaved and a
1.5 cm incision made to expose the subcutaneous space over the lateral aspect of the 
thorax. The minipump was gently inserted taking great care to limit trauma to the 
subcutaneous tissue. The incision was closed with Michel clips and animals were 
allowed to fully recover, prior to instillation of bleomycin, 24 hours later.
2.9.5 Experimental Groups
For each in vivo experiment, experimental groups were divided as shown in 
Table 2.3. A number of different parameters were analysed in rats and mice following 
bleomycin instillation. The minimum number of dedicated animals per experimental 
group for analysis of these various parameters was: lung collagen («=6), lung 
histology and immunohistochemistry (n=4), mRNA studies (n=6), BALF analysis 
(«=6), blood coagulation levels («=6).
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Intratracheal Osmotic
Instillation Minipump
Saline Saline
Saline UK-156406
Bleomycin Saline
Bleomycin UK-156406
Intratracheal Mouse
Instillation Strain
Saline Wild-Type
Saline PAR-1
Bleomycin Wild-Type
Bleomycin PAR-1
(a) Male Lewis Rats (b) PAR-1 and Wild-Type Mice
Table 2.3: Experimental Groups for in vivo experiments
2.10 Analysis of Tissue Following Bleomycin-Induced Lung Injury
2.10.1 Recovery of Tissue for Analysis
After 3, 6, 14 or 21 days following bleomycin or saline instillation rats and 
mice were given an injection of intraperitoneal pentobarbitone (0.6mls and 0.1ml 
respectively). Under deep anaesthesia, the abdominal cavity was opened, the aorta 
severed, and animals exsanguinated, apart from in rats where coagulation parameters 
were measured. In this case, blood was collected from the inferior vena cava 
following laparotomy and was immediately mixed, 10:1 with a solution of 3.8% 
trisodium citrate (w/v) and the aorta severed thereafter.
For mRNA analysis, the thoracic cavity was opened and lungs were carefully 
removed with sterile forceps, taking care to avoid contact with animal fur, which is 
rich in RNAses. Lungs were immediately snap-frozen in liquid nitrogen.
For assessment of total lung collagen, histological and immunohistochemical 
analysis, the thoracic cavity was opened and the lungs were perfused with 10 mis 
(rats) or 3 mis (mice) 0.9% saline respectively, via the inferior vena cava using a 22- 
gauge cannula. Great care was taken to avoid undue force to minimise artefactual
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damage to the pulmonary circulation. At this stage, for assessment of total lung 
collagen, lungs were removed from the thoracic cavity, blotted dry and the trachea 
and major airways removed. Lungs were weighed before being snap-frozen in liquid 
N2.
Lungs for histological and immunohistochemical analysis underwent a further 
fixation stage following perfusion. The trachea was cannulated via an 18-gauge 
cannula (24-gauge in mice) and lungs were fixed by intratracheal instillation of 
freshly prepared 4% paraformaldehyde in normal saline at a pressure of 25 cm H20 . 
Again, care was taken to avoid forceful instillation. Instillation was continued until no 
further flow was observed and the lungs had fully expanded on visual examination. 
The trachea was ligated and the inflated lungs and heart removed en bloc. After 4 
hours immersion in fresh fixative, lungs were transferred to 15% sucrose in PBS and 
left overnight at 4°C.
Finally, for BALF analysis, following exsanguination, a ventral incision was 
made in the midline from the neck to the diaphragm to allow cannulation of the 
trachea and instillation of normal saline by gentle lavage. Saline was gently instilled 
via an 18-gauge cannula in 5 ml aliquots (24-gauge; 0.5 ml in mice) over 15 seconds, 
left in situ for 30 seconds, and withdrawn over 15 seconds and stored in 
polypropylene tubes on ice. The procedure was repeated five times and greater than 
90% of the total instillate was recovered following lavage. BALF was centrifuged at 
300 x g for five minutes at 4°C (Beckman Coulter, High Wycombe, UK). The 
supernatant was removed and stored at -70°C, prior to analysis of thrombin levels and 
BALF total protein. The cell pellet was immediately re-suspended in TRIzol for 
Northern analysis or in DMEM for cytological analysis.
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2.10.2 Assessment of Blood Clotting Parameters in Rat Plasma
Following collection of blood from rats, plasma was prepared by 
centrifugation of citrated blood samples at 2000 x g for 15 minutes. The supernatant 
was carefully pipetted off taking care not to disturb the buffy coat. The plasma mean 
activated partial thromboplastin time (APTT) and the mean prothrombin time (PT) 
were assessed using Actin FS and Thromboplastin IS (Dade Behring, Marburg, 
Germany), respectively. Parameters were measured in duplicate using a mechanical 
KC-4A coagulometer (Amelung, Lemgo, Germany) in the Department of 
Haemastasis, University College London.
2.10.3 Northern Analysis of Lung Tissue
Northern analysis of total cellular RNA was performed on snap-frozen rat and 
mouse lung tissue, rat BALF inflammatory cells and human lung biopsy material, using 
a variety of cDNA probes. Rat, mouse and human lung tissue were crushed to a fine 
powder using a pestle and mortar on dry ice and kept frozen by addition of liquid 
nitrogen. Total RNA was isolated using 1 ml TRIzol per 100 mg lung tissue. Total 
RNA was isolated from BALF inflammatory cells by addition of 1 ml TRIzol to the 
cell pellet obtained following centrifugation (see Section 2.10.1). Following RNA 
extraction from the various tissue sources, five pg of total RNA from individual 
samples was mixed with RNA loading buffer containing ethidium bromide, heated to 
65°C for 10 minutes and electrophoresed on a formaldehyde 1% (w/v) agarose gel (as 
described in Section 2.7.2).
Following electrophoresis, transfer of RNA to nylon filters and hybridisation 
with cDNA probes, membranes probed for CTGF and FISP12 were rinsed at low 
stringency (2 x SSC, 0.1% SDS, for 5 minutes at room temperature), once at medium
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stringency (0.5 x SSC, 0.1% SDS, for 25 minutes at 65° C) and once at high 
stringency (0.1 x SSC, 0.1% SDS, for 5 minutes at 65° C). Membranes probed for 
ai(I) procollagen were rinsed at low stringency (2 x SSC, 0.1% SDS, 5 minutes at room 
temperature, followed by 20 minutes at 65° C) and high stringency (0.1 x SSC, 0.1% 
SDS for 20 minutes at 65° C). Membranes probed for human or rat PAR-1 were 
washed four times in 4X SSC. 0.1% SDS, for 25 minutes, at 55° C. All membranes 
were exposed to phosphorimage storage screens (Fuji); (2-4 hours for CTGF, FISP-12 
and ai(I) procollagen, 12 hours for PAR-1). Finally, mRNA levels were quantitated by 
phosphorimage analysis (Fuji FLA 3000), as described in Section 2.7.2.
2.10.4 Preparation of Lung Tissue for HPLC Analysis
For measurement of total lung collagen in vivo, snap-frozen lung tissue was 
crushed in a pestle and mortar in liquid nitrogen. Accurately weighed aliquots of 
powdered lung (approximately 100 mg for rats, 10 mg for mice) were hydrolysed in 3 
mis 6 M HC1 at 110°C for 16 hours. Hydrolysates were decolourised with charcoal, 
filtered and diluted 1:100. 150 pi aliquots were dried down by centrifugal vacuum 
concentration and prepared for HPLC analysis as described in Section 2.6.5. The total 
amount of collagen in each lung was calculated, assuming that lung collagen contains
12.2 % w/w hydroxyproline (Laurent et al, 1981) and results were expressed as total 
lung collagen (mg).
2.10.5 Preparation of Lung Tissue for Histology
Following immersion in 4% paraformaldehyde and 15% sucrose as described in 
Section 2.10.1, samples from each individual lobe of rat and mouse lungs were carefully
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dissected and the combined specimens from each lung were encased in plastic 
fenestrated mounts. The mounts were dehydrated in 50% ethanol, 70% ethanol, 80% 
ethanol, 90% ethanol, 100% ethanol and xylene, before embedding in paraffin wax. 
Lung tissue sections, 5 /mi thick were prepared using a microtome, placed on slides and 
baked overnight at 40°C, prior to staining with Massons trichrome.
Histological sections were initially dewaxed in xylene, rehydrated through 
decreasing concentrations of ethanol, and washed in PBS. Sections were subsequently 
stained for ten seconds in celestine blue solution (0.5% celestine blue (Sigma), 5% 
w/v ferric ammonium sulphate (Sigma), both in water, glycerin (Sigma) 14% v/v). 
Sections were then immersed for 10 seconds in Mayers haematoxylin (BDH/Merck) 
and for six minutes in 1% w/v ponceau red (BDH/Merck) in water. Sections were 
then decolourised in 1% w/v phosphomolybdic acid (Sigma) in water, prior to 
counter-staining with 0.5% v/w soluble methyl blue (Sigma) in 2.5% v/v acetic acid 
in water. After staining, sections were dehydrated through increasing concentrations 
of ethanol and xylene, prior to mounting in DPX (Merck, Poole, UK).
Histological changes in lung tissue sections from both rats and mice were both 
assessed using the Ashcroft scoring system (Ashcroft et al, 1988), Table 2.4. The 
Ashcroft system describes the histological evolution of lung fibrosis (viewed by light 
microscopy) and scores it numerically, ranging from normal lung (0) to complete fibrous 
obliteration (8). There are also specific histological descriptions between these 
parameters with defined scores (odd numbers, 1,3,5,7). If an observer assessed that the 
field of view represented an intermediate between these descriptions, the field was 
scored using even numbers (2,4,6). For rats, two independent observers blindly 
examined 25 fields (magnification x 400) per animal using an Olympus BX40 light 
microscope. A mean fibrosis score was determined for each animal and treatment groups
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were compared. For mice, two independent observers examined all five lung lobes, 
using light microscopy (x400), in order to determine a fibrosis score for each lobe. The 
mean Ashcroft fibrosis score was calculated as the average of the individual lobe fibrosis 
scores.
Lung histology for PAR-1 'A and wild-type mice following bleomycin 
instillation, was also compared using semi-quantitative image-analysis, to evaluate the 
percentage of new collagen content per lobe. This was performed using a JVC KY55B 
three chip camera and Kontron 3000 software. A function of the software is the ability to 
identify colour intensity by three-colour segmentation (thresholding). After scanning all 
lung tissue sections, the colour intensity taken to represent new lung collagen following 
bleomycin instillation was decided, and defined thresholds set. Lungs from treatment 
groups were evaluated by applying these defined thresholds and also using routine 
image-analysis criteria, including standardised fight intensity and microscope settings. 
Individual lobes of mouse lung were examined blind at a magnification of x 200 using 
an Olympus BX40 microscope. Fields were examined to cover the entirety of each lobe 
and were discarded if non-representative areas such as airway lumen occupied greater 
than 50% of the field of view. Two -  thirty five fields of vision were analysed for each 
lobe, depending on the size. This variance existed since the lobes of the mouse lung vary 
hugely in size from the very small cardiac lobe, to the left lobe, which effectively 
represents the whole of the left lung. The percentage area of new collagen was computed 
for each field, mean percentages of new collagen per lobe calculated and treatment 
groups compared.
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Grade Histological Features
0 Normal lung
1 Minimal fibrous thickening of 
alveolar/bronchial walls
2
3 Moderate thickening of walls without 
obvious damage to lung architecture
4
5 Increased fibrosis with definite damage to 
lung structure and formation of fibrous 
bands
6
7 Severe distortion of structure and large 
fibrous areas
8 Total fibrous obliteration of field
Table 2.4: Ashcroft Fibrosis Scoring
Histological changes in lung tissue sections from rats and mice were both 
assessed using the Ashcroft scoring system to determine mean fibrosis scores.
2.10.6 Immunohistochemical Localisation of Thrombin and PAR-1
Immunohistochemistry for thrombin and PAR-1 was performed on rat lung 
tissue, which was prepared using the same method as described in Section 2.10.5. 
Five pm thick transverse and longitudinal sections of lung tissue, were cut and 
mounted on glass slides. Sections were dewaxed in xylene, rehydrated through 
decreasing concentrations of ethanol, and washed in PBS. Tissue endogenous 
peroxidase activity was blocked by incubating sections with 3% hydrogen peroxide 
(Sigma, UK) for 3 minutes. Sections were washed three times for 5 minutes in PBS 
and incubated with normal goat serum (DAKO, High Wycombe, UK) (1:50 dilution) 
for 20 minutes. Active thrombin in lung sections was localised by incubating sections 
with recombinant hirudin (Sigma, UK) (1:50 dilution), followed by a purified rabbit 
anti-hirudin antibody (American Diagnostica, Greenwich, Connecticut, USA) (1:1200
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dilution) for one hour each at 37°C (please see Diagram 2.3). Hirudin is highly 
specific for the detection of active thrombin and does not bind to prothrombin.
For immunohistochemical localisation of PAR-1, sections were incubated with 
rabbit anti-rat PAR-1 primary antibodies (SFFL, 1:1000) for three hours at room 
temperature. After three 5 minute washes in PBS, all tissue sections were incubated 
with a biotinylated goat anti-rabbit secondary antibody (DAKO, High Wycombe, UK) 
(1:300 dilution) for 60 minutes at room temperature and similarly washed in PBS. 
Sections were incubated with a streptavidin/peroxidase complex (DAKO, High 
Wycombe, UK) (1:300 dilution) for a further 60 minutes, followed by a solution of 
600 /xg/ml 3,3’-diaminobenzidine (DAB, Sigma) and 0.03% hydrogen peroxide for 3 
minutes. Sections were washed, counterstained with Mayers haematoxylin 
(BDH/Merck), dehydrated and mounted with DPX mountant (Merck, Poole, UK). 
Control sections were incubated with normal goat serum or an isotype-specific rabbit 
IgG primary antibody (DAKO, High Wycombe, UK) instead of the primary antibody.
PAR-1 expression was also examined in rat BALF which was isolated and 
centrifuged as described in Section 2.10.1. Cell pellets were suspended in DMEM and 
cytospins were prepared by centrifuging 100 fi\ aliquots of the cell suspension for 3 
minutes at 450 rpm (Cytospin 2, Shandon, Southern Products Ltd, Cheshire, UK). 
Slides with adherent cells (cytospins) were allowed to air dry before 
immunocytochemistry for PAR-1 was performed, using the same method as described 
above. Expression of PAR-1 in human lung biopsy material was also assessed using 
this immunohistochemical protocol, but tissue sections were incubated with a rabbit 
anti-human PAR-1 primary antibody (SFLL, 1:1000), rather than a rat-specific 
primary antibody.
130
Streptavidin/HRP Complex 
& 3 ,3  - Diaminobenzidine
r-Hirudin
Thrombin
Active Site
anti r-Hirudn AB
Biotinylated 2  #AB
Diagram 2.3: Detection of Active Thrombin in Lung Tissue by Hirudin Binding
Active thrombin in lung sections was localised by incubating sections with 
recombinant hirudin, followed by a purified rabbit anti-hirudin antibody. Sections 
were incubated with an anti-rabbit secondary antibody followed by a solution of 
DAB, which elaborated a brown reaction product.
2.10.7 BALF Analysis 
BALF Thrombin Levels
Following isolation using the method described in Section 2.10.1, rat BALF 
supernatant was centrifuged at 2000 x g for 10 minutes at 4°C and thrombin levels 
were estimated using a previously described spectrophotometric assay (Idell et al,
1987). Initially, a thrombin standard curve was generated by diluting stock thrombin 
(lU/ml; certified value 0.32 mg/lOOOU) with 0.05 M Tris, 0.1 M NaCl (pH 7.35) buffer 
solution. Aliquots (100 pi) of each diluted sample, were pipetted into 96-well 
microplates, mixed with a further 50 pi of Tris buffer solution and warmed to 37°C for 
two minutes. Subsequently, 50 pi of the chromphore S2238 (1 mM; H-D-Phenylalanyl-
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L-pipecolyl-L-arginine-p-nitroaniline dihydrochloride, Chromogenix, Quadratech, 
Surrey, UK) was added to each sample and incubated at 37°C. Thrombin converts this 
chromophore into the chromogen, p-nitroaniline (pNA). The change in colour is detected 
spectrophotometrically and is directly proportional to thrombin proteolytic activity.
H-D-Phe-Pip-Arg-pNA 2>1°C 
 ► 
H-D-Phe-Pip-Arg-OH + pNA
Absorbance was serially read on a spectrophotometer at 405 nM every two 
minutes for one hour, until the reaction being was stopped by adding 100 /xl citric acid 
(1 M). The absorbance in each diluted thrombin sample was plotted graphically 
against time and the optimal standard curve was chosen, by selecting the thrombin 
concentration that demonstrated the steadiest rate of change in absorbance over the 
time course (Diagram 2.4). The rate of change in absorbance for this sample was then 
calculated, over the most linear part of the graph.
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Diagram 2.4: Thrombin Standard Curve
Aliquots (100 /xl) from each unconcentrated BALF supernatant were then 
incubated with Tris buffer and S2238, using the same method as above. At the end of 
the reaction, the rate of change in absorbance for each sample was calculated. BALF 
thrombin levels (ng/ml) were derived by comparing each absorbance with the rate of 
change in absorbance of the sample selected for the thrombin standard curve. Since 
this sample had a certified value of 0.32 mg thrombin/1000 U (320 ng/ml), BALF 
thrombin levels were calculated:
BALF Thrombin Levels = rate of change of absorbance (BALF) x 320 
rate of change of absorbance (Thrombin standard)
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The physiological concentration of BALF thrombin levels was also calculated, 
based on the molecular weight of thrombin (37,000). The mean BALF thrombin level 
following bleomycin instillation was 2.8 ng/ml (see Results Section 3.2.1) which 
represented a mean BALF thrombin concentration of approximately 75 nM.
BALF Total Protein
Total protein was assayed in BALF supernatant from rats and mice using a 
bicinchoninic acid (BCA) protein assay (Pierce, USA). This assay combines the 
reduction of Cu2+ to Cu1+ by protein in the presence of an alkaline medium (biuret 
reaction) with the colourimetric detection of Cu1+ ions, using BCA. The purple 
reaction product of this assay is formed by the chelation of two molecules of BCA 
with one Cu1+ ion. This water-soluble complex exhibits a strong absorbance that can 
be detected spectrophotometrically at 562 nm. The absorbance is linear with 
increasing protein concentration over a working range from 20 jLtg/ml to 2000 /zg/ml.
BCA working reagent (WR) was prepared by mixing 50 parts BCA reagent A 
with 1 part BCA reagent B (both reagents provided by manufacturers). Protein 
standard solutions of concentrations ranging from 20 /xg/ml to 2000 fig/ml were 
prepared by diluting a stock concentration of bovine serum albumin (2 mg/ml) in 
normal saline. 100 /xl of each standard solution and each BALF sample to be 
analysed, were pippeted into 15 ml plastic tubes. WR (2 ml) was added to each 
sample and the samples vortexed. Samples were incubated at 37°C for 30 minutes 
then cooled at room temperature. 50 jd of each standard protein solution and each 
BALF sample were then pipetted into 96-microwell plates (in triplicate) and the 
absorbance of each well measured spectrophotometrically at 562 nm. Using the 
absorbancies from samples of known protein concentration, a standard curve was
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generated (Diagram 2.5). By comparing the absorbancies from BALF samples 
standard curve, BALF protein concentration was determined.
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Diagram 2.5: Standard Curve for BCA Protein Assay
BALF Total Cell Number and Differential Cell Counts
Following BALF centrifugation and generation of a single cell suspension in 
DMEM (Section 2.10.1), BALF total cell number in rats and mice was calculated by 
direct cell counting using a standard haemocytometer. Cytospins of the single cell 
suspension were also prepared (as described in Section 2.10.6) which were stained 
with Diffquik Stain (Dade Behring, Dudingen, Switzerland). Two blinded 
investigators, who counted a minimum of 500 cells per slide, carried out differential 
cell counts of the slides. Cells were identified as macrophage/monocytes, neutrophils
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or lymphocytes and data was expressed as a percentage of the total number of 
lavageable cells.
2.11 Statistical Analysis
All data are presented as means ± standard error of the mean (SEM) for 6 
replicates, unless otherwise indicated. Statistical evaluation was performed using an 
unpaired Students t-test for single, and ANOVA for multiple group comparisons. A p  
value less than 0.05 was considered significant.
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Chapter 3
Results
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Overview
The results of experiments conducted in this thesis are presented in a number 
of sections. The first section shows the effect of the direct thrombin inhibitor, UK- 
156046 on thrombin-induced fibroblast responses, in vitro. The second section shows 
the characterisation of thrombin and PAR-1 in the bleomycin model of pulmonary 
fibrosis in male Lewis rats. In the third section, the effect of UK-156406 in 
bleomycin-induced pulmonary fibrosis in vivo is presented. The final section shows 
the effect of bleomycin instillation in PAR-1 knockout mice (PAR-1 "/") versus wild- 
type mice.
3.1 Effect of UK-156406 on Thrombin-Induced Fibroblast Responses 
in vitro
3.1.1 Effect of UK-156406 on Thrombin-Induced Fibroblast Proliferation in vitro
Thrombin is known to stimulate fibroblast proliferation, procollagen 
production and CTGF mRNA levels in vitro (Chambers et al, 1998, 2000). The effect 
of UK-156406 was therefore evaluated against these fibroblast responses, in three 
separate assays. For these experiments, human fetal lung fibroblasts (HFL-1) were 
utilised, since this cell line had been extremely well characterised in the host 
laboratory, and had been previously used to establish the effect of thrombin on the 
fibroblast responses described above. It was therefore decided that this was an ideal 
cell line for the initial experiments of this thesis to be conducted in.
Figure 3.1.1 shows a representative experiment for the effect of UK-156406 
on HFL-1 proliferation in response to thrombin (10 nM), using a spectrophotometric 
assay based on uptake and subsequent elution of the dye methylene blue, according to 
the method described by Oliver et al (1989). The concentration of thrombin used
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(lOnM) was chosen since it had previously been shown to stimulate fibroblast 
responses reproducibly, in this assay, (K Dabbagh, PhD thesis, 1997). Prior to 
addition to cell cultures, UK-156406 was pre-incubated with human a-thrombin at a 
range of concentrations (10 nM - 1 pM) in serum-free DMEM for 60 minutes at 37°C. 
To examine the effects of thrombin alone, the protease was similarly pre-incubated in 
serum-free DMEM under the same conditions.
The results are expressed as % cell proliferation above media control levels for 
six replicate cultures. In the experiment presented, thrombin stimulated fibroblast 
proliferation in serum-free conditions, assessed after 48 hours, by 72% ± 5%, relative 
to media control cells (p<0.01). This response to thrombin was inhibited by UK- 
156406 in a dose-dependent manner from equimolar concentration onwards (p<0.05), 
and was completely blocked when UK-156406 was added in 10-fold excess (p<0.01). 
Although UK-156406 is extremely potent with a dissociation constant (Ki) of 0.39 
nM, it is also a reversible inhibitor of thrombin proteolytic activity, which is the likely 
explanation behind the excess concentration required to block thrombin-induced 
fibroblast proliferation completely. Finally, UK-156406 had no effect on basal 
fibroblast proliferation at concentrations up to 1 pM. The results obtained are 
representative of three separate experiments performed, (see Appendix, Table 3.1.1).
3.1.2 Effect of UK-156406 on Thrombin-Induced Fibroblast Procollagen 
Production in vitro
Figure 3.1.2 shows a representative experiment for the effect of UK-156406 
on human fetal lung fibroblast (HFL-1) procollagen production, in response to an 
optimal concentration of thrombin (10 nM). Thrombin stimulated fibroblast
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procollagen production in serum-free conditions, assessed after 48 hours, by 121% ± 
6%, relative to media control cells (p<0.01). This response to thrombin was inhibited 
by UK-156406 in a dose-dependent manner from equimolar concentration onwards 
(p<0.05), and was again completely blocked when UK-156406 was added in 10-fold 
excess (p<0.01). In addition, UK-156406 had no effect on basal fibroblast procollagen 
production at concentrations up to 1 pM. This experiment was repeated three times 
and significant differences for the effect of UK-156406 on thrombin-induced 
fibroblast procollagen production were obtained on each occasion (see Appendix, 
Table 3.1.2).
3.1.3 Effect of UK-156406 on Thrombin-Induced Fibroblast CTGF Gene 
Expression in vitro.
It has been proposed that thrombin may exert its pro-fibrotic effects via the 
autocrine production of CTGF (Chambers et al, 2000). The effect of UK-156406 on 
thrombin-induced CTGF mRNA levels in HFL-1 fibroblasts, was therefore also 
examined by Northern analysis of total cellular RNA. Confluent cultures of 
fibroblasts were quiesced in serum-free DMEM for 16 hours and exposed to thrombin 
(10 nM) or thrombin and varying concentrations of UK-156406, in serum-free 
conditions, for 90 minutes. The results are expressed as fold increase above media 
controls for four replicate cultures and are shown in Figure 3.1.3 panel a. The 
characteristic increase in thrombin-induced CTGF mRNA levels at 90 minutes was 
decreased by 65% for fibroblasts exposed to thrombin in the presence of equimolar 
concentrations of UK-156406 (p<0.05), and was blocked by 88% when UK-156406 
was added in 10-fold excess (p<0.01). UK-156406 had no effect on basal CTGF
140
mRNA levels. Panel b shows a representative Northern blot demonstrating the single 
2.4kb CTGF mRNA transcript.
3.1.4 Summary
The results described in this section examining the effect of UK-156406 on three 
separate thrombin-induced fibroblast responses showed that:
(i) UK-156406 significantly inhibited thrombin-induced fibroblast
proliferation, procollagen production and CTGF mRNA levels.
(ii) In all three assays, thrombin-induced fibroblast responses were 
significantly inhibited at equimolar concentrations of UK-156406 to the 
protease. Complete blockade of all fibroblast responses was observed 
when the compound was used in 10-fold excess. The explanation for this 
effect is likely to be due to the fact that UK-156406 is a reversible 
inhibitor of thrombin proteolytic activity.
(iii) Since UK-156406 abrogated three individual fibroblast responses to
thrombin in vitro, and also based on available pharmacokinetic data
produced by Pfizer (UK), the compound was deemed a robust
pharmacological agent that could be utilised to examine the role of direct 
thrombin inhibition in the bleomycin model of pulmonary fibrosis in vivo.
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Figure 3.1.1 Effect of UK-156406 on Thrombin-Induced 
Fibroblast Proliferation in vitro.
Figure shows the effect of UK-156406 on thrombin-induced fibroblast 
proliferation. The results are expressed as % above media control. Each value 
represents mean ± S.E.M for 6 replicates from a representative experiment, at 
the end of a 48 hour incubation period. tf/^O .Ol indicates significance of this 
data compared with cells treated with media alone, *p<0.05; **/?<0.01 denote 
the statistical significance of the indicated data compared with cells treated with 
thrombin alone (10 nM). The data shown is representative of three separate 
experiments performed (see Appendix, Table 3.1.1).
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Figure 3.1.2 Effect of UK-156406 on Thrombin-Induced Fibroblast 
Procollagen Production in vitro.
Figure shows the effect of UK-156406 on thrombin-induced procollagen 
production. Data is expressed as mean ± S.E.M for 6 replicates from a 
representative experiment, at the end of a 48 hour incubation period. 
Procollagen production is based on hydroxyproline measured in the media and 
cell layer and values are corrected for hydroxyproline associated with the cell 
layer at the onset of the experiment. ff/><0.01 denotes the statistical 
significance of the indicated data compared with cells treated with media 
alone, */?<0.05; **/?<0.01 denote the statistical significance of the indicated 
data compared with cells treated with thrombin alone (10 nM). The data shown 
is representative of three separate experiments performed (see Appendix, 
Table 3.1.2),
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Figure 3.1.3 UK-156406 Blocks Thrombin-Induced Fibroblast CTGF Gene
Expression in vitro.
Panel a shows the mean fold increases in CTGF mRNA levels at 90 minutes, 
above control levels for four replicate cultures. Data is normalised for RNA loading 
based on densitometric quantitation of 18S rRNA. Panel b shows a phosphorimage 
of a representative Northern blot of the 2.4kb CTGF transcript and a laser scan of 
the corresponding ethidium bromide stained 18 S rRNA bands. Total RNA was 
extracted from confluent HFL-1 cultures and five pg for each sample was 
electrophoresed in a 1% agarose-formaldehyde gel. RNA was transferred to a nylon 
membrane and probed with a radiolabelled CTGF cDNA probe for 16 hours. After 
hybridisation and stringency washing, the membrane was exposed to a 
Phosphorlmager storage screen for 2-4 hours, f t  /K0.01 denote the statistical 
significance of the indicated data compared with cells treated with media alone. 
*/?<0.05; **/t<0.01 denote the statistical significance of the indicated data 
compared with cells treated with thrombin alone (10 nM).
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3.2 Thrombin and PAR-1 in Bleomycin-Induced Pulmonary Fibrosis
3.2.1 BALF Thrombin Levels in Bleomycin-Induced Pulmonary Fibrosis
Prior to the evaluation of UK-156406 in the bleomycin model of pulmonary 
fibrosis, extensive studies were undertaken to fully characterise thrombin and PAR-1 
in this model.
In a previous study, thrombin levels in BALF following bleomycin-induced 
lung injury, had been measured in male Wistar rats and were found to be elevated 
(Tani et al, 1991). In these experiments, BALF thrombin levels were assessed using a 
fluorometric assay, following intratracheal bleomycin instillation, and were found to 
be maximally elevated at day 6. In this thesis, male Lewis rats were utilised for in vivo 
experiments, since this strain of animal had previously been used in host laboratory 
for bleomycin studies. To examine whether BALF thrombin levels were also elevated 
in these animals following intratracheal bleomycin instillation, thrombin levels were 
measured at 6 days, using a previously described chromogenic assay (Idell et al, 
1987). Following collection, unconcentrated BALF was centrifuged and absorbance 
in the supernatant was serially measured using a spectrophotometer at 405 nM over 
one hour, and the rate of thrombin generation calculated. BALF thrombin levels were 
derived by extrapolation from a thrombin standard curve.
BALF thrombin levels were significantly increased 9.9 ± 2.3 fold, in rats 
given bleomycin compared with saline control animals (n=6,p<0.01) (Figure 3.2.1). 
From this data, it was calculated that the concentration of thrombin in the BALF of 
bleomycin-treated animals was 60.0 ±8 .1  nM (please see calculation in Methods 
Section 2.10.7). On comparison with the literature, this concentration was found to be
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Figure 3.2.1 Thrombin Levels in BALF Following Bleomycin Instillation.
This figure shows the effect of intratracheal bleomycin on BALF thrombin levels 
after 6 days. The p  value denotes the statistical significance of the indicated data 
compared with animals given intratracheal saline alone, (*p<0.05; n=6).
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physiologically relevant since it was similar to that seen during blood coagulation 
(Walz et al, 1985, Brummel et al, 2002).
3.2.2 Histological Time Course of Bleomycin-Induced Pulmonary Fibrosis
Before further assessment of thrombin and PAR-1 in the bleomycin model of 
pulmonary fibrosis, the histological appearance of rat lung was examined 3,6, 14 and 
21 days following saline and bleomycin instillation, to ensure that classical findings 
could be repeated. Representative lung tissue sections were stained with Massons 
trichrome, which stains collagen and extracellular matrix blue, and examined by light 
microscopy, (Figure 3.2.2, plates 1-4, panels a -  p).
In saline-instilled rats, lung histology appeared normal throughout the time 
course. In contrast, in the lungs of bleomycin-instilled rats, there was evidence of a 
diffuse inflammatory-cell influx at day 3, with areas of microvascular leakage (panel 
d, arrows). By day 6, interstitial fibrosis with multiple inflammatory foci and oedema 
in alveolar septa was evident (panel h, arrows). After 14 days, there was more 
mature regional fibrosis with a pronounced macrophage presence, with extensive 
remodeling of the alveolar unit (panel 1, arrows). Finally by day 21, established 
fibrotic lesions with re-epithelisation of alveolar septa with margination of 
macrophages and lymphocytes were present (panel p, arrows). These findings are 
consistent with those are reported by Mutsaers et al, 1998, (with thanks to Dr Martin 
Foster for help in interpretation of histology).
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Figure 3.2.2 Plate 1: Time Course of Bleomycin-Induced Pulmonary Fibrosis Day 3.
Figure 3.2.2, Plate 1, panels a, b, c and d show sections of rat lung, 3 days following intra-tracheal instillation of saline and bleomycin. Tissue 
sections were stained with Massons trichrome which stains collagen and extracellular matrix proteins blue. In saline-treated animals, lung 
architecture is preserved but following intra-tracheal instillation of bleomycin, there was evidence of a diffuse inflammatory cell influx (arrows). 
Magnification (xlOO and x400).
Bleomycin Day 3
Figure 3.2.2 Plate 2: Time Course of Bleomycin-Induced Pulmonary Fibrosis Day 6.
Figure 3.2.2, Plate 2, panels e, f, g and h show sections of rat lung, 6 days following intra-tracheal instillation of saline and bleomycin. In saline- 
treated animals, lung architecture remains preserved but following bleomycin instillation, interstitial fibrosis with multiple inflammatory foci have 
developed (arrows). Magnification (xlOO and x400).
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Figure 3.2.2 Plate 3: Time Course of Bleomycin-Induced Pulmonary Fibrosis Day 14.
Figure 3.2.2, Plate 3, panels i, j, k and 1 show sections of rat lung, 14 days following intra-tracheal instillation of saline and bleomycin. Lungs 
histology of saline-treated animals is normal but following bleomycin instillation mature regional fibrotic lesions associated with macrophage 
presence have developed (arrows). Magnification (xlOO and x400).
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Figure 3.2.2 Plate 4: Time Course of Bleomycin-Induced Pulmonary Fibrosis Day 21.
Figure 3.2.2, Plate 4, panels m, n, o and p show sections of rat lung, 21 days following intra-tracheal instillation of saline and bleomycin. In 
saline-treated animals, lung architecture is normal but bleomycin instillation has caused extensive fibrotic lesions with regional re-epithelisation 
to develop in the lung (arrows). Magnification (xlOO and x400).
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3.2.3 Optimisation of Thrombin Immunohistochemistry in Bleomycin-Induced 
Pulmonary Fibrosis
Having confirmed that classical temporal changes in lung histology could be 
demonstrated following bleomycin instillation, experiments were also performed in 
order to determine the immunohistochemical localisation of active thrombin within 
the lung following bleomycin-induced lung injury, over a similar time course. 
Previous investigators had shown that monoclonal antibodies, directed against the 
active site of thrombin had poor specificity and were unhelpful for localising 
thrombin immunohistochemically in intact tissue sections (Zacharski et al, 1995). For 
this reason the cellular localisation of thrombin in lung tissue following bleomycin 
instillation was detected by incubating tissue sections with hirudin. Hirudin binding 
was then detected using a polyclonal anti-hirudin antibody. Positive staining was 
identified by incubating sections with a biotinylated goat anti-rabbit secondary 
antibody followed by a streptavidin/peroxidase complex and a solution of 3,3’- 
diaminobenzidine (DAB), which generated a brown reaction product, (see Diagram
2.3 in Methods Section 2.10.6).
Experiments to localise active thrombin in these tissue sections proved to be 
technically challenging. In particular, both the concentration of hirudin and the anti­
hirudin antibody had to be fully optimised, since this method had not been used in this 
species before. Experiments in which higher concentrations of these reagents were 
used gave rise to a large amount of non-specific brown background staining, making 
interpretation of results impossible. A dilution table and photographic examples of 
preliminary experiments where different concentrations of reagents were used are 
shown in Appendix, Table 3.2.3.
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In final experiments, optimal concentrations of reagents produced repeatable 
and specific cellular staining for active thrombin. This was confirmed since control 
tissue sections which were incubated with serum alone, hirudin with an isotype- 
specific non-immune primary antibody, hirudin only and finally anti-hirudin antibody 
alone, showed no detectable staining (Figure 3.2.4, plate 5, panels q - x).
3.2.4 Time Course and Immunohistochemical Localisation of Thrombin in 
Bleomycin-Induced Pulmonary Fibrosis
Figure 3.2.4, Plates 1-4 show the immunohistochemical localisation of 
thrombin in bleomycin-induced pulmonary fibrosis. When tissue sections from saline- 
instilled animals were incubated with an optimal concentration of the hirudin and 
antihirudin antibody, very weak brown staining was observed, which was 
occasionally associated with resident macrophages. However, in the lungs of 
bleomycin-treated animals there was intense and widespread brown staining, which 
was predominantly associated with macrophages within inflammatory and 
fibroproliferative foci in the pulmonary interstitium and also with spindle-shaped 
interstitial cells in these areas. These changes were assessed by three independent 
observers who graded the intensity of positive staining on inflammatory and 
interstitial fibroblasts throughout the time-course. These cell types stained positively 
throughout the time-course but intensity was maximal 6 days after bleomycin 
instillation (Figure 3.2.4, Plate 2, panel h, arrows).
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Figure 3.2.4 Plate 1: Immunohistochemical Localisation of Thrombin in Bleomycin-Induced Pulmonary Fibrosis at 3 Days.
Figure 3.2.4, Plate 1 panels a, b, c, and d show sections of rat lung, 3, days following intra-tracheal instillation of saline or bleomycin. Following 
bleomycin instillation, there is positive brown staining for active thrombin which is associated with macrophages (see arrows in inset, panel d). 
Magnification (xlOO and x400); counterstained with Mayers haematoxylin.
Saline Day 3
Figure 3.2.4 Plate 2: Immunohistochemical Localisation of Thrombin in Bleomycin-Induced Pulmonary Fibrosis at 6 Days.
Figure 3.2.4, Plate 2 panels d, e, f and g show sections of rat lung, 6, days following intra-tracheal instillation of saline and bleomycin. There is 
extensive positive brown staining for active thrombin following bleomycin instillation, which is predominantly associated with macrophages in 
inflammatory and fibroproliferative foci (see large arrows) , but also present on interstitial cells (see arrows in inset, panel d). Three independent 
observers assessed the immunohistochemical changes and concluded that positive staining of inflammatory cells and interstitial fibroblasts was most 
intense at this time point. Magnification (xlOO and x400, inset panel h xlOOO); counterstained with Mayers haematoxylin.
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Figure 3.2.4 Plate 3: Im m unohistochem ical Localisation of Throm bin in Bleomycin-Induced Pulm onary Fibrosis a t 14 Days.
F igure 3.2.4, Plate 3 panels I, j, k  and 1 show sections of rat lung, 14 days following intra-tracheal instillation of saline or bleomycin. Staining for 
active thrombin remains positive on macrophages and interstitial cells in inflammatory and fibroproliferative foci (arrows). Magnification (xlOO 
and x400); counterstained with Mayers haematoxylin.
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Figure 3.2.4 Plate 4: Immunohistochemical Localisation of Thrombin in Bleomycin-Induced Pulmonary Fibrosis at 21 Days.
Figure 3.2.4, Plate 4 panels m, n, o and p show sections of rat lung, 21 days following intra-tracheal instillation of saline or bleomycin. 
Occasional brown staining for active thrombin associated with macrophages in inflammatory and fibroproliferative foci is seen following 
bleomycin instillation (arrows). Magnification (xlOO and x400); counterstained with Mayers haematoxylin.
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Figure 3.2.4 Plate 5: Immunohistochemical Localisation of Thrombin in Bleomycin-Induced Pulmonary Fibrosis (Controls). 
Figure 3.2.4, Plate 5 panels q-x show a sections of control rat lung tissue sections from different time points, following intra-tracheal 
instillation of saline or bleomycin. Lung tissue sections were incubated with serum, non-immune primary antibody, hirudin alone and anti­
hirudin antibody alone and no brown staining seen in any of the sections. Magnification (xlOO and x400); counterstained with Mayers 
haematoxylin.
3.2.5 Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced 
Pulmonary Fibrosis
Having demonstrated the immunohistochemical localisation of active 
thrombin within the lung following bleomycin instillation, further experiments were 
performed to assess the localisation of the major thrombin receptor, PAR-1 within the 
lung following bleomycin-induced lung injury using the same lung tissue samples.
Optimisation of the primary antibody on lung tissue sections proved less 
problematic than for thrombin since it had been previously used by other investigators 
to demonstrate PAR-1 expression in bone tissue, (Abraham et al, 1998). Based on 
published findings, a dilution series was constructed and lung tissue sections were 
incubated with a polyclonal, rabbit anti-rat PAR-1 primary antibody, for one hour at 
room temperature, at varying concentrations (Appendix Table 3.2.5). Positive 
staining for PAR-1 was detected by incubating sections with an optimal concentration 
of the primary antibody (1:1000), followed by a biotinylated goat anti-rabbit 
secondary antibody, a streptavidin/peroxidase complex and a solution of 3,3’- 
diaminobenzidine (DAB), which generated a brown reaction product. Highly specific 
staining for PAR-1 was confirmed since control tissue sections incubated with serum 
only and with an isotype-specific, non-immune primary antibody showed no 
detectable staining (Figure 3.2.5a, plate 5, panels q-t).
Throughout the time course, PAR-1 was consistently expressed on the 
bronchial epithelium of lung tissue sections from both bleomycin- and saline-treated 
animals and there was no obvious difference in the intensity of the staining between 
treatment groups, when assessed by three independent observers (Figure 3.2.5, Plates 
1 and 2, panels a -  h).
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Figure 3.2.5 Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis (Lung Epithelium).
Figure 3.2.5, Plate 1, panels a -  d show sections of rat lung, 3 and 6 days following intra-tracheal instillation of saline and bleomycin. There is 
positive brown staining for PAR-1 on the bronchial epithelium of all sections (arrows). Two independent observers assessed immunohistochemical 
changes and found staining was uniform throughout the time course. Magnification (x400 and xlOOO); counterstained with Mayers haematoxylin.
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Figure 3.2.5 Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis (Lung Epithelium).
Figure 3.2.5, Plate 2, panels f -  h show sections of rat lung, 14 and 21 days following intra-tracheal instillation of saline and bleomycin. Similarly to 
the changes at 3 and 6 days, there is positive brown staining for PAR-1 on the bronchial epithelium of all sections (arrows). Magnification (x400 and 
xlOOO); counterstained with Mayers haematoxylin.
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Figure 3.2.5a Plate 1: Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis at Day 3.
Figure 3.2.5a, Plate 1, panels a, b, c and d show sections of rat lung, 3, days following intra-tracheal instillation of saline or bleomycin. Weak 
positive brown staining for PAR-1 is seen in the lung parenchyma of these bleomycin-treated animals and is associated with macrophages (arrow). 
Magnification (xlOO and x400); counterstained with Mayers haematoxylin.
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Figure 3.2.5a Plate 2: Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis at Day 6.
Figure 3.2.5a, Plate 2 panels e, f, g and h show sections of rat lung, 6 days following intra-tracheal instillation of saline or bleomycin. Intense 
positive brown staining for PAR-1 is seen in the lung parenchyma of bleomycin-treated rats which was predominantly associated with macrophages 
in inflammatory and fibroproliferative foci (arrows). Immunohistochemical changes were assessed by three independent observers and positive 
staining was greatest at this time point. Magnification (xlOO and x400); counterstained with Mayers haematoxylin.
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Figure 3.2.5a Plate 3: Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis at 14 Days.
Figure 3.2.5a, Plate 3, panels i, j, k and 1 show sections of rat lung, 14 days following intra-tracheal instillation of saline or bleomycin. Positive 
brown staining for PAR-1 is still observed in the lung parenchyma of bleomycin-treated rats and again predominantly associated with macrophages 
in inflammatory and fibroproliferative foci (arrows). Magnification (xlOO and x400); counterstained with Mayers haematoxylin.
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Figure 3.2.5a Plate 4: Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis at 21 Days.
Figure 3.2.5a, Plate 4, panels m, n, o and p show sections of rat lung, 21 days following intra-tracheal instillation of saline or bleomycin. In 
bleomycin-treated rats, occasional brown staining predominantly associated with macrophages is observed (arrow). Magnification (xlOO and x400); 
counterstained with Mayers haematoxylin.
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Figure 3.2.5a Plate 5: Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis.
Figure 3.2.5a, Plate 5, panels q-t show control sections of rat lung, from different time points, following intra-tracheal instillation of saline or 
bleomycin. Sections were incubated with serum and non-immune primary antibody and showed no positive staining.
Magnification (xlOO and x400); counterstained with Mayers haematoxylin.
Figure 3.2.5a, Plates 1-4 show the immunohistochemical localisation of 
PAR-1 in the lung parenchyma in bleomycin-induced pulmonary fibrosis. The lung 
parenchyma in saline-treated animals was negative for PAR-1 staining throughout the 
time course. However, there was a dramatic increase in the expression of this receptor 
in the lung parenchyma of bleomycin-treated animals. PAR-1 expression 
predominantly appeared to be associated with macrophages in interstitial 
inflammatory and fibroproliferative foci but elongated spindle-shaped cells in these 
areas were also positively stained. These changes were also confirmed by three 
independent observers and appeared maximal on day 6 (Figure 3.2.5a, plate 2, panel 
h, arrows).
3.2.6 PAR-1 Gene Expression in Bleomycin-Induced Pulmonary Fibrosis
Since immunohistochemical studies demonstrated that expression of PAR-1 
was increased at the protein level following bleomycin instillation, experiments were 
also performed to determine whether this observation was preceded by a detectable 
change in PAR-1 mRNA levels, in the lungs of rats. Total cellular RNA was extracted 
from the lungs of rats following intratracheal saline or bleomycin instillation and 
Northern analysis performed using a radiolabelled rat-specific PAR-1 cDNA probe. 
The data is expressed as PAR-1 mRNA levels, normalised for RNA loading based on 
densitometric quantitation of 28S rRNA. Figure 3.2.6, panel a shows that PAR-1 
mRNA levels were increased by 3.0 ± 0.2- fold in bleomycin-treated animals above 
saline-treated control levels, at 6 days (p<0.01, n=6). Panel b shows a representative 
Northern blot, demonstrating that a single 3.6kb PAR-1 mRNA transcript was 
detected.
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Figure 3.2.6 PAR-1 mRNA Levels in Bleomycin-Induced Pulmonary Fibrosis. 
Panel a shows that PAR-1 mRNA levels in the lungs of bleomycin-treated animals 
were increased above saline-treated control levels, at 6 days, normalised for RNA 
loading based on densitometric quantitation of 28S rRNA (**/?<0.01, rr=6) Panel b 
shows a phosphorimage of a representative Northern blot for the 3.6kb PAR-1 mRNA 
transcript. The corresponding ethidium bromide stained 28 rRNA S bands are also 
shown. Total RNA was extracted from powdered lung tissue and five pg was 
electrophoresed in a 1% agarose-formaldehyde gel. RNA was transferred to a nylon 
membrane and probed with a radiolabelled PAR-1 cDNA probe for 16 hours. After 
hybridisation and stringency washing, the membrane was exposed to a 
Phosphorlmager storage screen for 12 hours for densitometric quantitation.
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3.2.7 Immunohistochemical Localisation of PAR-1 in BALF Inflammatory Cells 
in Bleomycin-Induced Pulmonary Fibrosis
One of the findings from the immunohistochemical experiments performed in 
Results Section 3.2.5 was that macrophages strongly expressed PAR-1 following 
bleomycin injury, but other inflammatory cells in lung tissue did not. Other studies 
have suggested that peripheral blood lymphocytes and neutrophils may also express 
PAR-1 (Macey et al, 1998, Kannan, 2002). To assess these observations further in the 
lung, immunocytochemistry for PAR-1 was performed on BALF inflammatory cells, 
6 days following intratracheal bleomycin or saline instillation. Figure 3.2.7, panel a 
shows a control BALF cytospin slide from a bleomycin-treated rat, which was 
incubated with an isotype-specific, non-immune primary antibody. Inflammatory 
cells were identified on the cytospin slide, but there was no positive staining detected. 
Panel b shows a cytospin, from a saline-treated rat, incubated with a PAR-1 primary 
antibody, which demonstrated weak staining, associated with macrophages. Panel c 
shows a cytospin from a bleomycin-treated rat also incubated with a PAR-1 primary 
antibody. Intense staining for PAR-1 was detected associated with macrophages 
(arrows) but lymphocytes and neutrophils appeared negative. These findings 
correlated with the immunohistochemical localisation of PAR-1 in lung tissue 
sections, following bleomycin and saline instillation (see Figure 3.2.5a).
3.2.8 PAR-1 Expression in Primary Rat Lung Fibroblasts in vitro
Another finding from the immunohistochemical studies in Section 3.2.5 was 
that, in addition to the macrophage, PAR-1 was expressed on epithelial cells and 
elongated spindle-shaped interstitial cells, consistent with a fibroblastic phenotype, in 
the lungs of animals following bleomycin instillation. It is well known that conclusive
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Figure 3.2.7 Immunohistochemical Localisation of PAR-1 in BALF 
Inflammatory Cells in Bleomycin-Induced Pulmonary Fibrosis.
Panel a shows a representative BALF cytospin slide from an animal, 6 days 
following intra-tracheal instillation of bleomycin. The slide was incubated with a 
isotype-specific control antibody for PAR-1 and no positive staining was detected. 
Panel b is a BALF cytospin, from a saline instilled animal at 6 days, incubated with 
a PAR-1 specific antibody. There is weak positive brown staining on macrophages. 
Panel c shows the immunohistochemical localisation of PAR-1, in BALF 
inflammatory cells, 6 days after intra-tracheal bleomycin instillation. Intense brown 
staining for PAR-1 (arrows) was associated with macrophages, and was increased 
compared with saline-treated controls. (Magnification xlOOO; counterstained with 
Mayers haematoxylin).
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Figure 3.2.8 PAR-1 Expression in Primary Rat Lung Fibroblasts
in vitro.
Figure 3.2.8, panel a shows a phosphorimage of a representative Northern 
blot showing that the 3.6 kb PAR-1 mRNA transcript is basally expressed by 
cultured primary rat lung fibroblasts. The corresponding ethidium bromide 
stained 28 rRNA S bands are also shown. Total RNA was extracted from 
confluent cultures of rat lung fibroblasts and five pg for each sample was 
electrophoresed in a 1% agarose-formaldehyde gel. RNA was transferred to 
a nylon membrane and probed with a radiolabelled PAR-1 cDNA probe for 
16 hours, prior to visualisation of the 3.6kb molecular weight signal.
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Figure 3.2.8 PAR-1 Expression in Primary Rat Lung Fibroblasts in vitro. 
Figure 3.2.8, panels b and c show photographs of cultured primary lung 
fibroblasts, following incubation with an isotype-specific control antibody, and 
no staining is detected. Panels d and e show photographs of these cells after 
incubation with a PAR-1 specific primary antibody. Positive staining for PAR-1 
was detected on all fibroblasts in the culture. (Magnification, x400 and xlOOO)
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demonstration of fibroblasts in histological sections by light microscopy is difficult 
because the interstitial fibroblast has such an elongated morphology within the 
pulmonary parenchyma.
Since it is possible that thrombin-induced PAR-1-dependant fibroblast 
responses may be important in the pathogenesis of bleomycin-induced pulmonary 
fibrosis, primary rat lung fibroblasts were cultured from male Lewis rats and 
experiments performed to further assess PAR-1 expression in these cells. Total 
cellular RNA was extracted from confluent cell cultures, which had been quiesced in 
serum-free conditions, and Northern analysis was performed. Figure 3.2.8, panel a 
shows a Northern blot, which confirmed that the single 3.6 kb PAR-1 mRNA 
transcript could be detected for cultured lung fibroblasts in vitro.
Subsequently, fluorescent immunocytochemistry was also performed to 
further assess PAR-1 expression at the protein level. Rat lung fibroblasts were 
incubated with an isotype-specific, non-immune primary antibody as a control 
(panels b, c), and a PAR-1 primary antibody (panels d, e). A strong fluorescent 
signal for PAR-1 was detected on fibroblasts incubated with PAR-1 antibody (1:25 
dilution), which was completely absent on cells incubated with the isotype-specific, 
non-immune primary antibody.
3.2.9 Effect of Thrombin and PAR-1 Specific Agonist (TFLLR) on Primary Rat 
Lung Fibroblast CTGF mRNA Levels
Having demonstrated that primary rat lung fibroblasts expressed PAR-1 at the 
mRNA and protein level, to assess if  receptors were functional, cells were exposed to 
thrombin and a selective PAR-1 agonist, TFLLR, to examine if they exhibited typical 
thrombin-induced responses.
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Initially the effect of thrombin (25 nM) and a selective PAR-1 agonist, TFLLR 
(200 /xM) on CTGF mRNA levels, were examined. The concentrations of thrombin 
and TFLLR were chosen, based on previous studies showing that CTGF mRNA 
levels were maximally stimulated at these concentrations in human and mouse 
fibroblasts (Chambers et al, 2000). Confluent cultures of primary rat lung fibroblasts 
were quiesced in serum-free media and exposed to thrombin or TFLLR, in serum-free 
conditions, for 90 minutes. Figure 3.2.9, panel a shows the results, expressed as a 
fold increase in CTGF mRNA levels above media control levels, for four replicate 
cultures. In rat lung fibroblasts exposed to thrombin, CTGF mRNA levels were 
increased 5.0 ± 0.2 -fold above basal levels (p<0.01). In addition, TFLLR mimicked 
the effects obtained with thrombin as CTGF mRNA levels were increased 4.1 ± 0.2 - 
fold above media control values (p<0.01). Panel b shows a representative Northern 
blot of this data demonstrating that a single 2.4 kb CTGF mRNA transcript was 
detected.
3.2.10 Effect of Thrombin and PAR-1 Specific Agonist (TFLLR) on Primary Rat 
Lung Fibroblast Proliferation
To further assess whether rat lung fibroblasts exhibited functional PAR-1 
responses, the effect of thrombin (25 nM) and a PAR-1 selective agonist, TFLLR (50 
fiM), on cell proliferation were investigated using a spectrophotometric assay based 
on uptake and subsequent elution of the dye methylene blue, as described above in 
Methods Section 2.5. The results are expressed as mean absorbance at 650 nM for six 
replicate cultures. Figure 3.2.10 shows a representative experiment in which 
thrombin stimulated fibroblast proliferation by 62 ± 0.1%, relative to media control
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Figure 3.2.9 Effect of Thrombin and a PAR-1 Specific Agonist (TFLLR) on 
Primary Rat Lung Fibroblast CTGF mRNA Levels.
Panel a shows that CTGF mRNA levels were increased above media-control 
levels, following stimulation with thrombin (25 nM) and TFLLR (200 pM) for 90 
minutes, normalised for RNA loading based on densitometric quantitation of 28S 
rRNA The p  values denote the statistical significance of the indicated data 
compared with media control cells; **p<0.01. Panel b shows a phosphorimage of a 
representative Northern blot of the 2.4kb CTGF transcript and a laser scan of the 
corresponding ethidium bromide stained 28 S rRNA bands. Total RNA was 
extracted from confluent rat lung fibroblast cultures and five pg for each sample 
was electrophoresed in a 1% agarose-formaldehyde gel. RNA was transferred to a 
nylon membrane and probed with a radiolabelled CTGF cDNA probe for 16 hours. 
After hybridisation and stringency washing, the membrane was exposed to a 
Phosphorlmager storage screen for 2-4 hours for densitometric quantitation.
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Figure 3.2.10 Effect of Thrombin and a PAR-1 Specific Agonist (TFLLR) 
on Primary Rat Lung Fibroblast Proliferation.
This figure shows the effect of thrombin (25 nM) and TFLLR (50 pM) on 
fibroblast proliferation at the end of a 48 hour incubation period. The results are 
expressed as mean absorbance at 650 nm. Each value represents mean ± S.E.M 
for 6 replicates from a representative experiment. The p  values denote the 
statistical significance of the indicated data compared with media control cells; 
**/?<0.01. The data shown is representative of two separate experiments 
performed (see Appendix, Table 3.2.10).
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cells (p<0.01), in serum free conditions, after 48 hours. This fibroblast response to 
thrombin was mimicked by TFLLR, which stimulated fibroblast proliferation by 29 ± 
0.1% relative to media control cells (p<0.01), when assessed at the same time point. 
The reproducibility of these findings was confirmed in two separate experiments (see 
Appendix, Table 3.2.10).
The concentration of TFLLR (50 /xM) used in fibroproliferation experiments, 
was lower than that used to assess the effect of TFLLR on CTGF mRNA levels in 
these cells (200/xM). At higher concentrations of TFLLR (100 /xM and 200 /xM), in 
fibroproliferation assays, microscopic examination of cultures revealed cell death 
after 48 hours, when compared with control cell cultures. It was concluded that this 
was due to a toxic effect of DMSO in which TFLLR was reconstituted prior to use, 
rather than a toxic effect of TFLLR per se. This was because similar effects were also 
noted on parallel cell cultures when spiked with DMSO alone and examined after 48 
hours. Furthermore, in the RNA experiments described in Section 3.2.9, although cell 
cultures were exposed to TFLLR (200 /xM), this was only for 90 minutes. In these 
experiments the induction in CTGF mRNA levels in response to both thrombin and 
TFLLR were virtually the same, suggesting that the toxicity of DMSO had a neglible 
effect over this time period.
3.2.11 PAR-1 Expression in Human Lung Biopsy Specimens
After confirming that expression of PAR-1 was increased in bleomycin- 
induced pulmonary fibrosis, experiments were also conducted to examine the 
expression of PAR-1 at the mRNA and protein level, in a limited number of normal 
and fibrotic human lung biopsy specimens, available in the host laboratory.
A 32P radiolabelled human PAR-1 cDNA probe was supplied by a collaborator 
for use in these experiments. However, since lung biopsy material was extremely 
precious, total cellular RNA was initially extracted from human fetal lung fibroblasts, 
and Northern analysis performed with the probe, to establish whether a molecular 
weight band of the correct weight for PAR-1 could be detected in this cell line, which 
had previously been shown to exhibit functional responses to PAR-1 agonists 
(Chambers et al, 1998). Figure 3.2.11 panel a shows a Northern blot which 
confirmed that a single 3.6 kb PAR-1 mRNA transcript was expressed in these cells.
Having confirmed that a robust signal for PAR-1 could be detected, total 
cellular RNA was extracted from normal and fibrotic lung biopsy specimens. Due to 
the difficulty in obtaining open lung biopsy material and unavoidable degradation of 
RNA (when biopsies were excised at initial surgical procedure), it was only possible 
to isolate RNA of good integrity from a small number of biopsy specimens.
Fibrotic lung biopsy specimens are known to contain increased amounts of 
collagen at the mRNA and protein level, when compared with normal lung tissue. In 
order to confirm that the biopsy specimens provided were representative of this 
observation, Northern analysis of total RNA was initially performed with a specific 
cDNA probe for ai(I) procollagen. Figure 3.2.11, panel b shows a Northern blot 
demonstrating that the 5.8kb and 4.8kb oil (I) procollagen transcripts were easily 
detectable in the fibrotic lung biopsy specimens and absent in the single normal lung 
biopsy specimen examined.
Subsequently, PAR-1 gene expression was also assessed in these samples. 
Figure 3.2.11, panel c shows a Northern blot revealing that the 3.6 kb PAR-1 
transcript could be identified in fibrotic biopsy specimens, but not in the normal
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specimen. This data was considered unsuitable for statistical analysis due to the small 
sample numbers.
PAR-1 expression at the protein level was assessed by examining the 
immunohistochemical localisation of PAR-1 in histological human biopsy specimens 
from patients with pulmonary fibrosis and also in normal control lung tissue. In 
fibrotic lung tissue incubated with an isotype-specific, non-immune primary antibody, 
no staining was detected (Figure 3.2.11, panel d). Weak staining for PAR-1, 
associated with resident alveolar macrophages, was detected when a PAR-1 specific 
antibody was incubated with normal control lung tissue (panel e). However, when 
lung tissue sections taken from patients with established pulmonary fibrosis were 
incubated with this antibody (see representative example, panel f), there was intense 
and widespread positive staining for PAR-1. Staining was predominantly associated 
with macrophages in fibroproliferative and inflammatory foci and also elongated 
spindle shaped cells with a typical fibroblastic morphology (arrowhead).
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Figure 3.2.11 PAR-1 Expression in HFL-1 Fibroblasts.
Figure 3.2.11, panel a shows a phosphorimage of a representative Northern 
blot demonstrating that a single 3.6 kb PAR-1 mRNA transcript was expressed 
by cultured human fetal lung fibroblasts. The corresponding ethidium bromide 
stained 28 rRNA S bands are also shown. Total RNA was extracted from 
confluent cultures of human fetal lung fibroblasts and five pg was 
electrophoresed in a 1% agarose-formaldehyde gel. RNA was transferred to a 
nylon membrane and probed with a radiolabelled PAR-1 cDNA probe for 16 
hours prior to visualisation of the PAR mRNA transcript.
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Figure 3.2.11 Procollagen and PAR-1 Gene Expression in 
Human Lung Biopsy Specimens.
Figure 3.2.11, panel b shows a phosphorimage of a representative Northern 
blots for the 5.8kb and 4.8kb a ,(I) procollagen transcripts in normal and fibrotic 
lung biopsy specimens. The corresponding ethidium bromide stained 28 rRNA S 
bands are also shown. Panel c shows a phosphorimage of a representative 
Northern blot for the 3.6kb PAR-1 transcript in normal and fibrotic lung biopsy 
specimens. In addition, the corresponding ethidium bromide stained 28 rRNA S 
bands are also shown. In both experiments total cellular RNA was extracted 
from lung biopsy material and five pg was electrophoresed in a 1% agarose- 
formaldehyde gel. RNA was transferred to a nylon membrane and probed with 
radiolabelled 0^(1) procollagen and PAR-1 cDNA probes, respectively, for 16 
hours. After hybridisation and stringency washing, membranes for a^I) 
procollagen were exposed to a Phosphorlmager storage screen for 4 hours, and 
for PAR-1, 12 hours, prior to visualisation of the respective transcripts.
3.6 kb
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Figure 3.2.11 Immunohistochemical Localisation of PAR-1 in 
Human Biopsy Specimens.
Figure 3.2.11, panel d shows a section of fibrotic lung incubated with a isotype- 
specific PAR-1 control antibody and no positive staining is detected. Panel e is a 
tissue section, o f normal control lung tissue incubated with a PAR-1 specific 
antibody, showing weak positive staining on resident alveolar macrophages. Panel f 
is a lung tissue section taken from a patient with pulmonary fibrosis, and incubated 
with a PAR-1 specific antibody. There is extensive staining for PAR-1, which is 
predominantly associated with macrophages in inflammatory and fibroproliferative 
foci, but also present on elongated interstitial cells (arrowhead). Magnification 
(x400); counterstained with Mayers haematoxylin.
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3.2.12 Summary
The results described in this section examining thrombin and PAR-1 in the 
bleomycin model of pulmonary fibrosis in male Lewis rats showed that:
(i) BALF thrombin levels at 6 days were elevated in bleomycin-treated rats 
compared with saline-treated controls.
(ii) A corresponding increase in active thrombin was observed in bleomycin- 
treated rats compared with saline-treated controls, when assessed 
immunohistochemically. Active thrombin was localised to macrophages 
and spindle-shaped interstitial cells in bleomycin-treated animals and 
appeared maximal after 6 days.
(iii) PAR-1 was increased in bleomycin-treated rats compared with saline 
treated controls at both the mRNA and protein level. 
Immunohistochemical studies showed that PAR-1 was localised to 
macrophages and spindle- shaped interstitial cells in bleomycin-treated 
animals and appeared maximal after 6 days.
(iv) Primary lung fibroblasts cultured from rat lungs expressed PAR-1 and 
responded to the pro-fibrotic effects of thrombin.
(v) PAR-1 expression was increased in lung biopsy specimens derived from 
patients with pulmonary fibrosis compared with control normal lung 
tissue. Immunohistochemical studies on fibrotic lung tissue showed that 
PAR-1 was associated with macrophages and spindle-shaped interstitial 
cells in inflammatory and fibrotic foci.
In conclusion, these findings show that thrombin and PAR-1 are increased in
bleomycin-induced pulmonary fibrosis.
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3.3 Effect of UK-156406 on Bleomycin-Induced Pulmonary Fibrosis
3.3.1 Effect of UK-156406 on Blood Clotting Parameters in vivo
Having confirmed the efficacy of UK-156406 in blocking fibroblast responses 
in vitro and fully characterised thrombin and PAR-1 in the bleomycin model of 
pulmonary fibrosis, the effect of UK-156406 was assessed in this animal model.
Since the half-life of UK-156406 is approximately one hour (based on 
available pharmacokinetic data from Pfizer, UK) and also since thrombin is generated 
chronically following bleomycin injury, a parenteral route of drug administration was 
required. It was therefore decided that the drug would be delivered by a continuous 
infusion, via a subcutaneous minipump. Initial experiments were conducted to 
establish that UK-156406 could be delivered at an anticoagulant (and therefore 
therapeutic) dose, without causing undesirable bleeding complications.
To assess whether UK-156406 was administered to animals at an 
anticoagulant dose, two ex-vivo assays of thrombin-dependent coagulation, the mean 
APTT and PT, were measured in rat serum, at a time when steady-state concentration 
of the compound would have been attained.
Prior to measuring these coagulation parameters in animals treated with UK- 
156406, baseline APTT and PT levels were established in sham, saline and 
bleomycin-treated animals, since reference ranges for rat coagulation parameters in 
male Lewis rats had not described in the literature. Figure 3.3.1 (panels a and b) 
show that the PT and APTT in all treatment groups was the same (n=6). Having 
established baseline PT and APTT in animals, the effect of UK-156406 on PT and 
APTT was investigated.
In an initial pilot study, a dose of UK-156406 (1.5 mg/kg/hr) was used. This 
dose was extrapolated from further pharmacokinetic data from Pfizer (UK), where the 
compound had been administered to animals intravenously. Unfortunately, at this 
concentration, UK-156406 caused local subcutaneous bleeding around the insertion 
site of osmotic minipumps, which proved to be fatal in a number of rats. In addition, 
in these animals the APTT and PT became unrecordably high (>180 s). Further pilot 
studies at different doses (1 mg/kg/hr) and (0.7 mg/kg/hr) also lead to haemostatic 
complications. A dose of 0.5 mg/kg/hour was finally selected which caused no 
obvious bleeding complications.
The effect of this dose of UK-156406 on PT and APTT in experimental 
animals are shown in panels c and d. In bleomycin and saline-treated animals 
receiving UK-156406, the PT and APTT were both prolonged, compared with rats 
given drug vehicle control. Prolongation of these coagulation parameters was similar 
for rats given either intratracheal bleomycin or saline. The two graphs therefore show 
this data grouped together for clarity. In all rats treated with UK-156406 the mean PT 
was prolonged from 24.5 ±1.1 seconds to 31.4 ± 1.6 seconds (p<0.01), n=6, (panel c) 
and the mean APTT was increased from 17.0 ± 0.8 seconds to 24.5 ±1.1 seconds 
0?<0.01), n=6 (panel d), compared with animals receiving drug vehicle alone.
For all remaining experiments, animals were administered UK-156406 at this 
dose, 12 hours prior to receiving a single intratracheal dose of saline or bleomycin so 
that a steady-state concentration of the drug would have been established at the time 
of intratracheal challenge.
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Figure 3.3.1 Baseline Rat Blood Coagulation Parameters.
Figure 3.3.1 panels a and b show baseline PT and APTT in sham-treated, saline 
and bleomycin instilled rats. There was no detectable difference in either the PT or 
APTT in any experimental group (data expressed as mean ± SEM, n=6).
Vehicle UK-156406
Vehicle UK-156406
Figure 3.3.1 Effect of UK-156406 on Rat Blood Coagulation Parameters. 
Figure 3.3.1 panels c and d show that the mean PT and APTT of rats treated with 
UK-156406 was significantly prolonged compared with animals receiving drug 
vehicle alone. The p  values denote the significance of the indicated data compared 
with animals treated with a continuous infusion of drug vehicle alone. **p<0.01, 
n=6.
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3.3.2 Effect of UK-156406 on Rat Body Weight in Bleomycin-Induced 
Pulmonary Fibrosis
Figure 3.3.2 shows the effect of UK-156046 (0.5 mg/kg/hour) on rat body 
weight following bleomycin or saline instillation over a 14 day period. All animals 
initially lost weight, as a result of the instillation procedure and anaesthetic. However, 
animals given intratracheal bleomycin continued to lose body weight until day 5, 
when they returned to their start weights. By day 14, animals given intratracheal 
saline alone, had increased their mean body weight by 38.7 ± 1 .4  %, whereas 
bleomycin-treated animals only increased their body weight by 22.6 ± 3.8%. This 
figure also shows that UK-156406 had no effect on body weight in either saline or 
bleomycin-instilled animals over the time period of the experiment.
In terms of animal survival, a 5-10% mortality rate in all treatment groups was 
observed immediately following intratracheal saline or bleomycin instillation. This 
observation has also been documented by other investigators (Marshall -  PhD thesis, 
2001). Sporadic cases of delayed mortality occurred in all groups at variable time 
points in both saline and bleomycin-treated animals. However, mortality rate was not 
influenced by UK-156406 in either saline or bleomycin-treated animals.
3.3.3 Effect of UK-156406 on Lung Collagen Accumulation in Bleomycin- 
Induced Pulmonary Fibrosis after 14 Days
Having established that a therapeutic dose of UK-156406 could safely be 
delivered to animals in vivo, the effect of this compound on lung collagen 
accumulation following bleomycin instillation was assessed. Previous studies had 
shown that following a single dose of intratracheal bleomycin (1.5 mg/kg), total lung 
collagen doubles after 14 days (Mutsaers et al 1998). Lung collagen accumulation
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Figure 3.3.2 Effect of UK-156406 on Rat BodyWeight in 
Bleomycin-Induced Pulmonary Fibrosis.
Figure 3.3.2 shows the effect of UK-156406 (0.5 mg/kg/hr) on rat body weight 
following a single intratracheal injection of bleomycin (1.5 mg/kg body weight), or 
saline. Results are expressed as mean increase in body weight (%) compared with 
day 0 value. Appendix, Table 3.3.2 shows this data as mean ± S.E.M («=6) for all 
treatment groups.
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was therefore evaluated by quantitating hydroxyproline levels in lung hydrolysates, at 
this time point. Representative lung weight data used to calculate total lung collagen 
are presented in Appendix, Table 3.3.3a.
In an initial pilot experiment using n=3 per experimental group (see 
Appendix, Table 3.3.3, (Expt 1), UK-156406 appeared to attenuate lung collagen 
accumulation in bleomycin-instilled animals, compared with animals given bleomycin 
and drug vehicle alone. A larger study was undertaken (Expt 2), but in this 
experiment, total lung collagen only increased by 37% following bleomycin 
instillation compared with saline-treated controls. In these animals, UK-156406 
completely abrogated lung collagen accumulation when compared with animals given 
bleomycin and drug vehicle alone. Although the results of this experiment were 
extremely encouraging, it was repeated, since it was felt that the increase in total lung 
collagen in bleomycin-instilled animals, did not reflect classical findings. This may 
have led to an over-estimation in the protective effect of UK-156406 in this treatment 
group.
Figure 3.3.3 shows the results of a further experiment (Expt 3). In bleomycin- 
instilled animals, total lung collagen was increased by 124% compared with animals 
given intra-tracheal saline (p<0.01, n=6). This increase in lung collagen accumulation 
was reduced by 35% (p<0.05, n=6) in bleomycin-treated rats given UK-156406 
compared with animals given bleomycin and drug vehicle alone. In addition, UK- 
156406 had no effect on basal lung collagen levels in animals given intra-tracheal 
saline. This result was accepted as definitive evidence that direct thrombin inhibition 
attenuated bleomycin-induced pulmonary fibrosis.
The appendix also shows results from another experiment (Expt 4), where a 
non-significant trend towards a attenuation in bleomycin-induced pulmonary fibrosis
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Figure 3.3.3 Effect of UK-156406 on Lung Collagen Accumulation in 
Bleomycin-Induced Pulmonary Fibrosis.
Figure 3.3.3 shows the effect of a continuous subcutaneous infusion of UK- 
156406 (0.5 mg/kg/hr) on lung collagen accumulation 14 days following a single 
intra-tracheal instillation of bleomycin (1.5mg/kg). The total amount of collagen in 
each lung was calculated, assuming that lung collagen contains 12.2 % w/w 
hydroxyproline. **(/x0.01) denotes the statistical difference in total lung collagen 
between bleomycin and saline-treated animals, whereas *(/?<0.05) indicates the 
statistical difference in lung collagen accumulation in bleomycin-treated rats given 
UK-156406 and rats given bleomycin alone, n=6. Appendix, Table 3.3.3 shows 
this data and results of other representative experiments at this time point.
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occurred in bleomycin-treated rats given UK-156406, compared with animals given 
bleomycin and drug vehicle alone. However, in this experiment a lower dose of UK- 
156406 (0.33 mg/kg/hr) was used and the experiment took place over a longer time 
point (21 days).
3.3.4 Effect of UK-156406 on BALF Total Protein in Bleomycin-Induced 
Pulmonary Fibrosis
There are a number of potential mechanisms by which direct thrombin 
inhibition may have reduced lung collagen accumulation in this model, including 
blocking the procoagulant (i.e. fibrin deposition) or cellular effects of the protease 
(please see Discussion Section, Diagram 4.1). To begin to examine the mechanism 
by which direct thrombin inhibition exerted its protective effect in this model, a series 
of experiments were performed.
Vascular permeability in the lung is rapidly increased following bleomycin 
instillation and is reflected by an increase in BALF total protein levels (Hay et al, 
1991). Thrombin increases microvascular permeability in the lung via a number of 
direct and indirect mechanisms but downstream effects of the protease may also serve 
to limit this process, since fibrin microaggregates have been shown to reduce vascular 
permeability in the lung (Johnson et al, 1982).
The effect of the UK-156406 on BALF total protein levels was therefore 
assessed 3 and 6 days following bleomycin instillation, since these time points 
reflected maximal microvascular permeability in the lung following intratracheal 
insult (Hay at al, 1991). In addition, thrombin levels had been shown to be highly 
elevated in this model at this time point (Results Section, 3.2.1, Tani et al, 1991). 
BALF total protein was measured using a colourimetric assay. In this assay, protein
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Figure 3.3.4 Effect of UK-156406 on BALF Total Protein in 
Bleomycin-Induced Pulm onary Fibrosis a t 3 and 6 Days.
F igure 3.3.4 panels a and b show the effect of a continuous subcutaneous 
infusion of UK-156406 (0.5 mg/kg/hr) on BALF total protein, following a single 
intra-tracheal instillation of bleomycin (1.5mg/kg), after 3 and 6 days respectively. 
ttftxO .01) denotes the statistical difference in BALF total protein between 
bleomycin-treated rats and respective saline-treated controls, n= 6. *(p<0.05) 
denotes the statistical difference in BALF total protein between bleomycin-treated 
animals and bleomycin-treated given UK-156406, n=6.
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reduces Cu2+ to Cu1+ in the presence of an alkaline medium and Cu1+ ions convert 
bicinchoninic acid (BCA) to a purple reaction product, which exhibits a strong 
absorbance that can be detected spectrophotometrically.
Figure 3.3.4 shows that at 3 and 6 days BALF total protein was increased in 
bleomycin-treated animals compared with saline-treated controls, (6.5 ± 0.2 fold and
6.9 ± 0.5 fold, respectively, both /?<0.01, w=6). There was a slight but significant 
increase in BALF total protein levels in bleomycin-treated animals receiving UK- 
156406, compared with animals receiving bleomycin alone, at both time points (7.5 ± 
0.2 fold and 8.2 ± 0.4 fold),/?<0.05, n=6). In contrast, BALF total protein levels were 
not elevated in saline-instilled animals given UK-156406, when compared with 
animals given drug vehicle alone.
This data can be interpreted in a number of ways, but it is feasible that 
fibrinous plugging of damaged blood vessels in the injured lung may have been 
altered by direct thrombin inhibition, thus increasing vascular permeability and BALF 
protein levels.
3.3.5 Effect of UK-156406 on Lung CTGF and «i(I) Procollagen mRNA Levels in 
vivo
It is hypothesised that the direct pro-fibrotic cellular effects of thrombin may 
be important in the pathogenesis of bleomycin-induced pulmonary fibrosis. Results 
from Section 3.1.1 showed that UK-156406 abrogated thrombin-mediated fibroblast 
proliferation, procollagen production and CTGF mRNA levels in vitro. Rat CTGF and 
ai(I) procollagen mRNA levels were therefore measured in bleomycin-treated rats 
given UK-156406 at 6 days, to examine whether they were altered compared with rats
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Figure 3.3.5 UK-156406 Attenuates CTGF and a,(I) Procollagen mRNA Levels 
in Bleomycin-Induced Pulmonary Fibrosis After 6 Days.
Panel a shows data for bleomycin-treated animals expressed as fold increases in lung 
CTGF and 0^(1) procollagen mRNA levels above saline control animals, normalised for 
RNA loading based on densitometric quantitation of 28S rRNA (mean ± S.E.M, n=6). 
**(/?<0.01) denotes the statistical increase in CTGF and 0^(1) procollagen mRNA levels 
in bleomycin-treated animals compared with control animals, whereas * (p<0.05) 
indicates the reduction in these levels in bleomycin-treated animals given UK-156406, 
n=6. Panels b and c show phosphorimages of representative Northern blots for the 
2.4kb CTGF mRNA transcript and the 5.8kb and 4.8kb <Xj(I) procollagen transcripts 
with corresponding ethidium bromide stained 28S rRNA bands. Total cellular RNA 
was extracted from lung tissue and five pg was electrophoresed in a 1% agarose- 
formaldehyde gel. RNA was transferred to a nylon membrane and probed with 
radiolabelled 0^(1) procollagen and CTGF cDNA probes, respectively, for 16 hours. 
After hybridisation and stringency washing, membranes for 0^(1) procollagen were 
exposed to a Phosphorlmager storage screen for 12 hours, and for CTGF, 4 hours, for 
densitometric quantitation.
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given bleomycin alone and whether they preceded the changes observed in lung 
collagen accumulation.
Northern analysis of total cellular RNA extracted from lung tissue using 32P 
radiolabelled CTGF and «i(I) procollagen cDNA probes was performed. Figure 3.3.5 
shows the data expressed as fold increases in CTGF and ai(I) procollagen mRNA 
levels in bleomycin-treated rats, above saline-treated control levels, assessed on day 6, 
for 6 animals per group, (panel a). Representative Northern blots are shown in panels 
b and c and demonstrate that a single 2.4kb CTGF mRNA transcript and both 5.8kb 
and 4.8kb O'i(I) procollagen transcripts were present.
In lung tissue from bleomycin-treated animals, CTGF and ai(I) procollagen 
mRNA levels were increased 6.3 ± 0.4 -fold and 3.0 ± 0.4 -fold, respectively 
(p<0.01). However, these mRNA levels were reduced by 35% for CTGF and by 50% 
for Ofi(I) procollagen in bleomycin-treated rats given UK-156406, compared with 
bleomycin-treated rats given drug vehicle alone (»=6; /?<0.05). Finally, UK-156406 
had no effect on CTGF and ai(I) procollagen mRNA levels in saline-treated control 
animals.
3.3.6 CTGF Gene Expression in Primary Cultured Lung Fibroblasts and BALF 
Inflammatory Cells
Previous experiments showed that the CTGF mRNA transcript was expressed 
basally by cultured primary rat lung fibroblasts and that levels increased following 
stimulation with thrombin (see Results Section 3.2.9). To begin to elucidate the cell 
type(s) responsible for CTGF production in the bleomycin model, CTGF gene 
expression by confluent cultures of primary rat lung fibroblasts and freshly isolated
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Figure 3.3.6 CTGF Gene Expression in BALF Inflammatory Cells and 
in Cultured Rat Lung Fibroblasts.
Figure 3.3.6 shows a phosphorimage of a representative Northern blot for CTGF 
mRNA levels. The 2.4 kb rat CTGF transcript was undetectable in total RNA 
isolated from BALF inflammatory cells, in six separate animals receiving saline 
or bleomycin instillation. However, the CTGF transcript was easily detected in 
total RNA extracted from six replicate cultures of primary rat lung fibroblasts. 
The corresponding ethidium bromide stained 28 rRNA bands are also shown. 
After extraction from cells, total cellular RNA (five pg) was electrophoresed in a 
1% agarose-formaldehyde gel. RNA was transferred to a nylon membrane and 
probed with a radiolabelled CTGF cDNA probe for 16 hours. After hybridisation 
and stringency washing, membranes were exposed to a Phosphorlmager storage 
screens for densitometric quantitation. After 4 hours exposure, the 2.4 kb CTGF 
transcript was detectable in fibroblasts but remained absent in inflammatory cells, 
after 48 hours exposure.
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BALF inflammatory cells, following saline and bleomycin instillation, was compared. 
Since serum is known to stimulate CTGF production, confluent cultures of primary 
rat lung fibroblasts were carefully quiesced in serum-free conditions. Subsequently, 
Northern analysis of total RNA isolated from BALF inflammatory cells and cultured 
lung fibroblasts using a P radiolabelled CTGF probe was performed.
Figure 3.3.6 shows a representative Northern blot demonstrating that when similar 
amounts of total RNA from BALF inflammatory cells and primary rat lung fibroblasts 
were loaded on an agarose gel, CTGF mRNA was undetectable for BALF 
inflammatory cells following either saline or bleomycin instillation, but easily 
detectable in primary rat lung fibroblasts. Although comparison of these cell types by 
this in vitro system may be artificial, this result at least implies that the fibroblast, as 
opposed to inflammatory cells, may be an important source of CTGF production in 
the lung following bleomycin instillation.
3.3.7 Effect of UK-156406 on BALF Inflammatory Cell Number and Differential 
Proportions in Bleomycin-Induced Pulmonary Fibrosis
Thrombin exerts potent effects on inflammatory cell trafficking in vitro and in 
vivo (Bar-Shavit et al, 1983, Bizios et al, 1986). In order to assess whether direct 
thrombin inhibition affected inflammatory cell recruitment in this model, the effect of 
UK-156406 on total inflammatory cell number and the relative proportions of 
inflammatory cells in BALF were assessed. Experiments were conducted 3 and 6 days 
following bleomycin instillation, since these time points are known to reflect maximal 
inflammation in the lung following initial intratracheal insult (Izbicki et al, 2002).
To assess total cell inflammatory number, BALF was centrifuged, the 
supernatant removed and cell pellets were re-suspended in DMEM. BALF total cell
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Figure 3.3.7 Effect of UK-156406 on BALF Inflammatory Cell Number in 
Bleomycin-Induced Pulmonary Fibrosis at 3 and 6 Days.
Figure 3.3.7, panels a and b show the effect of UK-156406 (0.5 mg/kg/hr) on 
BALF total inflammatory cell number following a single intratracheal injection of 
bleomycin (1.5 mg/kg), or saline after 3 and 6 days respectively. ** (/K0.01) 
denotes the statistical difference in BALF total inflammatory cell number between 
bleomycin-treated rats and respective saline-treated controls. There was no 
significant difference in BALF total inflammatory cell number (ns) in bleomycin- 
treated animals given UK-156406 compared with animals given bleomycin alone, 
at either time point, n=6. This data is also shown in Appendix, Table 3.3.7.
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Figure 3.3.7 Effect of UK-156406 on BALF Inflammatory Cell Proportions in 
Bleomycin-Induced Pulmonary Fibrosis at 3 and 6 Days.
Figure 3.3.7 Panels c, d, e and f show representative cytospin slide photographs for 
the effect of UK-156406 (0.5 mg/kg/hr) on BALF total inflammatory cell 
proportions following a single intratracheal injection of bleomycin (1.5 mg/kg) or 
saline, after 3 and 6 days. Cells were identified as macrophages/monocytes, 
poymorphonuclear cells or lymphocytes and differential cell counts performed by 
counting at least 500 cells/slide. Typical cell morphology is shown below. In 
bleomycin-treated animals there was a characteristic significant increase in the 
proportion of both neutrophils and lymphocytes and a corresponding reduction in 
the proportion of macrophages, compared with saline-treated controls. However, 
UK-156406 had no effect on the relative proportion of inflammatory cells in 
bleomycin or in saline-treated control animals. The absolute values and statistical 
analysis o f this data is presented in Appendix, Table 3.3.7. (Magnification x400, 
x800)
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number was calculated by direct cell counting using a standard haemocytometer. 
Cytospins were also prepared in order for differential cell counts to be assessed. 
Figure 3.3.7 shows that total inflammatory cell number in BALF was dramatically 
increased in bleomycin-treated animals compared with saline controls at 3 and 6 days 
(p<0.01). However, UK-156406 had no effect on BALF total cell number at either 
time point, although a non-significant trend towards a reduction was seen on day 6 
(panels a and b and Appendix, Table 3.3.7).
Two independent observers assessed the differential BALF inflammatory cell 
populations by direct cell counting after representative cytospin samples had been 
stained with haematoxylin and eosin. Each investigator identified cells as 
macrophage/monocytes, neutrophils or lymphocytes and data was expressed as a 
percentage of the total number of lavageable cells. In bleomycin-treated animals there 
was a characteristic and significant increase in the proportion of both neutrophils and 
lymphocytes and a corresponding reduction in the proportion of macrophages, 
compared with saline-treated control animals (p<0.01). However, UK-156406 had no 
effect on the relative proportion of inflammatory cells in bleomycin or in saline- 
treated control animals (Figure 3.3.7 panel c, d, e and f  and Appendix, Table 3.3.7).
3.3.8 Effect of UK-156406 on Lung Histology in Bleomycin-Induced Pulmonary 
Fibrosis
Having demonstrated that lung collagen was decreased at the mRNA and 
protein level in bleomycin-treated animals given UK-156406, compared with animals 
given bleomycin alone, semi-quantitative lung histology was performed at 14 days to 
assess if histopathological changes in the lungs of these animals correlated with these
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findings. Representative lung tissue sections from all treatment groups were stained 
with Massons trichrome.
Control lung tissue from animals instilled with intratracheal saline and given 
UK-156406 or drug vehicle alone, showed entirely normal lung parenchymal 
architecture (Figure 3.3.8 panels a and b). Extensive areas of patchy fibrotic foci and 
mature regional interstitial fibrosis, with increased deposition of collagen, were 
present in the lungs of bleomycin-treated animals given drug vehicle, and also in 
bleomycin-treated animals given UK-156406 (panels c and d).
These changes were assessed by Ashcroft scoring (see Methods 2.10.5). Two 
independent observers examined 25 high power fields per animal and a mean fibrosis 
score was determined. Significant differences were identified in fibrosis scores 
between bleomycin-treated animals and their respective control groups. However, 
there was no significant difference in fibrosis scores in bleomycin-instilled animals 
given drug vehicle compared with bleomycin-instilled animals treated with UK- 
156406. It is well documented that comparing histological fibrosis scores in rats 
following bleomycin instillation can be problematic, so that quantitating differences 
in lung collagen between treatment groups can be difficult. The interpretation of this 
result is elaborated further in the Discussion 4.3.7.
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3.3.8 UK-156406 Has No Effect on Lung Histopathology in 
Bleomycin-Induced Pulmonary Fibrosis at 14 Days.
Figure 3.3.8 shows the effect of a continuous subcutaneous infusion of UK- 
156406 (0.5 mg/kg/hr) on lung histology, following a single intra-tracheal 
instillation of bleomycin (1.5 mg/kg) or saline, after 14 days. Massons trichrome 
was used to stain extracellular matrix and collagen blue (see below). Lung tissue 
sections from animals instilled with intratracheal saline and given UK-156406 or 
drug vehicle alone, showed entirely normal lung parenchymal architecture (Figure
3.3.8 panels a and b). Extensive areas of patchy fibrotic foci and mature regional 
interstitial fibrosis, with increased deposition of collagen, were present in the 
lungs o f bleomycin-treated animals given drug vehicle, and also in bleomycin- 
treated animals given UK-156406 (panels c and d). No significant difference in 
the severity of the histological damage in the lungs of bleomycin-treated animals 
given UK-156406 was demonstrated as assessed by Ashcroft scoring, when 
compared with animals given bleomycin alone. Data is also shown in Figure 3.3.8 
panel e.
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Figure 3.3.8 UK-156406 Has No Effect on Lung Histopathology in 
Bleomycin-Induced Pulmonary Fibrosis at 14 Days.
Figure 3.3.8, panel e shows the effect of a continuous subcutaneous infusion of 
UK-156406 (0.5 mg/kg/hr) on Ashcroft fibrosis scores, following a single intra­
tracheal instillation of bleomycin (1.5 mg/kg) or saline, after 14 days. Two 
independent observers examined 25 high power fields per animal and a mean 
fibrosis score was determined (mean ± S.E.M, n=4). The data shown represents 
the mean fibrosis score/experimental group for both observers. Mean fibrosis 
scores were significantly increased in bleomycin-treated animals compared with 
saline-treated controls **(/?<0.01). There was no significant difference in fibrosis 
scores for bleomycin-treated animals given UK-156406 compared with animals 
given bleomycin alone or in saline-treated animals given UK-156406, compared 
with saline control animals given drug vehicle (ns).
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3.3.9 Summary
The results of this section examining the effect of UK-156406 on bleomycin- 
induced pulmonary fibrosis showed the following:
(i) UK-156406 was safely administered at a therapeutic dose that significantly 
prolonged rat baseline coagulation parameters (PT and APTT).
(ii) UK-156406 significantly attenuated lung collagen accumulation in 
bleomycin-induced pulmonary fibrosis, at 14 days.
(iii) BALF total protein was slightly but significantly increased in bleomycin- 
instilled animals given UK-156406 compared with bleomycin-treated 
animals receiving drug vehicle alone, at 3 and 6 days.
(iv) Intratracheal instillation of bleomycin-induced rat CTGF and «i(I) 
procollagen mRNA levels compared with animals receiving saline alone, 
at 6 days. UK-156406 caused coordinate downregulation of both rat CTGF 
and ofi(I) procollagen mRNA levels in bleomycin-treated animals 
compared with animals receiving bleomycin alone, at this time point.
(v) BALF inflammatory cell number was unaffected in bleomycin-instilled 
animals given UK-156406 compared with bleomycin-treated animals 
receiving drug vehicle alone, at 3 and 6 days.
(vi) In contrast, the severity of lung histopathological changes were unaffected 
in bleomycin-instilled animals given UK-156406 compared with 
bleomycin-treated animals receiving drug vehicle alone, at 14 days, as 
assessed by Ashcroft scoring.
In conclusion, these findings showed that direct thrombin inhibition reduced lung
collagen accumulation in bleomycin-induced pulmonary fibrosis which was
preceded by a reduction in «i(I) procollagen and CTGF mRNA levels but not 
inflammatory cell recruitment.
3.4 Role of PAR-1 in Bleomycin-Induced Pulmonary Fibrosis
3.4.1 Establishing a Colony of PAR-1 _/"Mice
After demonstrating that direct thrombin inhibition attenuated lung collagen 
accumulation following bleomycin-induced lung injury, the effect of bleomycin- 
induced pulmonary fibrosis in PAR-1 and wild-type mice was evaluated, to 
establish the contribution of PAR-1-mediated cellular effects in this model.
For the following experiments, PAR-1 v' mice, which had been extensively 
backcrossed (>97%) onto the C57BL/6 background, (Cunningham et al, 2000) were 
used. Homozygote breeding pairs of PAR-1 'A mice were mated and selected weaned 
offspring from the resultant litters were subsequently inter-bred, such that 20 litters 
were produced in total. The average litter size was 5 ± 2 live bom mice, which was 
approximately 50% less than that of control litters from C57BL/6 wild-type mice. The 
number of live bom male and female mice varied for each individual litter. However, 
when the cumulative sum of male and female mice bom from each breeding pair was 
calculated, there was no disparity in male/female ratio (Appendix Table 3.4.1).
3.4.2 Genotyping of PAR-1_/' Mice
Although PAR-1 "/_ breeding pairs provided were homozygote, after initial 
mating, the genotype of the live bom was verified for some litters and was compared 
with the genotype of wild-type control mice. The livers of PAR-1 ''' and wild-type 
mice were removed, DNA extracted and the genotype of the mice was confirmed by 
Polymerase Chain Reaction (PCR), using commercially available primers (see 
Methods, 2.9.2). Placement of the primers generated a single 545 base pairs (bp)
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Figure 3.4.2 Genotyping of PAR-1-/' and Wild-Type Mice.
Figure 3.4.2 shows shows the PCR product generated for PAR-1 "A and WT mice 
(«=3). Livers of PAR-1 _/" and wild-type mice were removed and snap-frozen in 
liquid nitrogen. DNA was extracted and the genotype of the mice was confirmed 
by Polymerase Chain Reaction (PCR), using commercially available primers. A 
545 base pairs (bp) product was produced in WT mice and in the PAR-1 "/_ mice, 
a smaller 280bp product. This confirmed that the PAR-1 gene had been disrupted 
in PAR-1 "A mice. Lad on figure indicates molecular weight ladder. PAR-1 _/' = 
protease activated receptor knockout mice (homozygote). WT = wild type mice.
208
product in wild-type mice. In PAR-1 '/_ mice, where the PAR-1 gene is disrupted, as 
expected, a smaller single 280 bp product was obtained, (Figure 3.4.2),
3.4.3 Effect of Bleomycin Instillation on Body Weight in PAR-1 and Wild-Type 
Mice
Once sufficient live-born mice had been bred, experimental groups were 
constructed and the effect of bleomycin instillation was evaluated in these animals. 
PAR-1 '/_ and wild-type mice (aged 6-8 weeks) were given a single intratracheal dose 
of bleomycin (1 mg/kg) reconstituted in saline, or saline alone, in a total volume of 45 
jul, under deep anaesthesia. Figure 3.4.3 shows the effect of bleomycin or saline 
instillation on body weight in PAR-1 _/' and wild-type mice. All mice initially lost 
weight, which reached a nadir by day 3, as a result of the anaesthetic and instillation 
procedure. All animals given intratracheal bleomycin continued to lose weight. By 
day 14, wild-type animals given intratracheal saline alone, had increased their body 
weight by 7.57 ± 1 .3  %. Bleomycin-treated wild-type mice increased their body 
weight by 4.5 ±1.2 %. PAR-1_/" mice given saline or bleomycin had similar increases 
in body weight to wild-type mice, over the time period of the experiment.
In terms of survival, unlike rats, no mortality was observed in mice 
immediately following intratracheal saline or bleomycin instillation. Isolated cases of 
delayed mortality were observed at variable time points. However, the rate of 
mortality was the same for PAR-1 v' and wild-type mice.
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Figure 3.4.3 Effect of Bleomycin Instillation on Body Weight in 
PAR-1'/_ and Wild-Type Mice.
Figure 3.4.3 shows the effect of a single intratracheal bleomycin (1 mg/kg body 
weight) or saline instillation, on body weight for PAR-1 A and WT mice. Results 
are expressed as mean increase in body weight (%) compared with day 0 value. 
Appendix, Table 3.4.3 shows this data as mean ± S.E.M (n=6) for all treatment 
groups.
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3.4.4 Effect of Bleomycin Instillation on Lung Collagen in PAR-1 ''' and Wild- 
Type Mice at 14 Days
At the end of the 14 day time point, lungs were harvested from experimental 
groups. Similarly to rats, reverse-phase high-pressure liquid chromatography (HPLC) 
was used to quantify hydroxyproline levels in lung hydrolysates and total lung 
collagen was calculated, assuming that lung collagen contains 12.2% w/w 
hydroxyproline. Lung weight data used to calculate total lung collagen are presented 
in Appendix, Table 3.4.4a.
Figure 3.4.4 shows the effect of bleomycin and saline instillation on total lung 
collagen accumulation in PAR-1 'A and wild-type mice at 14 days. After 
administration of intra-tracheal saline, PAR-1 ''' and wild-type mice demonstrated no 
significant difference in basal lung collagen levels. Following bleomycin instillation, 
total lung collagen in wild-type mice was increased by 68.2 ± 5.0%, compared with 
wild-type controls given with saline (p<0.01). However, in bleomycin challenged 
PAR-1 _/" mice, total lung collagen was only increased by 24.2 ±8.1%  compared with 
PAR-1 'A animals given saline. This represents a 58.6 ± 5.5% reduction in lung 
collagen accumulation compared with wild-type animals given bleomycin (p<0.01). 
The results presented in Figure 3.4.4 were derived from the combination of two 
individual experiments where n= 15. Statistically significant differences in total lung 
collagen between PAR-1 mice instilled with bleomycin, compared with wild-type 
animals given bleomycin, were obtained in both individual experiments (see 
Appendix, Table 3.4.4).
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Figure 3.4.4 Effect of Bleomycin Instillation on Lung Collagen in PAR-1_/'
and Wild-Type Mice.
Figure 3.4.4 shows the effect of a single intra-tracheal instillation of bleomycin 
(1 mg/kg) or saline on total lung collagen at 14 days, for PAR-1 'A and WT mice. 
tt(p<0.01) denotes the statistical difference in total lung collagen between 
bleomycin and saline-treated WT mice. **(/k0.01) denotes the statistical 
difference in lung collagen accumulation in bleomycin-treated PAR-1 'A mice 
compared with WT mice given bleomycin. There was no statistical difference in 
total lung collagen between bleomycin and saline-treated PAR-1 mice. Data 
shown is derived from the combination of two experiments, where n= 15 in total, 
and statistical significance was obtained in both individual experiments 
(Appendix, Table 3.4.4),
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3.4.5 Effect of Bleomycin Instillation on Lung Histology in PAR-1 and Wild- 
Type Mice at 14 Days
Histopathological changes in the lungs of PAR-1 ‘A and wild-type mice 
following bleomycin instillation were assessed, to establish whether changes at the 
biochemical level correlated with histological evidence of reduced collagen 
accumulation. Representative lung tissue sections from all treatment groups were 
stained with Massons trichrome.
In saline-treated PAR-1 "A and wild-type mice, lung architecture was entirely 
normal (Figure 3.4.5, panels a and b). In contrast, lung tissue sections from wild-type 
mice given bleomycin showed extensive patchy areas of regional interstitial fibrosis 
with marked disruption of the alveolar unit and increased deposition of collagen, 
(Figure 3.4.5, panels a and c). However, in PAR-1 ''' mice given bleomycin, the 
structural integrity of the lung was more intact, with less evidence of fibrotic 
obliteration and destruction of the alveolar unit (Figure 3.4.5, panel d).
In order to quantify the severity of fibrosis in these animals, lung sections 
were initially assessed using Ashcroft scoring. Two independent observers examined 
all five lobes for each mouse lung, («=8) using light microscopy, at a high power 
(x400), in order to determine a fibrosis score for each lobe. The mean Ashcroft 
fibrosis score was calculated as the average of the individual lobe fibrosis scores.
In addition, lung histology was also quantified by semi-quantitative image 
analysis to evaluate the percentage of newly synthesised collagen content/lobe, using 
previously described methods (Mutsaers et al, 1998). The percentage area of newly 
synthesised collagen was computed for each field after thresholds had been purposely 
set through contrast enhancement. Individual lobes were examined blindly under high 
power (x200) and each lobe was covered in entirety, such that 2-35 fields of vision
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Figure 3.4.5 Effect of Bleomycin Instillation on Lung Histopathology in PAR-1
and Wild-Type Mice at 14 Days.
Representative lung tissue sections from PAR-1 and wild-type mice following 
bleomycin and saline instillation, were stained with Massons trichrome to assess 
histopathological changes. Lung architecture was normal in wild-type and PAR-1 A 
mice given intratracheal saline (panels a and b). Extensive patchy fibrotic foci, with 
increased deposition of collagen were detected in the lungs of wild-type mice given 
bleomycin compared with saline-treated controls at 14 days (Figure 3.4.5, panels a 
and c). The severity of lung fibrosis was reduced in PAR-1 _/"mice given bleomycin 
compared with bleomycin-treated wild-type mice (panel d) (x 400) when assessed 
using Ashcroft fibrosis scoring and semi-quantitative image analysis. These 
histological changes are represented statistically in Figure 3.4.5, panels d and e.
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Figure 3.4.5 Effect of Bleomycin Instillation on Lung Histopathology in 
PAR-1 and Wild-Type Mice at 14 Days.
Lung histopathology for bleomycin-treated PAR-1 mice and wild-type controls 
was quantitated by Ashcroft scoring (panel e), and by semi-quantitative image 
analysis (panel f). (For further details on methodology see Section 2.2.5) 
Significant differences in mean Ashcroft fibrosis score were observed between 
bleomycin-treated PAR-1 "A and wild-type mice and their respective saline-treated 
control groups ff(/?<0.01, n=8). Image-analysis, which determined the percentage 
o f newly synthesised collagen/lobe in the lungs o f animals, showed a significant 
difference between bleomycin-treated wild-type and saline-treated mice ff(/?<0.01, 
n=8). Both methods of quantitation showed that histological changes were 
significantly less in PAR-1 *A mice given bleomycin, compared with corresponding 
wild-type mice *(p<0.05, n=8). There were no differences in the histological 
scoring indices for wild-type and PAR-1 'A mice given intratracheal saline.
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were analysed, depending on the lobe size. This variance existed since the lobes of the 
mouse lung vary hugely in size from the very small cardiac lobe, to the left lobe, 
which effectively represents the whole of the left lung, (for further details please see 
Methods 2.10.5).
Ashcroft scoring and semi-quantitative image analysis both showed significant 
differences in severity of fibrosis between bleomycin-treated wild-type mice and 
corresponding saline-treated control groups (p<0.01, n=8). When the extent of 
histological damage was compared in bleomycin-treated PAR-1 "/_ and wild-type 
mice, the severity of fibrosis measured by Ashcroft scoring and the percentage of 
newly synthesised collagen content/lobe were both significantly reduced in PAR-1 "A 
mice (p<0.05, n=8), (Figure 3.4.5, panel e and f).
3.4.6 Effect of Bleomycin Instillation on BALF Inflammatory Cell Number and 
Differential Cell Proportions in PAR-1''' and Wild-Type Mice at 6 Days
PAR-1 is expressed on cell types known to be integral in inflammatory cell 
recruitment and endothelial cell permeability (Dery et al, 1998). Since these processes 
are dramatically affected following bleomycin injury, the next experiments of this 
thesis were aimed at elucidating if these mechanisms were altered in PAR-1 'A mice.
To examine whether inflammatory cell burden was altered in the lungs of 
bleomycin-treated PAR-1 mice compared with wild-type mice, BALF total cell 
number and the relative proportions of these cells was assessed, 6 days after initial 
lung insult. As described previously in Section 3.3.7, this time-point was chosen since 
pulmonary inflammation and thrombin levels are known to be at maximal levels, 6 
days following bleomycin instillation (Izbicki et al 2002, Tani et al, 1991).
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Figure 3.4.6 Effect of Bleomycin Instillation on BALF Inflammatory Cell 
Number in PAR-1 ''' and Wild-Type Mice at 6 Days.
Figure 3.4.6, panel a shows the effect of a single intra-tracheal instillation of 
bleomycin (1 mg/kg) on BALF total inflammatory cell number for PAR-1 7' and 
wild-type mice at 6 days. Significant differences in mean BALF total 
inflammatory cell number were observed between bleomycin-treated wild-type 
and PAR-1 '/_ mice and their respective saline-treated control groups ff(p<0.01, 
n=8) and «=8), respectively. **(p<0.01) denotes the statistical
difference in BALF total inflammatory cell number which was observed in 
bleomycin-treated PAR-1 _/' mice compared with wild-type mice given bleomycin. 
Appendix, Table 3.4.6 shows this data expressed as mean ± S.E.M for all 
treatment groups.
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Figure 3.4.6 Effect of UK-156406 on BALF Inflammatory Cell Proportions in 
Bleomycin-Induced Pulmonary Fibrosis at 6 Days.
Figure 3.4.6 Panels b, c, d and e show representative cytospin slide photographs 
for the effect of bleomycin (1 mg/kg) on BALF total inflammatory cell proportions 
in PAR-1 ''' and wild-type mice at 6 days. Cells were identified as 
macrophages/monocytes, poymorphonuclear cells or lymphocytes and differential 
cell counts performed by counting at least 500 cells/slide. Typical cell morphology 
is shown below. In bleomycin-treated PAR-1 A and wild-type mice, there was a 
characteristic significant increase in the proportion of both neutrophils and 
lymphocytes and a corresponding reduction in the proportion of macrophages, 
compared with saline-treated controls. However, disruption in the PAR-1 gene did 
not have any effect on these relative proportions in bleomycin or in saline-treated 
mice, when compared with wild-type control animals. The absolute values and 
statistical analysis of this data is presented in Appendix, Table 3.4.6. 
(Magnification x400, x800)
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In wild-type and PAR-1 "A mice given intratracheal saline, no significant 
difference in BALF total cell number was detected. In wild-type mice given 
bleomycin, total inflammatory cell number was increased by 6.03 ± 0.85-fold 
compared with saline controls (p<0.01, n -8), (Figure 3.4.6, panel a and Appendix 
Table 3.4.6). However, in bleomycin-treated PAR-1 '/' mice, BALF total 
inflammatory cell number was only increased by 2.47 ± 0.49-fold, compared with 
PAR-1 _/' mice given saline alone (p<0.05, «=8). BALF total inflammatory cell 
number was reduced by 41.0 ± 1.5% in PAR-1 '7‘ given bleomycin, compared with 
bleomycin-treated wild-type mice.
The differential BALF inflammatory cell populations were assessed by direct 
cell counting after representative cytospin samples had been stained with 
haematoxylin and eosin. There was no difference in the relative proportions of BALF 
inflammatory cells when saline-treated wild-type or PAR-1 'A mice were compared. 
Characteristic increases in the proportion of both neutrophils and lymphocytes and a 
corresponding reduction in the proportion of macrophages, in wild-type and PAR-1 
mice given bleomycin were observed, when compared with respective saline-treated 
controls (p<0.01). However, there was no difference in the relative proportion of 
inflammatory cells between bleomycin-treated wild-type and PAR-1 ‘A mice, (panels 
b, c, d and e and Appendix Table 3.4.6).
3.4.7 Effect of Bleomycin Instillation on BALF Total Protein in PAR-1 "/' and 
Wild-Type Mice at 6 Days
In order to investigate if vascular leak was altered in the lungs of PAR-1 ~/' and 
wild-type mice following bleomycin instillation, BALF total protein levels, were
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Figure 3.4.7 Effect of Bleomycin Instillation on BALF Total Protein in 
PAR-1 and Wild-Type Mice at 6 Days.
Figure 3.4.7 shows the effect of a single intra-tracheal instillation of 
bleomycin (1 mg/kg) on BALF total protein for PAR-1 '/_ and wild-type mice 
at 6 days. Significant differences in BALF total protein were observed 
between bleomycin-treated wild-type and PAR-1 mice and their respective 
saline-treated control groups ft(/?<0.01, n=8). *(p<0.05) denotes the statistical 
difference in BALF total protein between bleomycin-treated PAR-1 "A and 
corresponding wild-type control mice.
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measured 6 days following initial intratracheal injection (Figure 3.4.7). BALF total 
protein was measured using the same method as used for rats (see Section 3.3.4).
There was no difference between BALF total protein levels in wild-type and 
PAR-1 "7' mice given intratracheal saline. BALF total protein was significantly 
increased in wild-type and PAR-1 '7' mice given bleomycin by 24.5 ± 4.7-fold and 
11.5 ± 3.0-fold, respectively, compared with respective saline-treated controls 
(p<0.01, n=8). BALF total protein levels were significantly reduced by 33.3 ± 1.0% in 
bleomycin-treated PAR-1 *7' mice, compared with corresponding wild-type mice given 
bleomycin.
Having shown that inflammatory cell burden and microvascular permeability 
were both reduced in the lungs of bleomycin-treated PAR-1 '7‘ mice compared with 
wild-type controls, it was also assessed whether these changes correlated with a 
reduction in lung weight at this time point. Appendix Table 3.4.7 shows this data and 
as expected, lung weight was significantly reduced by 43.7 ± 4.2% in bleomycin- 
treated PAR-1 '7' mice compared with bleomycin-treated wild-type controls (p<0.01).
3.4.8 Effect of Bleomycin Instillation on FISP12 mRNA Levels in PAR-1 ~h and 
Wild-type mice at 6 Days
Experiments performed in rats showed that direct thrombin inhibition reduced 
lung CTGF levels in bleomycin-treated animals compared with animals receiving 
bleomycin alone, at 6 days. (Results Section, 3.3.5). Since CTGF is proposed to 
mediate downstream pro-fibrotic effects of thrombin following activation of PAR-1, 
in the final experiments of this thesis, FISP 12 mRNA levels (the mouse orthologue of
CTGF), were compared in bleomycin-treated PAR-1'/_ and wild-type mice, at 6 days, 
to assess if levels of this growth factor were altered in these animals.
Total cellular RNA was extracted from lung tissue and Northern analysis 
performed using a 32P radiolabelled FISP12 cDNA probe. Figure 3.4.8, panel a 
shows a graphical representation of the data expressed as FISP12 mRNA levels, 
normalised for RNA loading based on densitometric quantitation of 28S RNA. 
FISP12 mRNA levels were virtually undetectable in saline-treated PAR-1'/_ and wild- 
type mice were not quantifiable. However, the 2.4 kb FISP12 mRNA transcript was 
easily identified in PAR-1 '7‘ and wild-type mice given bleomycin. FISP12 mRNA 
levels in bleomycin-treated PAR-1 ''' mice were reduced by 39% ± 7.0% compared 
with wild-type mice given bleomycin (p<0.01, n=8). A representative Northern blot 
of this data is shown in panel b.
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Figure 3.4.8 Effect of Bleomycin Instillation on Lung FISP12 mRNA 
Levels in PAR-1 and Wild-Type Mice at 6 Days.
Panel a shows data for bleomycin-treated PAR-1 'A and wild-type mice animals 
expressed as FISP12 mRNA levels, normalised for RNA loading based on 
densitometric quantitation of 28S RNA (mean ± S.E.M, n= 8). The FISP12 
mRNA transcript was not detected in PAR-1 'A and wild-type mice given 
intratracheal saline. **(/?<0.01) indicates the reduction in FISP12 mRNA levels 
in PAR-1 mice given bleomycin compared with bleomycin-treated wild-type 
mice.
Panel b shows a phosphorimage of a representative Northern blot for the 2.4kb 
FISP12 mRNA transcript with corresponding ethidium bromide stained 28S 
rRNA bands. Total cellular RNA was extracted from lung tissue and five pg was 
electrophoresed in a 1% agarose-formaldehyde gel. RNA was transferred to a 
nylon membrane and probed with a radiolabelled FISP12 cDNA probe, for 16 
hours. After hybridisation and stringency washing, the membrane was exposed to 
a Phosphorlmager storage screen for 4 hours, for densitometric quantitation.
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3.4.9 Summary
The results of this section examining the effect of bleomycin-induced pulmonary 
fibrosis in PAR-1 'A and wild-type mice showed the following:
(i) Lung collagen accumulation and lung weight at 14 days were significantly 
abrogated in PAR-1 ''' mice instilled with bleomycin, compared with wild- 
type animals given bleomycin.
(ii) Changes at the biochemical level of reduced collagen accumulation in the 
lungs of PAR-1 _/" and wild-type mice following bleomycin instillation, 
correlated with histopathological evidence, at 14 days.
(iii) BALF total inflammatory cell number at 6 days was significantly reduced 
in bleomycin-instilled PAR-1 7' mice compared with bleomycin-treated 
wild-type controls. BALF inflammatory cell proportions were unaffected 
when these groups of animals were compared.
(iv) BALF total protein at 6 days was significantly reduced in PAR-1 _/' mice 
given bleomycin compared with bleomycin-instilled wild-type animals. 
The attenuation in BALF total inflammatory cell number and total protein 
in bleomycin-treated PAR-1 '/_ mice compared with wild-type control 
animals, correlated with a significant reduction in lung weight at this time 
point.
(v) Lung FISP 12 mRNA levels were significantly reduced in bleomycin- 
treated PAR-1 _/' mice when compared with wild-type mice receiving 
bleomycin.
In conclusion, PAR-1 mice are protected from bleomycin-induced pulmonary 
fibrosis.
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Chapter 4
Discussion
225
Overview
There is compelling evidence that the coagulation cascade is activated in the 
lungs of patients with pulmonary fibrosis, but the role of thrombin in this disease 
remains unknown. The aim of this thesis was to examine the hypothesis that persistent 
and excessive generation of thrombin plays a role in promoting lung collagen 
accumulation in pulmonary fibrosis, via activation of its major cellular receptor, PAR-
1.
To address this hypothesis, the initial experiments of this thesis investigated 
the effect of a potent and highly selective direct thrombin inhibitor, UK-156406 
(Pfizer Central Research, UK) on thrombin-induced fibroblast responses in vitro. 
Subsequently, thrombin and PAR-1 were fully characterised in the bleomycin model 
of pulmonary fibrosis in rats and the effect of UK-156406 assessed in this model. In 
addition, the role of PAR-1 in experimental pulmonary fibrosis was evaluated by 
comparing the effects of bleomycin-induced lung injury in PAR-1 7" versus wild-type 
mice.
This thesis reports a number of novel observations. First, UK-156406 
abrogated thrombin-induced fibroblast responses in vitro. Second, thrombin and PAR- 
1 were both increased in the lungs of rats following bleomycin instillation, compared 
with saline-treated controls, when assessed immunohistochemically. Third, direct 
thrombin inhibition attenuated lung collagen accumulation in this model. 
Furthermore, the reduction in lung collagen accumulation was preceded by an 
abrogation in ai(I) procollagen and CTGF mRNA levels, but not inflammatory cell 
recruitment. Finally, PAR-1 ''' mice were protected from bleomycin-induced 
pulmonary fibrosis, since lung collagen accumulation was reduced in bleomycin-
treated PAR-1_/' mice compared with corresponding wild-type mice. In addition, this 
observation correlated with a reduction in CTGF mRNA levels. Furthermore, in 
contrast to studies with UK-156406 in rats, inflammatory cell recruitment and 
vascular leak were attenuated in bleomycin-treated PAR-1 mice compared with 
wild-type mice given bleomycin.
Taken together, the studies performed in this thesis support the hypothesis that 
thrombin and its major cellular receptor, PAR-1, play an important role in the 
pathogenesis of pulmonary fibrosis. The following sections will discuss these studies 
and the results obtained in greater detail.
4.1 Effect of UK-156406 on Thrombin-Induced Fibroblast Responses 
in vitro
4.1.1 UK-156406 Abrogates Thrombin-Induced Fibroblast Proliferation, 
Procollagen Production and CTGF Gene Expression in vitro
In order to examine the hypothesis that thrombin plays a role in promoting 
lung collagen accumulation in bleomycin-induced pulmonary fibrosis, a suitable 
pharmacological tool had to be identified for experimental studies in vivo. A number 
of direct inhibitors of thrombin proteolytic activity have been generated and used 
experimentally, all of which act by binding to the active (catalytic) site of the protease 
(for reviews see Tapparelli et al, 1993, Walker and Royston 2002). Of note, thrombin- 
induced fibroblast proliferation, procollagen production and CTGF levels in human 
fetal lung fibroblasts in vitro have been shown to be abrogated by the direct thrombin 
inhibitors, PPACK (D-phenylalanine-proline-arginine-methylchloride) and hirudin, 
(Chambers et al, 1998, 2000). However, costs associated with hirudin would have
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been prohibitive for in vivo studies and although PPACK is known to be a potent 
direct thrombin inhibitor, it is not very selective.
Subsequently, Pfizer (UK) were approached and as a result, an ideal 
pharmacological agent (direct thrombin inhibitor, UK-156406) was provided for 
unrestricted use in the experiments of this thesis. UK-156406 is a hydrophilic, low 
molecular weight, peptide-based, reversible, direct inhibitor of thrombin proteolytic 
activity. It is very potent, has a dissociation constant (Kj) of 0.39 nM and displays 
excellent selectivity over other coagulation proteases, including factor Xa, plasmin 
and Factor Vila (Table 4.1. In addition, UK-156406 has also been screened against 
other proteases such as elastase, chymotrypisn, cathepsins B, D, E and G, renin, 
pepsin, gastricin, leucine aminopeptidase, and carboxypeptidase A and the I C 5 0  for all 
enzymes was >10^ M (data provided by Pfizer, UK, patent # W 09513274). A number 
of the proteases described above are released following intratracheal bleomycin 
instillation and some are known to influence the fibrotic response in this model (Idell 
et al, 1987). The highly selective nature of UK-156406 was therefore critical to 
ensure that when the compound was used in vivo, that it only inhibited thrombin 
proteolytic activity.
Table 4.1: The Selectivity of UK-156406
Enzyme Ki(M) Selectivity Ratio 
(compared to thrombin)
Thrombin 3.9 x 10 ' lu 1
Trypsin 1 . 6  x 1 0  ■“ 40
Factor Xa 5.1 x 10 ’ 7 1300
Factor Vila 2.9 x 10 7440
Plasmin 3 .6 x 1 0 ’ 6 9200
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UK-156046 was initially designed for use in the field of vascular biology. Its 
pharmacological properties (small, fast, selective with reversible inhibition of the 
catalytic site of thrombin and ability to inhibit both clot-bound and soluble thrombin) 
make it an ideal anticoagulant agent for intravascular thrombotic events. Following 
intratracheal bleomycin instillation, both intravascular and extravascular thrombin are 
generated chronically in the lung (Tani et al, 1991, please also see Discussion Section 
4.2.1), so an important initial consideration was whether UK-156406 would be 
capable of inhibiting thrombin proteolytic activity outside the vasculature. 
Furthermore, since the half-life of UK-156406 is approximately one hour, an effective 
route of delivery had to be identified whereby the compound could be delivered 
continuously in vivo. Experiments addressing these issues are elaborated upon in 
Discussion Section 4.3. A further concern that had to be addressed was whether UK- 
156406 could inhibit thrombin-induced cellular effects in the fibrotic lung, in 
particular, fibroblast responses. This was particularly critical since thrombin has such 
a high affinity for its receptor (Kuliopulos et al, 1999). For this reason, the effect of 
UK-156406 was initially assessed on thrombin-induced lung fibroblast proliferation, 
procollagen production and CTGF mRNA levels in human lung fibroblasts in vitro.
In these experiments, UK-156406 significantly inhibited thrombin-induced 
lung fibroblast proliferation, procollagen production and CTGF mRNA levels in a 
dose-dependent manner from equimolar concentrations of the protease onwards (see 
Figures 3.1.1, 3.1.2 and 3.1.3). These effects were comparable to those obtained with 
hirudin and PPACK in previous reports (Chambers et al, 1998, 2000). However, in 
order to obtain complete abrogation of fibroblast responses, the compound needed to 
be used in 10-fold excess. A possible explanation behind this result is that although 
UK-156406 is a highly potent and selective inhibitor of thrombin, the protease also
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has a high affinity for PAR-1. It is therefore possible that at lower concentrations of 
UK-156046, thrombin preferentially binds to and activates PAR-1, stimulating 
downstream functional effects, whereas at higher concentrations of UK-156406, 
thrombin proteolytic activity is blocked more efficiently.
These in vitro observations provided an early indication of the steady-state 
level of UK-156406 that would need to be attained, in order to be sufficient to block 
thrombin proteolytic activity in the bleomycin-injured lung. This issue will be 
elaborated upon further in Discussion, Section 4.3. However, the overall conclusion 
of these in vitro experiments was that this compound was deemed suitable for further 
evaluation in the bleomycin model of pulmonary fibrosis.
4.2 Thrombin and PAR-1 in Bleomycin-Induced Pulmonary Fibrosis
4.2.1 BALF Thrombin Levels in Bleomycin-Induced Pulmonary Fibrosis
Before assessing the role of UK-156406 in the bleomycin model of pulmonary 
fibrosis, extensive studies were performed to fully characterise thrombin and PAR-1 
in this model. Following intratracheal bleomycin instillation, there are rapid and 
sustained changes in procoagulant activity in the injured lung due to a number of 
mechanisms. Bleomycin causes acute endothelial and epithelial injury, which results 
in intravascular coagulopathy but also facilitates leakage of plasma components, 
including coagulation proteases, into the interstitial and alveolar space (Idell et al,
1989). Local activation of coagulation in the lung by intravascular and extravascular 
cells that express tissue factor, the primary cell-surface initiator of the extrinsic 
coagulation cascade, results in deposition of fibrin in the microvasculature and intra- 
alveolar space (Idell et al, 1987, 1989, Olman et al 1995, Ruf and Riewald, 2003).
In terms of thrombin activity following bleomycin instillation, a previous 
time-course study conducted in male Wistar rats, had demonstrated that thrombin 
levels in BALF were increased. Thrombin levels in response to bleomycin were 
elevated from day 2 onwards, peaking at day 6  and falling by day 15 (Tani et al, 
1991). This study employed a fluorogenic substrate (7-amino-4-methylcoumarin) to 
detect thrombin activity, using a previously described method (Morita et al, 1977). 
However, fluorogenic substrates are now not widely used since they require 
complicated and expensive equipment. In this thesis, male Lewis rats were used, since 
they are routinely used in the host laboratory for bleomycin studies with a highly 
reproducible doubling in lung collagen after 14 days (Mutsaers et al, 1998). In order 
to establish if thrombin activity was elevated in the lung following intratracheal
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bleomycin in this rat strain, BALF thrombin levels were measured at 6  days. BALF 
thrombin activity was measured using a spectrophotometric assay, based on the 
chromogenic substrate S2238 (H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline 
dihydrochloride), (for further details of this assay, see Methods Section 2.10.7), In 
these experiments, thrombin levels were dramatically elevated by approximately 1 0 - 
fold in bleomycin-treated rats compared with saline-treated controls at this time point. 
This corresponds to a concentration of BALF thrombin in the range of 50 -100 nM. 
These levels are similar to the concentration of thrombin detected in BALF from 
patients with pulmonary fibrosis with systemic sclerosis (Hemandez-Rodriguez et al, 
1995) and also during blood coagulation following vascular injury (Walz et al, 1985).
The detection of increased BALF thrombin activity following bleomycin 
instillation suggested that the active protease may leak into the extravascular alveolar 
space from the intravascular compartment as a result of chronic activation of the 
coagulation cascade, following the extensive and continued endothelial injury caused 
by bleomycin. The significance of this observation will be elaborated in Section 4.2.3. 
However, these experiments did not provide any information on the localisation of 
thrombin in the injured lung. In order to examine this further, novel 
immunohistochemical studies were performed and are described in the next section.
4.2.2 The Immunohistochemical Localisation of Thrombin in Bleomycin-Induced 
Pulmonary Fibrosis
Active thrombin was localised in the injured lung, by performing 
immunohistochemical experiments at several time points following bleomycin 
instillation. Active thrombin was detected by hirudin binding and visualised using an 
anti-hirudin antibody and conventional immunohistochemical methods (see Section
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2.10.6). Hirudin is a highly selective polypeptide inhibitor of thrombin proteolytic 
activity that acts by irreversibly binding to the anion binding exosite of thombin via 
its a long carboxyl tail. This creates a 1:1 stoichiometric complex, with a dissociation 
constant as low as 20 fM (Stone et al, 1986). These properties of hirudin ensure that 
this immunohistochemical technique provides highly specific staining for thrombin. 
These experiments revealed that the protease was predominantly localised to 
macrophages in inflammatory and fibroproliferative foci, and also on interstitial cells, 
presumably fibroblasts, in these areas (Figure 3.2.4). Furthermore, immunoreactivity 
for thrombin was maximal 6  days following bleomycin instillation. This is in 
accordance with previous reports of peak thrombin levels (Tani et al, 1991) and 
maximal procoagulant activity associated with alveolar macrophages (Kobayashi et 
al, 1990), in BALF from bleomycin-treated rats and correlates with the data described 
in Section 4.2.1.
4.2.3 Potential Mechanisms Leading to Increased Expression of Active Thrombin 
in Pulmonary Fibrosis
There are a number of potential mechanisms which may lead to increased 
expression of active thrombin on macrophages and interstitial cells following 
bleomycin injury. For example, the active protease may leak into the alveolar space 
from the intravascular compartment as described above. However, it is also known 
that resident lung cells, including alveolar macrophages, fibroblasts and alveolar 
epithelial cells constitutively express tissue factor (Drake et al 1989, Olman et al, 
1995, Gross et al, 1992). It is also recognised that tissue factor expression by 
fibroblasts and epithelial cells is inducible by tissue injury or inflammatory stimuli 
such as TNFo' or TGF/3 (Idell et al, 1992, 1994) and that fibroblasts can sustain
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membrane-dependent coagulation reactions between tissue factor and factor VII in the 
injured lung (Olman et al, 1995). Furthermore, expression of tissue factor is increased 
on both fibroblasts and macrophages in developing fibroproliferative lesions, 
following bleomycin instillation (Olman et al, 1995). In addition, membrane assembly 
sites for the generation of the prothrombinase complex, responsible for activating the 
intrinsic coagulation cascade, are expressed on macrophages (McGee et al, 1986, 
1990), (for further discussion of the coagulation cascade see Introduction Section
1.6). It is therefore thought that macrophages and fibroblasts are able to accelerate 
membrane-dependent coagulation reactions and facilitate the local extravascular 
generation of thrombin, independent of classical blood coagulation. Indirect support 
that these mechanisms are important in the human lung has come from studies 
showing that thrombin is present on the surface of normal human alveolar 
macrophages (Zacharski et al, 1995) and that expression of tissue factor on these cells 
is dramatically increased in patients with pulmonary fibrosis (Imokawa et al, 1997). 
This evidence suggests that extravascular coagulation events in the alveolar- 
interstitial compartment, on the surface of both macrophages and fibroblasts, may 
contribute to the fibrotic response in the injured lung.
4.2.4 The Immunohistochemical Localisation of PAR-1 in Bleomycin-Induced 
Pulmonary Fibrosis
Further experiments were also performed to examine the expression of PAR-1, 
since this had never been previously described for the lung. Indirect evidence that 
PAR-1 was present in the lung had come from studies showing that PAR-1 mRNA 
could be detected in cultured alveolar macrophages derived from BALF isolated from 
healthy control subjects (Nelken et al, 1995). Furthermore, specific agonists of this
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receptor were shown to cause bronchoconstrictor responses in rats (Cicala et al, 
1999), suggesting that functional PAR-1 receptors were present in the lungs of these 
animals.
A more recent study, published during the course of this thesis, showed that 
PAR-1 was present on the bronchial epithelium of asthmatic and normal control 
subjects (Knight et al, 2001). Consistent with this observation, immunohistochemical 
studies performed as part of this thesis showed that PAR-1 was expressed on the 
bronchial epithelium of lung tissue from male Lewis rats. Furthermore, there was no 
evidence of altered expression of PAR-1 on the bronchial epithelium, following saline 
or bleomycin instillation (Figure 3.2.5).
In contrast, expression of PAR-1 in the lung parenchyma was different for 
bleomycin-treated animals compared with saline-treated controls. Similarly to 
thrombin, following bleomycin instillation, positive staining was predominately 
associated with macrophages in interstitial inflammatory and fibroproliferative foci 
and also with elongated spindle-shaped cells in these areas, taken to represent 
fibroblasts. Time course studies further revealed that as for thrombin, expression was 
maximal at 6  days (Figure 3.2.5a).
Having demonstrated such a dramatic increase in the expression of PAR-1 in 
the lungs of bleomycin-treated rats, PAR-1 gene expression was examined in these 
animals to determine if  changes at the protein level were preceded by alterations at the 
mRNA level. These studies confirmed that PAR-1 mRNA levels in lungs of rats were 
significantly increased by approximately three-fold following bleomycin instillation 
compared with animals given saline alone. A number of different cell type(s) may 
have contributed to this increase in PAR-1 gene expression. The 
immunohistochemical studies of this thesis suggest that likely cells would include
macrophages, epithelial cells and fibroblasts. However, PAR-1 has also been detected 
on vascular smooth muscle cells, endothelial cells, lymphocytes and neutrophils in 
other tissues (Nelken et al, 1995, Griffin et al, 2001, Macey et al, 1998, Kannan,
2002). As a further assessment of PAR-1 expression by inflammatory cells in the 
lung, immunocytochemistry was performed on freshly isolated BALF inflammatory 
cells, following bleomycin or saline instillation. Interestingly, these experiments 
correlated with studies performed in lung tissue sections, revealing increased 
expression of PAR-1 associated with macrophages following bleomycin instillation 
but no staining associated with lymphocytes or neutrophils, suggesting that PAR-1 
mediated cellular responses by these cell types may be less important in this model.
Elongated spindle-shaped interstitial cells with a typical fibroblast morphology 
and localisation also stained positively for PAR-1 following bleomycin instillation. 
However, it was difficult to definitively conclude that these cells were fibroblasts due 
to the morphology of the interstitial fibroblast within the pulmonary parenchyma. This 
can make specific staining using conventional immunohistochemisty and light 
microscopy problematic, a phenomenon also recognised by other investigators. Since, 
there is currently no specific immunohistochemical marker for fibroblasts, primary rat 
lung fibroblasts were cultured from male Lewis rats, and PAR-1 expression was 
further evaluated in these cells in vitro.
In these experiments, primary rat lung fibroblasts expressed PAR-1 at both the 
mRNA and protein levels, when assessed by Northern analysis and 
immunocytochemistry, respectively. Experiments were conducted in serum-free 
conditions in order to reduce any confounding effect of serum on PAR-1 expression. 
These experiments confirmed, at least in vitro, that PAR-1 was expressed in the lung, 
on the cell-type responsible for mediating the direct pro-fibrotic effects of thrombin.
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In order to investigate whether primary rat lung fibroblasts also exhibited functional 
PAR-1-mediated cellular responses, fibroblast proliferation and CTGF gene 
expression were assessed in response to thrombin and a PAR-1 specific agonist. 
Primary rat lung fibroblasts responded to thrombin, proliferating by approximately 
two-fold and increasing CTGF mRNA levels by three-fold, in serum free conditions 
after quiescence. These responses were mimicked with a PAR-1-specific agonist 
(TFLLR) but were less robust than for the optimal stimulatory dose of thrombin. 
Other investigators have also noted this observation (K Dabbagh, PhD Thesis, 
Chambers et al, 1998) and there are a number of proposed explanations for this 
observation. First, proteolytic cleavage of the receptor by thrombin itself may be 
necessary in order to obtain a frill stimulatory response. Second, it is possible that the 
tethered ligand generated following receptor cleavage by thrombin may adopt a more 
appropriate orientation than TFLLR at critical sites on the body of the receptor. The 
exact reason for this observation remains uncertain, but the conclusion from these 
experiments was that primary rat lung fibroblasts expressed functional PAR-1 
receptors.
PAR-1 expression was also assessed in a limited number of biopsy specimens 
from patients with pulmonary fibrosis and also in normal control lung tissue to assess 
if findings in the bleomycin model correlated with human disease. Although, these 
results were not completely conclusive, PAR-1 mRNA could not be detected in lung 
tissue obtained from control patients but was present in lung biopsy specimens from 
patients with pulmonary fibrosis. Immunohistochemical studies further revealed weak 
staining for PAR-1, associated with resident alveolar macrophages, in the normal 
lung. However, in lung tissue sections taken from patients with established pulmonary 
fibrosis, there was intense and widespread positive staining for PAR-1. Similar to
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bleomycin-instilled rats, staining was predominantly associated with macrophages in 
fibroproliferative and inflammatory foci and also with elongated spindle-shaped cells 
(Figure 3.2 11).
4.2.5 Potential Mechanisms Leading to Increased PAR-1 Expression in 
Pulmonary Fibrosis
There are a number of possible factors that may be responsible for increased 
expression of PAR-1 in the fibrotic lung, as a number of studies have shown that 
PAR-1 expression is altered in response to a variety of insults and stimuli. For 
example, in vitro studies have shown that when monocytes differentiate into 
macrophages, following stimulation with either interferon 7 , granulocyte-macrophage 
colony stimulating factor (GM-CSF) or macrophage colony stimulating factor (M- 
CSF), PAR-1 expression is increased and furthermore, that differentiated cells 
become more responsive to thrombin (Naldini et al, 1998, Colognato et al, 2003). All 
of these inflammatory stimuli are released following lung injury and GM-CSF has 
been shown to be one of the earliest mediators released by recruited inflammatory 
cells in alveoli following bleomycin instillation (Andreutti et al, 1998). In addition, 
the process of fibroblast differentiation into myofibroblasts has also been shown to 
correlate with increased expression of PAR-1. PAR-1 mRNA levels progressively 
increase in rat liver stellate cells as they adopt a myofibroblastic phenotype, when 
activated by culture on plastic in vitro (Gaca et al, 2002). Consistent with this 
observation, PAR-1 expression is increased in mesenchymal cells within fibrous septa 
in biopsies from patients with liver cirrhosis (Marra et al, 1998). Further evidence that 
PAR-1 expression and fibroblast differentiation may be an important mechanism in 
vivo has been provided by a study of bladder inflammation in rats. In this study,
immunohistochemical expression of PAR-1 in fibroblasts underwent a dramatic 
transition as the model progressed. In the acute stage, PAR-1 was virtually 
undetectable in fibroblasts, but in the chronic phase of the model, which is 
complicated by fibrosis, PAR-1 expression was markedly elevated (D’Andrea et al,
2003). Furthermore, PAR-1 expression has also been shown to be upregulated when 
stromal fibroblasts surrounding carcinoma cells, differentiate into O '-smooth muscle 
actin positive fibroblasts as a result of exposure to tumour cells (D’Andrea et al,
2001) and also during skeletal muscle differentiation (Chevessier et al, 2001). 
Although these final studies were not performed using lung cells, they provide 
evidence that cellular differentiation and PAR-1 expression may be intimately linked.
PAR-1 expression is also increased in response to a number of mediators 
derived from different cell types. Of note, thrombin itself induces PAR-1 gene 
expression by endothelial cells by activating the PAR-1 promoter (Ellis et al, 1999). It 
has been proposed that this may be an important mechanism in explaining increased 
PAR-1 gene expression in endothelial cells in chronic allograft nephropathy in 
humans, a fibrotic condition complicating renal transplants (Grandaliano et al, 2001). 
In addition, PAR-1 expression is increased by angiotensin II in vascular smooth 
muscle cells (Fisslthaler et al, 1997), by IL-1, TNFa and TGF/? in skeletal muscle 
cells (Mbebi et al, 2001) and by TGF/3 in osteoblasts (Abraham et al, 1999). The 
exact role of these mediators in regulating PAR-1 expression in the fibrotic lung has 
not been investigated, but it is possible that they may play a role in explaining the 
immunohistochemical findings of this thesis, since they are abundant following 
bleomycin instillation.
Finally, a number of direct insults to different tissues have been shown to 
correlate with increased expression of PAR-1. For example, intestinal radiation to the
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gut has been shown to upregulate PAR-1 expression in vascular and smooth muscle 
cells in an animal model (Wang et al, 2002). Shear-stress in vascular smooth muscle 
cells also increases PAR-1 gene expression (Papadaki et al, 1998). In addition, PAR-1 
expression is increased in a number of injurious conditions affecting the central 
nervous system, including cerebral ischaemia (Riek-Burchardt et al, 2002, Striggow 
et al, 2001), human immunodeficiency virus encephalitis (Boven et al, 2003) and 
spinal cord trauma (Citron et al, 2000). Again, the relevance of these observations in 
relation to the lung is yet to be confirmed but these studies provide interesting insight 
into the ubiquitous distribution and regulation of PAR-1 in normal and diseased 
mammalian tissue.
In summary, the immunohistochemical studies described in this thesis have 
shown that expression of thrombin and PAR-1 by macrophages and fibroblasts is 
increased in the fibrotic lung. As discussed above, a major conclusion from these 
observations is that extravascular generation of thrombin, independent of classical 
blood coagulation, occurs following bleomycin instillation. Since PAR-1 was 
localised on the same cells as the protease, it is also feasible that thrombin-dependent 
PAR-1-mediated responses may be propagated in the fibrotic lung, resulting in the 
creation of a local fibrogenic microenvironment. This is in accordance with the 
current hypothesis regarding the pathogenesis of pulmonary fibrosis in which fibrotic 
foci have been proposed to be of great importance in disease progression (Pardo and 
Selman, 2002).
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4.3 Effect of UK-156406 on Bleomycin-Induced Pulmonary Fibrosis
4.3.1 UK-156406 Prolongs Rat Blood Clotting Parameters in vivo
Experiments discussed in Discussion Section 4.1.1 showed that UK-156406 
was capable of abrogating thrombin-induced lung fibroblast responses in vitro. 
Having demonstrated that both thrombin and PAR-1 were increased in bleomycin- 
induced pulmonary fibrosis, the effect of this compound was assessed in this animal 
model. As elaborated upon in Results Section 3.3.1 the short half-life of UK-156406 
necessitated a parenteral route of drug administration. Furthermore, since thrombin is 
generated chronically following bleomycin injury, a continuous infusion of the 
compound was required, so the drug was delivered by subcutaneous osmotic 
minipump. Subsequently, pilot experiments were conducted to establish that a safe 
and therapeutic dose of UK-156406 could be delivered to rats in vivo.
These pilot experiments were predictably difficult since rats are exquisitely 
sensitive to anticoagulant agents. This property has been known for many years and 
classic dicoumarin anticoagulants, such as warfarin, form the basis of domestic rat 
poison. Warfarin acts by inhibiting vitamin K epoxide reductase which results the 
ineffective post-translational carboxylation of vitamin-K dependent clotting factors, 
II, VII, IX and X. Although UK-156406 only selectively blocks the activated form of 
factor II (thrombin), as the compound was being administered in rats, it was evident 
that it would have a very narrow therapeutic window.
To assess whether UK-156406 was administered to animals at an 
anticoagulant, two ex-vivo assays of thrombin-dependent coagulation, the mean APTT 
and PT, were measured in rat plasma, at a time when the steady-state concentration of 
the compound would have been attained. However, baseline measurements for these
parameters had never been determined in male Lewis rats, so this had to be performed 
first (described in Results Section 3.3.1). Once these had been established, the effect 
of UK-156406 on these coagulation parameters was assessed. In final experiments, a 
dose of 0.5 mg/kg/hour proved optimal, as it caused significant prolongation of the 
APTT and PT, without noticeable haemostatic complications (Figure 3.3.1). In 
addition, at this dose, subcutaneous delivery of UK-156406 proved as effective at 
prolonging the APTT and PT as previously reported in in vivo studies, where hirudin 
was administered as a continuous intravenous infusion (Hoffmann et al, 1990, 
Schmidt et al, 1996), or twice daily by subcutaneous injection (Cunningham et al, 
2000).
It was further calculated that this dose of UK-156406 would generate a plasma 
steady-state concentration approaching 1 /xM. As discussed previously, the 
concentration of thrombin detected in BALF following bleomycin instillation would 
be in the range of 50 - 100 nM (see Discussion Section 4.2.1) which corresponds to 
the plateau concentration at which fibroblast responses to thrombin are exerted in 
vitro (Chambers et al, 1998, 2000, O Blanc-Brude, PhD thesis, 1999). The 
experiments discussed in Section 4.1.1 also showed that a 10-fold nanomolar excess 
of UK-156406 had to be used to fully abrogate thrombin-induced fibroblast responses 
in vitro. However, the steady-state level of UK-156406 in plasma was calculated to be 
at least 10-fold greater than BALF thrombin levels (based on data provided by Pfizer, 
UK). Since UK-156406 has a small molecular weight (611.7) and microvascular 
damage following bleomycin injury is widespread and associated with extensive 
vascular leak (Hay et al, 1991), it is at least theoretically possible that the 
concentration of UK-156406 within the pulmonary interstitium may approach that of 
plasma, and be sufficiently high to inhibit thrombin-mediated responses in the lung.
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4.3.2 UK-156406 Attenuates Lung Collagen Accumulation in Bleomycin-Induced
Pulmonary Fibrosis
UK-156406 was continuously administered to experimental rats for a 14 day 
time period. Throughout this time, animal body weight was recorded, which is a 
minimum requirement in terms of animal husbandry and a good surrogate marker for 
assessing the effect of a particular treatment on the general physical condition of 
experimental animals. Analysis of this data revealed that UK-156406 was delivered at 
a dose that was well tolerated and not obviously deleterious, compared with animals 
receiving drug vehicle alone.
After 14 days, the effect of UK-156406 on lung collagen accumulation in 
bleomycin-induced pulmonary fibrosis was evaluated. These experiments generated 
one of the most important findings of this thesis as the characteristic doubling in total 
lung collagen that occurs in animals receiving intratracheal bleomycin alone, was 
attenuated by up to 40%, in animals given bleomycin and UK-156406 (Figure 3.3.3), 
Since UK-156406 blocks thrombin proteolytic activity, there are a number of 
potential mechanisms by which direct thrombin inhibition may have afforded 
protection in this model, including blocking the procoagulant (i.e. fibrin deposition) or 
the cellular effects of the protease (please see Diagram 4.1).
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Fibrin
Catalytic TriadUK-156406
Procoagulant Effects Cellular Effects
Fibrin Formation Pro-inflammatory Pro-fibrotic
Platelet aggregation 
and degranulation
Vascular tone and 
permeability
Inflammatory cell 
trafficking and 
mitogenesis
Fibroblast proliferation, 
chemotaxis and differentiation
Connective tissue 
synthesis, deposition 
and remodelling
Pro-inflammatory Pro-fibrotic growth
cytokine production factor production
Diagram 4.1: Potential Mechanisms of Protection by Direct Thrombin Inhibition in Bleomycin-Induced Pulmonary Fibrosis
4.3.3 The Role of Fibrin in Bleomycin-Induced Pulmonary Fibrosis
Intra-alveolar accumulation of fibrin has been extensively documented in 
bleomycin-induced pulmonary fibrosis and in human studies of fibrotic lung disease 
(Idell et al, 1987, 1989, Chapman et al, 1986, Ikeda et al, 1989, Kotani et al, 1995). 
Fibrin is thought to influence the tissue repair/fibrotic response by acting in 
combination with fibronectin to provide a provisional matrix, on which fibroblasts can 
proliferate and produce collagen (Pohl et al, 1979). There is also evidence that fibrin 
can act as a reservoir of fibrogenic growth factors and cytokines which are released 
during fibrinolysis (Grainger et al, 1995). Fibrin has further been shown to protect 
active thrombin from inhibition from its physiological inhibitors so that it is able to 
exert its biological effects when bound to the provisional matrix (Bar-Shavit et al,
1990).
Fibrin deposition in the lung following injury can be affected via enhancing 
procoagulant activity in the lung or by altering regulatory mechanisms which control 
the clearance of deposited fibrin (fibrinolysis). Examples of factors which may control 
the prevailing balance between the pro- and anti-coagulant state in the fibrotic lung 
have been provided in the Introduction, Section 1.6.3. For example, human and 
animal studies have shown that there is increased expression of PAI-1 in pulmonary 
fibrosis, thus favouring fibrin persistence (Kotani et al, 1995, Olman et al, 1995). In 
addition to this evidence, a number of studies using various genetically-modified mice 
have provided support for a role for persistent fibrin deposition in experimental 
pulmonary fibrosis. When mice overexpressing PAI-1 (favouring fibrin persistence) 
were challenged with bleomycin, lung collagen deposition was increased above 
bleomycin-treated wild-type levels. Conversely, in bleomycin-treated PAI-1-deficient 
mice (favouring fibrin clearance), collagen levels were similar to unchallenged wild-
type controls (Eitzman et al, 1996), suggesting that inhibiting fibrinolysis in this 
model increases lung collagen accumulation and vice versa. Other investigators have 
altered fibrinolytic activity by increasing the amount of the plasminogen activator, 
uPA in the lung. Studies have shown that when uPA is either delivered systemically, 
intratracheally or when the uPA gene to the lung is delivered using an adenoviral 
vector system, that experimental pulmonary fibrosis is attenuated (Ikeda et al, 1989, 
Hart et al, 1994, Sisson et al, 1999). In addition, transgenic mice capable of 
generating inducible, lung specific uPA, also showed reduced collagen accumulation 
following bleomycin instillation (Sisson et al, 2002).
However, the role of fibrin in this model currently remains controversial, as 
two independent studies have shown that fibrinogen knockout mice are not protected 
from developing pulmonary fibrosis in response to bleomycin (Ploplis et al, 2000, 
Hattori et al, 2000). Although not universally accepted, these studies suggest that the 
protection afforded in bleomycin-induced pulmonary fibrosis by PAI-1 deficiency is 
not due to an accelerated clearance of fibrin per se. It has therefore been suggested 
that activation of the plasminogen system in this model produces its beneficial effects 
by degrading pro-fibrotic substrates other than fibrin and stimulating other anti- 
fibrotic pathways (Hattori et al, 2000). Studies that support this hypothesis have 
shown that plasmin contributes to the clearance of extracellular matrix components 
directly (Vassalli et al, 1991), and indirectly by activating zymogens such as latent 
matrix metalloproteinases (Carmeliet et al, 1997), which may be important in 
reducing matrix deposition in the fibrotic lung. Furthermore, plasmin also activates 
latent growth factors such as hepatocyte growth factor in vitro (Naldini et al, 1992), 
which has been shown to attenuate bleomycin-induced pulmonary fibrosis, possibly 
by promoting alveolar epithelial cell repair (Yaekashiwa et al, 1997).
4.3.4 UK-156046 and the Procoagulant Effects of Thrombin in Bleomycin-
Induced Pulmonary Fibrosis
In this thesis, in order to assess the potential importance of the procoagulant 
effects of thrombin, the effect of UK-156046 on vascular permeability was assessed, 
by measuring BALF total protein levels following bleomycin instillation as a 
surrogate marker (Figure 3.3.4). Vascular permeability in the lung is regulated by a 
complex series of interactions and when increased, is reflected by a rise in BALF total 
protein levels. As elaborated upon previously, following bleomycin injury, 
extravasation of plasma proteins with resultant oedema formation occurs through 
damaged alveolar walls and a host of pro-inflammatory cytokines and growth factors, 
including thrombin, are subsequently released, that further augment microvascular 
permeability (Hay et al, 1991, Idell 2001). There are a number of direct and indirect 
mechanisms by which thrombin increases microvascular permeability in the lung 
following injury (also see Introduction Section 1.9). In terms of direct effects, 
thrombin causes cultured endothelial cells to change shape, disrupts endothelial cell­
cell junctions and increases the permeability of endothelial cell monolayers (Lum et 
al, 1993, Rabiet et al, 1996). Thrombin also influences microvascular permeability 
indirectly, predominantly through the production of secondary mediators, such as 
serotonin from platelets, histamine from mast cells (Cirino et al, 1996) and 
stimulating the release of a range of pro-inflammatory mediators from endothelial and 
inflammatory cells (Johnson et al, 1998, Naldini et al, 2000).
The role of fibrin in regulating vascular permeability is complex. Fibrin has 
intrinsic vasoactive properties and its degradation products have been shown to 
increase vascular permeability in vitro and in vivo (Francis et al, 1993, Johnson et al 
1982). However, since fibrin obliterates the damaged microvasculature and alveolar
ultrastructure in the bleomycin-injured lung as part of a wound healing response, 
vascular permeability may be expected to decrease as vessels are plugged. Consistent 
with this hypothesis, systemic instillation of fibrin reduces pulmonary vascular 
permeability in sheep (Johnson et al, 1982).
In the experiments of this thesis, UK-156406 significantly increased BALF 
total protein levels in bleomycin-treated animals compared with animals given 
bleomycin alone. Since UK-156406 was delivered in the systemic circulation at an 
anticoagulant dose, fibrinous plugging of damaged microvasculature may have been 
reduced, leading to an elevation in BALF total protein levels in bleomycin-treated 
animals given UK-156406, compared with animals given bleomycin alone. If this is 
correct, it provides indirect evidence that modification of fibrin deposition by direct 
thrombin inhibition correlates with reduced lung collagen accumulation in this model.
Another recent study has shown that intratracheal administration of activated 
protein C (APC) was also protective in bleomycin-induced pulmonary fibrosis (Yasui 
et al, 2001). APC has both anticoagulant properties (it catalyses the inhibition of 
Factor Va and Factor Villa, therefore reducing thrombin activity) and profibrinolytic 
properties (it inactivates PAI-1) (for further information please see Introduction 
Section 1.6). The results of this study showed that intratracheal administration of 
APC to bleomycin-treated animals reduced BALF thrombin activity, markers of 
procoagulant activity and total protein levels, compared with saline-treated controls, 
which correlated with a reduction in lung collagen accumulation.
It is possible that the reduction in BALF protein levels in bleomycin-treated 
animals given APC was due to an inhibition of BALF thrombin activity and 
subsequent reduction in microvascular permeability. However, the reduction in BALF 
protein levels seen in bleomycin-treated animals given APC could also have been
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completely independent of any effect on coagulation since APC has also been shown 
to inhibit the production of pro-inflammatory cytokines such as IL-1, IL- 6  and TNFa 
(reviewed in Idell, 2002). In this study, blood clotting parameters were also measured 
in animals receiving APC. Of particular relevance to the results of this thesis, APC 
treatment did not significantly prolong these parameters. As discussed above, APC 
also neutralises PAI-1 activity in vitro, thereby promoting fibrinolysis (Esmon et al, 
1987). It would be interesting to know whether APC would increase BALF protein 
levels in bleomycin-treated animals, if  it were delivered at an anticoagulant dose.
Although unsubstantiated by experimental evidence, the authors’ favoured 
explanation by which APC exerted its effect on lung collagen accumulation was by 
blocking thrombin proteolytic activity and abrogating its cellular effects. The next 
section of this discussion elaborates on experiments performed in this thesis, which 
began to investigate whether UK-156406 may have exerted its protective effects in 
this model via modulation of the cellular effects of thrombin.
4.3.5 UK-156406 Attenuates Rat Lung CTGF and ai(T) Procollagen mRNA 
Levels in vivo
The cellular effects of thrombin can be divided into pro-fibrotic and pro- 
inflammatory. Some of the earlier experiments conducted in this thesis support the 
hypothesis that UK-156406 may have exerted its protective effect by directly 
interfering with thrombin-mediated fibroblast responses since thrombin-induced 
fibroblast proliferation, procollagen production and CTGF mRNA levels were 
completely abrogated in in vitro studies, when the inhibitor was used at 
concentrations which may be attained at the dose used in this study in vivo. Indirect 
evidence, concordant with this hypothesis, was provided by experiments showing that
the previously reported increases in both CTGF and ai(I) procollagen mRNA levels 
in response to bleomycin-induced lung injury (Lasky et al, 1998, Raghow et al, 1985) 
were dramatically reduced in animals given UK-156406 (Figure 3.3.5). There is 
increasing in vitro evidence that thrombin exerts its pro-fibrotic effects via the 
upregulation of a number of secondary mediators, including PDGF and CTGF (Ohba 
et al, 1994, Chambers et al, 2000; see Introduction Section 1.10). However, the role 
of CTGF in mediating the pro-fibrotic effects of thrombin, as well as the contribution 
of CTGF to lung collagen accumulation following bleomycin-induced lung injury is 
not yet fully elucidated.
This is the first report that a reduction in CTGF mRNA levels has been shown 
to correlate with reduced ai(I) procollagen mRNA levels and ultimately lung collagen 
accumulation in an animal model of tissue fibrosis. Although the in vivo experiments 
do not test causality directly, the coordinate downregulation of both CTGF and 
procollagen mRNA levels by direct thrombin inhibition makes it tempting to 
speculate that the effects of thrombin on lung collagen deposition, may be mediated, 
at least in part, via a CTGF-dependent mechanism.
The immunohistochemical localisation of CTGF in the normal and fibrotic 
human lung (Pan et al, 2001) has recently been described. In this study, there was a 
marked increase in CTGF expression by activated fibroblasts and type II alveolar 
epithelial cells, at both the mRNA and protein level, in lung biopsy tissue from 
patients with pulmonary fibrosis, compared with normal control lung biopsy 
specimens. Previous investigators have also found that CTGF gene expression was 
increased in BALF inflammatory cells, derived from patients with CFA/IPF and 
sarcoidosis (a fibroproliferative and inflammatory condition, complicated by 
pulmonary fibrosis), (Allen et al, 1999).
In an attempt to begin to identify which cell types might be responsible for the 
production of CTGF following bleomycin instillation in the present study, CTGF 
mRNA levels in freshly isolated BALF inflammatory cells were compared, following 
saline and bleomycin instillation and also in cultures of primary rat lung fibroblasts 
from male Lewis rats. These experiments showed that the CTGF mRNA transcript 
was easily detectable in cell cultures of primary rat lung fibroblasts, in serum-free 
conditions, but not for isolated BALF inflammatory cells. Since fibroblasts used in 
this assay also expressed functional PAR-1 receptors and exhibited typical PAR-1 
mediated responses, including upregulation of CTGF gene expression (please see 
Discussion Section, 4.2.4), it is possible that thrombin-dependent, PAR-1 mediated- 
CTGF production by fibroblasts may be an important source of this growth factor in 
the bleomycin-injured lung. Furthermore, although speculative, this experiment 
suggested that inflammatory cells are not a major source of CTGF following 
bleomycin instillation. However, it is possible that the abundance of the CTGF 
mRNA transcript may have been below the detection limit for Northern analysis.
4.3.6 BALF Total Inflammatory Cell Number and Differential Cell Proportions 
are Unaffected by UK-156406 in Bleomycin-Induced Pulmonary Fibrosis
An additional mechanism by which direct thrombin inhibition could have 
influenced the fibrotic response in this model is by modulation of thrombin’s pro- 
inflammatory actions. As elaborated upon in Introduction, Section 1.9, thrombin is a 
potent chemoattractant for inflammatory cells (Bar-Shavit et al, 1983) and stimulates 
the release of a number of pro-inflammatory cytokines and cell surface adhesion 
molecules via PAR-1 mediated effects (Marin et al 2001, Mari et al, 1994, Sower et 
al, 1995, Ueno et al, 1996, Naldini et al, 2002, Sugama et al, 1992, Shankar et al,
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1994, Kaplanski et al, 1998). Although there was a trend towards a reduction at 6 
days, BALF total inflammatory cell number and differential proportions were not 
significantly influenced by UK-156406 following bleomycin injury. Although 
inflammatory cell recruitment was not altered by direct thrombin inhibition, UK- 
156406 may still have altered the profile of pro-inflammatory and pro-fibrotic 
cytokines secreted from activated resident and recruited inflammatory cells in the 
injured lung. For example, thrombin increases the production of IL-1, IL-6, IL-8 and 
PDGF from monocytes/macrophages in vitro (Naldini et al, 2000, Naldini et al, 1998, 
Suk et al, 1999, Tani et al, 1997) and all of these mediators have been shown to affect 
the fibrotic response in pulmonary fibrosis (Carre et al, 1993). It is possible that 
abrogation of these effects may have been additional mechanisms by which direct 
thrombin inhibition afforded protection from fibrosis in this model.
4.3.7 Effect of UK-156406 on Lung Histology in Bleomycin-Induced Pulmonary 
Fibrosis
In this thesis, the effect of UK-156406 on lung histology following bleomycin- 
induced lung injury was assessed using Ashcroft scoring (for further description of 
methodology, please see Methods Section 2.10.5). Ashcroft scoring is a histological 
tool designed to grade the severity of pulmonary fibrosis in treatment groups on a 
numerical scale, which can be analysed statistically. In these experiments, there was 
no significant difference in the severity of the histological changes in the lungs of 
bleomycin-treated animals given UK-156406 compared with animals given 
bleomycin alone.
This result conflicts with the biochemical results described in Discussion 
Section 4.3.2, but this is not an uncommon finding. Other observers have also noted
that changes in lung collagen in drug-treated bleomycin-instilled rats are difficult to 
detect by quantitative histology, when compared with bleomycin-treated rats given 
drug-vehicle control, even though clear differences in lung collagen may have been 
demonstrated biochemically between respective treatment groups (Simler et al, 2002, 
R Marshall PhD thesis, 2001).
The main explanation for this discrepancy is that the mature regional fibrotic 
foci that develop in the lung following bleomycin instillation are patchy in 
distribution (Mutsaers et al, 1998). Although a standardised method is used for 
processing and generation of tissue sections (see Methods Section 2.10.5), the 
heterogeneous distribution of fibrotic lesions means that sampling error can easily 
occur. Another possibility is that Ashcroft scoring is not as sensitive as high 
performance liquid chromatography (HPLC) for detecting changes in lung collagen 
between treatment groups. For this reason, alternative methods for assessing lung 
histology in rats were explored. During this thesis, the author was involved in a 
separate study, examining the effect of a modified form of the macrolide antibiotic 
rapamycin (SDZ-RAD), in bleomycin-induced pulmonary fibrosis. In this study, lung 
collagen accumulation was reduced by up to 60% in bleomycin-treated rats receiving 
the compound compared with rats receiving drug vehicle alone when assessed 
biochemically. Lung histology was assessed by Ashcroft scoring, semi-quantitative 
image-analysis and electron microscopy, but all three methods failed to show 
significant differences in lung fibrosis between these treatment groups (Simler et al,
2002). Since exhaustive attempts at correlating biochemical and histological changes 
in lung collagen in this particular study failed, the observation showing that there was 
no detectable difference in lung histology between bleomycin-treated animals given 
UK-156406 and animals given bleomycin alone, was interpreted with caution. In
particular, since significant differences in lung collagen had already been detected at 
both the mRNA and protein level in bleomycin-treated animals given UK-156406 
compared with animals given bleomycin alone, it was concluded that the histological 
experiments described in this section may have underestimated the protective effect of 
direct thrombin inhibition in this model. Of note, a gold-standard histological method 
for assessing changes in lung collagen between treatment groups in bleomycin- 
induced pulmonary fibrosis in rats has yet to be identified. A recent study 
characterising histological changes in this animal model using nuclear magnetic 
resonance imaging has shown some promise (Cutillo et al, 2002), but accurately 
quantifying regional changes in lung histology in rats following bleomycin instillation 
remains a challenge.
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4.4 Bleomycin-Induced Pulmonary Fibrosis in PAR-1 ~7~ Mice
4.4.1 PAR-1"/_ Mice: Background and Phenotype
The results presented thus far have shown that systemic administration of a 
direct thrombin inhibitor attenuated lung collagen accumulation in bleomycin-induced 
pulmonary fibrosis. In addition, mechanistic studies have added support to the 
hypothesis that the receptor-mediated pro-fibrotic effects of thrombin may be 
important in this animal model. To directly assess the role of PAR-1 in bleomycin- 
induced pulmonary fibrosis, the effect of bleomycin instillation was evaluated in wild- 
type and PAR-1 mice.
PAR-1 _/" mice (strain C57BL/6-129/Sv) were originally generated in Prof S 
Coughlin's laboratory, UCSF (Connolly et al, 1996). They were created following 
disruption of the PAR-1 gene in wild-type mice, by homologous recombination. After 
heterozygous intercrossing, approximately half of PAR-1 ''' mouse embryos exhibit 
transient growth retardation and die at mid-gestation due to multiple bleeding 
complications, predominantly in the exocoelomic or pericardial cavities. The cellular 
basis of this observation has recently been elucidated by elegant studies which 
showed that a PAR-1 transgene driven by an endothelial cell-specific promoter, 
rescued PAR-1 _/" mouse embryo partial lethality and restored normal development 
(Griffin et al, 2001). The conclusion of these experiments was that bleeding 
complications in PAR-1 mouse embryos were not due to a defect in thrombin’s 
actions on platelets, mesenchymal cells or fibrinogen, but occurred as a result of 
PAR-1 deficiency in the vasculature. It is now realised that PAR-1 plays a critical role 
in endothelial cell function in developing blood vessels. However, it appears that 
PAR-1 deficiency does not prevent vessel formation per se but impairs the
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stabilisation and maturation of new vessels, thereby rendering them abnormally 
fragile and at risk of breakage (Griffin et al, 2001). Paradoxically, those PAR-1 7" 
mice that do survive during development are phenotypically normal at birth and have 
normal coagulation and grossly normal wound healing (Connolly et al, 1996). 
Although these mice do not express PAR-1, their platelets respond to thrombin 
predominantly through PAR-3 and PAR-4, whereas fibroblasts from these mice 
completely lose their ability to respond to thrombin (Trejo et al, 1996).
The original strain of mice (C57BL/6-129/Sv) described above, were 
extensively backcrossed (>97%) onto the C57BL/6 background prior to the 
experiments of this thesis (Cunningham et al, 2000). C57BL/6 mice are known to be 
sensitive to bleomycin-induced lung injury and produce a highly reproducible fibrotic 
response (Shazeidi et al, 1991). A breeding colony of this strain of PAR-1 7' mice was 
established at UCL as a result of a collaboration with Dr P Tipping (Monash, 
Australia) and subsequently used in the experiments of this thesis. Homozygote 
breeding pairs of PAR-1 7‘ mice were mated and the average litter size was 
approximately 50% less than that of control litters on the same background, which 
was consistent with findings described by Connolly and colleagues (also see 
Appendix Table 3.4.1).
4.4.2 Effect of Bleomycin Instillation in PAR-1"/" and Wild-Type Mice at 14 
Days: General Observations
An initial observation of these experiments was that PAR-17' and wild-type 
mice tolerated intratracheal bleomycin injection much better than rats and there were 
no cases of mortality in animals as a result of the procedure itself. As expected, PAR- 
l '1' and wild-type mice receiving intratracheal bleomycin gained weight slower than
256
mice given intratracheal saline. In addition, the mean percentage increase in body 
weight over the 14 day time period was significantly lower for bleomycin-treated 
mice compared with saline-treated mice. Importantly, PAR-1 ’A mice receiving saline 
or bleomycin instillation had directly comparable increases in body weight to 
correspondingly treated wild-type mice, throughout the time period of the experiment 
(Figure 3.4.3). Of note, there were no bleeding complications detected in PAR-1 'A 
mice throughout the duration of the experiments. In addition, the small neck incisions 
performed to facilitate the initial intratracheal injection, healed entirely normally, as 
had been previously reported for skin wounds in PAR-1 mice (Connolly et al, 
1997). Following bleomycin instillation, lungs of mice were examined after they had 
been dissected from the thoracic cavity, prior to biochemical analysis. Lungs of PAR- 
1 _/" and wild-type mice given intratracheal saline appeared entirely macroscopically. 
As expected, lungs of wild-type mice given bleomycin were larger with many obvious 
areas of focal haemorrhage, affecting whole lobes in the worst cases. In comparison, 
the lungs of bleomycin-treated PAR-1 */_ mice were markedly less injured when 
examined macroscopically with far less areas of focal haemorrhage. This was also 
reflected in the lung weights of these mice, which were significantly lighter than the 
lungs of bleomycin-treated wild-type mice.
4.4.3 Total Lung Collagen is Reduced Biochemically and Histologically in PAR-1 
_/' Mice Compared with Wild-Type Mice Following Bleomycin Instillation
Assessment of the effect of bleomycin instillation on total lung collagen 
accumulation in PAR-1 '/_ and wild-type mice generated a critical result. Lung 
collagen accumulation was attenuated by up to 60% in PAR-1 '/_ mice instilled with 
bleomycin, compared with wild-type mice controls, when assessed by HPLC based on
lung hydroxyproline (Figure 3.4.4). Lung histology was also assessed at this time 
point. PAR-1 and wild-type mice given intratracheal saline had grossly normal lung 
architecture. However, the large focal areas of interstitial fibrosis seen in wild-type 
mice following bleomycin instillation were significantly reduced in PAR-1 ''' mice 
given bleomycin, when quantified both by Ashcroft scoring and semi-quantitative 
image analysis, the latter technique evaluating the percentage of newly synthesised 
collagen content/lobe, (Mutsaers et al, 1998) (Figure 3.4.5).
The pattern of lung histological damage following bleomycin instillation in 
mice is similar to rats in its patchy distribution. However, quantitation of histological 
changes between treatment groups, following bleomycin instillation is much easier in 
mice. A major reason for this is that the five lobes of the mouse lung are smaller than 
the lobes of rat lung so that complete transverse sections of each mouse lobe can be 
cut in a standardised fashion, and all lobes mounted on the same microscope slide. 
This is particularly beneficial when comparing lung histology by Ashcroft scoring and 
also by semi-quantitative image analysis.
Semi-quantitative image analysis was superior to histological evaluation by 
Ashcroft scoring, since it produced an objective and standardised computed figure for 
the percentage of newly synthesised collagen content/lobe. When using Ashcroft 
scoring, this assessment is more subjective and there is greater inter-observer 
variability (Ashcroft et al, 1988). However, the technique of image analysis also has 
limitations. Whilst analysing whole lung lobes, non-representative areas such as 
airway lumens and vasculature are also evaluated, which could confound results. In 
addition, the technique is dependent on even staining of all tissue sections. In cases 
where staining was uneven, an enhanced or lower percentage could have been
obtained. However, rigorous attempts were made to minimise these limitations as far 
as possible.
The conclusion of the biochemical and histological results presented above 
confirmed that PAR-1 plays a critical role in the development of pulmonary fibrosis 
in this animal model. The following sections elaborate on further studies performed to 
elucidate some of the possible mechanisms behind this observation.
4.4.4 Inflammatory Cell Recruitment is Abrogated in PAR-1 Mice Compared 
with Wild-Type Mice Following Bleomycin Instillation
As discussed in previous sections, PAR-1 is expressed on cell types known to 
play a role in inflammatory cell recruitment and this process is modulated following 
bleomycin injury (Dery et al, 1998, Izbicki et al, 2002). Previous experiments to 
determine whether the cellular effects of thrombin were important in inflammatory 
cell recruitment following bleomycin instillation showed that direct thrombin 
inhibition did not affect this process in rats (please see Discussion Section 4.3.6). 
However, there is evidence in the literature that activation of PAR-1 by thrombin, 
plays a role in glomerulonephritis, an inflammatory renal disease (Cunningham et al, 
2000). In this study, a murine model of this condition was established by 
administering a nephritogenic antigen to mice. Experiments showed that the direct 
thrombin inhibitor, hirudin, attenuated inflammatory cell recruitment and fibrin 
deposition in this model. Furthermore, inflammatory cell recruitment was also 
reduced in PAR-1 _/" mice compared with wild-type control mice, after both groups of 
mice received the nephritogenic insult. Finally, administration of a selective PAR-1 
activating peptide to these groups of mice showed that histological and functional 
indices of glomerulonephritis were augmented in wild-type mice, compared with
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PAR-1 mice receiving the PAR-1 agonist. This study therefore demonstrated a 
pivotal pro-inflammatory role for PAR-1 in vivo in this condition.
To examine whether inflammatory cell recruitment was altered in bleomycin- 
treated PAR-1 mice compared with wild-type controls, BALF total cell number and 
the relative proportions of these cells was assessed at 6 days. As described previously 
in Section 3.3.7, this time-point was chosen since the pulmonary inflammatory 
response is at maximal levels, 6 days following bleomycin instillation (Izbicki et al
2002). Furthermore, thrombin levels were also elevated and a dramatic increase in 
PAR-1 expression associated with macrophages had also been demonstrated in the 
bleomycin-injured rat lung, compared with saline-treated control rats, at this time- 
point (see Results Section 3.2.5).
The results of these experiments showed that BALF total inflammatory cell 
number was significantly reduced in bleomycin-treated PAR-1 'A mice compared with 
wild-type mice receiving bleomycin, although differential cell counts were similar in 
both groups of animals. The reduction in BALF total inflammatory cell number in 
bleomycin-treated PAR-1 '/_ mice may be explained in a number of ways since 
thrombin exerts potent direct and indirect chemotactic and mitogenic effects on 
inflammatory cells, via PAR-1-dependent mechanisms (please see Introduction, 
Section 1.9). However, this result conflicted with the observations obtained in 
bleomycin-treated rats given UK-156406 (Discussion Section 4.3.6), showing that 
direct thrombin inhibition failed to significantly alter BALF total inflammatory cell 
number, although there was a trend towards a reduction.
This result could be explained by pharmacological properties of the direct 
thrombin inhibitor. Although not functionally assessed in this thesis, it is possible that 
thrombin proteolytic activity was not fully blocked by UK-156406. Since thrombin
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has such a high affinity for PAR-1, the drug may not have been potent enough to 
abrogate all of thrombin’s effects on inflammatory cells in this model. Conversely, in 
PAR-1 _/' mice, thrombin’s’ pro-inflammatory effects mediated via this receptor 
would have been completely blunted.
It is now known that a number of other coagulation proteases other than 
thrombin, which are known to be elevated following bleomycin instillation, mediate 
functional pro-inflammatory effects following activation of PAR-1. This will be 
elaborated upon further in Discussion Section 4.4.7, but it is proposed that PAR-1 
may act as a central downstream receptor for pro-inflammatory coagulation proteases, 
which may explain why inflammatory cell recruitment was so markedly attenuated in 
bleomycin-treated PAR-1 "A mice but not in bleomycin-treated rats given the thrombin 
inhibitor.
4.4.5 Lung FISP-12 mRNA Levels are Reduced in PAR-1"/" Mice Compared with 
Wild-Type Mice Following Bleomycin Instillation
Experiments were also performed to examine if the receptor-mediated effects 
pro-fibrotic of thrombin were altered in PAR-1 mice following bleomycin injury. 
As has been discussed previously in this thesis (Discussion Section 4.3.5), it has been 
suggested that CTGF (or its murine orthologue FISP12), may be important in 
mediating thrombin’s direct pro-fibrotic effects following PAR-1 activation.
The effect of bleomycin instillation on lung FISP12 gene expression in PAR-1 
'A and wild-type mice revealed that FISP12 mRNA levels were significantly reduced 
in bleomycin-treated PAR-1 _/" mice compared with wild-type mice receiving 
bleomycin. This result provided further indirect evidence that the effects of thrombin 
on lung collagen deposition following bleomycin instillation, may be mediated, at
least in part, via a FISP12/CTGF-dependent mechanism. The exact role of CTGF in 
the pathogenesis of fibrotic lung disease is still unknown but a recent study has 
provided further insight into its potential importance, since overexpression of this 
mediator by adenoviral gene transfer induced transient pulmonary fibrosis in mice 
(Bonniaud et al, 2003). In addition to thrombin, coagulation proteases such as factor 
Vila and factor Xa and the archetypal pro-fibrotic mediator, TGF/3 also stimulate the 
production of CTGF in human lung fibroblasts (Pendurthi et al, 2000, Chambers et al, 
2000, Grotendorst et al, 1996) and are all elevated in the fibrotic lung. It has therefore 
been suggested that CTGF may be a common downstream mediator in pulmonary 
fibrosis and may represent an attractive therapeutic target (Chambers et al, 2000).
Another proposal that implicates the pro-fibrotic receptor-mediated effects of 
thrombin, and may help explain why PAR-1 _/" mice were protected from bleomycin 
injury, is that thrombin-induced myofibroblast differentiation may have been affected 
in these mice, which has recently been shown to be a PAR-1-dependent process 
(Bogatkevich et al, 2001). This question was not specifically addressed in this thesis 
but may be an additional mechanism as the myofibroblast has been shown to be a 
major producer of extracellular matrix in pulmonary fibrosis (Kuhn et al, 1991). In 
addition, this cell is thought to be important in the development of fibrotic foci, which 
have been proposed to represent active pulmonary microenvironments that determine 
disease progression in CFA/IPF (Selman et al, 2001), (also see Introduction Section 
1.3).
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4.4.6 Vascular Leak is Attenuated in PAR-1 "/" Mice Compared with Wild-Type 
Mice Following Bleomycin Instillation
The effect of bleomycin instillation on BALF total protein levels, as an index 
of vascular leak, was also assessed in PAR-1 _/' and wild-type mice, since thrombin 
exerts direct and indirect effects on pulmonary microvascular permeability via PAR-1 
dependent mechanisms (as reviewed in Introduction Section 1.9). These experiments 
showed that BALF total protein levels were significantly reduced in bleomycin- 
treated PAR-1 'A mice compared with wild-type mice given bleomycin. This result 
was consistent with those obtained in another study in an ex vivo model showing that 
thrombin and PAR-1 agonist peptides increase indices of microvascular permeability 
in the intact pulmonary microcirculation in wild-type mice but these responses were 
completely absent in PAR-1_/‘ mice (Vogel et al, 2000). Taken together, this evidence 
suggests that PAR-1 is critical in mediating the permeability-increasing effects of 
thrombin in the intact and injured pulmonary microvasculature.
In terms of the functional significance of this observation, in addition to 
altering microvascular permeability following bleomycin injury, it has been proposed 
that thrombin may also activate endothelial PAR-1 to facilitate platelet, leucocyte and 
effector protein recruitment to facilitate the surveillance of the local milieu for tissue 
damage (Coughlin et al 2000). In addition, thrombin-induced activation of endothelial 
cells via PAR-1 may play a role in the process of angiogenesis in this model. It has 
been recognised for a number of years that neovascularisation occurs in the lungs of 
patients with pulmonary fibrosis (Turner-Warwick et al, 1963). In addition, a study 
has shown that a geometric increase in neovascularisation facilitates fibroplasia and 
deposition of extracellular matrix in bleomycin-induced pulmonary fibrosis and 
occurs when the fibrotic response is maximal in this model (Peao et al, 1994).
Furthermore, other studies have shown that there is an increase in pro-angiogenic 
cytokines such as vascular endothelial growth factor (VEGF) and a reduction in pro- 
angiostatic chemokines, such as interferon gamma inducible protein 10 (IP-10), 
following bleomycin injury. In addition, these observations correlate with increased 
lung collagen deposition in this model (Fehrenbach et al, 1999, Keane et al, 1999). 
This suggests that a delicate balance between pro-angiogenic and pro-angiostatic 
factors may contribute to lung collagen accumulation following bleomycin injury.
Both thrombin and PAR-1 are involved in processes such as endothelial cell 
detachment from basement membrane components (Maragoudakis et al, 2001), 
endothelial cell proliferation and growth (Tsopanoglou et al, 1999) and the production 
of the pro-angiogenic cytokines (Naldini et al, 2000) (please see Introduction 
Section 1.9). Further support for a role for thrombin and PAR-1 in angiogenesis has 
been provided by studies performed in P A R - 1 m i c e  during embryonic development 
(also see Discussion Section 4.4.1) since PAR-1 is particularly important for 
stabilisation and maturation of newly forming blood vessels in the embryo (Griffin et 
al, 2001). It is clear from these studies that during embryonic development, the 
processes of coagulation and angiogenesis are intimately linked. However, it is yet to 
be demonstrated to what extent these interactions occur in pathological conditions in 
the adult, where angiogenesis is known to be a feature. These events may be of 
relevance during the vascular remodeling process that occurs following bleomycin 
injury in the lung. Although it remains speculative, since pro-angiogenic mechanisms 
correlate with changes in lung collagen accumulation following bleomycin 
instillation, this is another potential mechanism to explain the protective effects 
demonstrated in bleomycin-treated PAR-1_/' mice.
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4.4.7 New Concepts Regarding Protease Activated Receptors
As briefly mentioned in the Discussion Section 4.4.4, during the course of the 
thesis, a number of recent studies have generated fascinating observations that have 
challenged conventional dogma about coagulation cascade proteases and PAR 
activation. Previously, it had been thought that thrombin was the only major activator 
of PAR-1, -3 and -4 and that trypsin and mast cell tryptase activated PAR-2 (reviewed 
in MacFarlane et al, 2001). However, it is now realised that thrombin is not the only 
coagulation protease that is capable of exerting functional responses via proteolytic 
cleavage of PAR-1, (please see Diagram 4.2).
Although proteases such as trypsin, elastase and the neutrophil protease, 
cathepsin G, are known to cleave PAR-1 (reviewed in Dery et al, 1998, Nakayama et 
al, 2003), they do so at non-activating sites, and therefore do not produce functional 
effects. However, it is now known that limited proteolysis of PAR-1 by factor Xa 
initiates downstream functional effects, such as fibroblast proliferation (Blanc-Brude 
et al, 2001). In addition, studies conducted in HeLa cells revealed that CTGF 
production by factor Xa was also mediated following PAR-1 activation (Riewald et 
al, 2001). Furthermore, plasmin has been shown to increase expression of Cyr 61 
following activation of PAR-1 (Pendurthi et al, 2002). Cyr 61 is a member of the 
CCN family of proteins of which CTGF also belongs.
It has also been shown that nascent factor Xa, in the procoagulant transient 
tissue factor-factor Vlla-factor Xa ternary complex, which is generated following 
activation of the extrinsic coagulation cascade, signals via both PAR-1 and PAR-2 in 
endothelial cells and Chinese hamster ovary cells (Riewald et al, 2001). Furthermore, 
PAR-2 can be transactivated by the cleaved PAR-1 receptor (O’Brien et al, 2001) and
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the tissue factor-factor Vila complex also signals via PAR-2 in endothelial cells and 
keratinocytes (Camerer et al, 2000).
These studies have lead to the evolution of two important novel concepts. 
First, it is now generally accepted that PARs are common and cellular receptors for a 
number of coagulation proteases. Second, the observation that the transient tissue 
factor-factor Vlla-factor Xa complex can signal via both PAR-1 and PAR-2, has 
demonstrated that tissue factor dependent initiation of the coagulation cascade is 
mechanistically coupled to cellular signalling. This is in opposition to the classical 
view that these effects would only occur later in the coagulation cascade, following 
downstream generation of active thrombin and subsequent PAR activation.
It has been reported that in the bleomycin model of pulmonary fibrosis, levels 
o f substrate factor X are reduced in the alveolar space compared with plasma. 
Furthermore, this may prevent full saturation of the tissue factor-factor Vlla-factor Xa 
complex, thereby promoting efficient downstream thrombin signalling via PAR-1 
(Ruf and Riewald, 2003). However, it is plausible that PAR-1 dependant signalling 
via thrombin, factor Xa and the tissue factor-factor Vlla-factor Xa complex will be 
reduced in bleomycin-treated PAR-1 'A mice. This represents a potential mechanism 
to explain why these mice were protected over and above the beneficial effects 
observed when bleomycin-treated rats were given UK-156406. This observation may 
be particularly pertinent in understanding why inflammatory cell recruitment was 
attenuated in bleomycin-treated PAR-1 ''' mice but was unaffected in corresponding 
rats receiving the direct thrombin inhibitor.
Another study has provided further insight into the role of PAR-1 in 
the vasculature since the anticoagulant, activated protein C (APC) utilises the 
endothelial protein C receptor (EPCR) as a co-receptor for cleavage of PAR-1 in
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endothelial cells (Riewald et al, 2002). This leads to the production of the 
immunomodulatory agent MCP-1, which may be a protective anti-inflammatory 
mechanism to regulate normal homeostasis of the endothelium (Riewald et al, 2002). 
In terms of the relevance of this observation in disease processes, in the bacterial 
endotoxin model of sepsis, which is characterised by excessive intravascular 
coagulation, escalation in protease-dependent inflammation is typically delayed in 
lethally-challenged animals. This suggests that the anti-inflammatory actions of the 
protein C pathway may initially control disease progression (Taylor et al, 2000). 
Furthermore, MCP-1 has been shown to be protective in animal models of sepsis 
(Zisman et al, 1997, Bone Larson et al, 2000).
APC-dependant activation of PAR-1 may also play a role in classical 
pathways involved in activation of the coagulation cascade (reviewed in Ruf and 
Riewald, 2003). It is hypothesised that different threshold concentrations of thrombin 
exist in the vasculature, exerting opposing effects. The mechanism proposes that at 
low concentrations of thrombin, below the procoagulant threshold, the protease binds 
to thrombomodulin. Formation of the resultant stoichiometric complex inhibits the 
enzymatic activity of thrombin and blocks direct PAR-1 activation. Thrombin bound 
to thrombomodulin favourably cleaves zymogen protein C to its product, APC. Both 
substrate and product of this reaction bind to the EPCR and endogenous production of 
APC by thrombin is dependant on EPCR binding. EPCR-bound APC subsequently 
cleaves PAR-1 and induces anti-inflammatory events. When thrombin is generated at 
higher concentrations that exceed the procoagulant threshold, PAR-1 is activated via 
the transient tissue factor-factor Vlla-factor Xa complex when coagulation is initiated 
and in the propagation phase of thrombin generation, which is required for the 
conversion of fibrinogen to fibrin. In terms of the relevance of these events to
excessive intravascular coagulation, such as in sepsis syndromes, once the 
procoagulant threshold is exceeded, disease progression is rapid and this may negate 
the protective effects of EPCR-bound APC activation of PAR-1 (Riewald and Ruf, 
2003).
An important consideration is the significance of these observations in the 
bleomycin-injured lung, since conceptually, the idea that PAR-1 activation may be a 
protective mechanism might sound contradictory to the hypothesis of this thesis. First, 
APC-dependent activation of PAR-1 is an endothelial-specific intravascular event and 
its relevance to the bleomycin model, where excessive extravascular coagulation 
occurs remains unknown. Second, if this mechanism is of importance in the 
bleomycin model, it is thought that the procoagulant threshold for thrombin 
generation is exceeded in the extravascular compartment, meaning that any protective 
effect of APC via PAR-1 may be of less significance (reviewed in Ruf and Riewald,
2003). Third, as discussed earlier, intratracheal administration of APC has been 
shown to be protective in bleomycin-induced pulmonary fibrosis (Yasui et al, 2001). 
There are a number of mechanisms that might explain this effect since APC is anti­
coagulant (catalyses the inhibition of Factor Va and Factor Villa, therefore reducing 
thrombin activity), anti-inflammatory (inhibits the production of TNFa, IL-6 and EL-8 
in vitro) and fibrinolytic (inactivates PAI-1). Although speculative, it is possible that 
direct pulmonary administration of APC in excess may reduce the local procoagulant 
threshold in the extravascular compartment, and thus favour anti-inflammatory, 
protective effects in this model via activation of PAR-1, rather than thrombin- 
dependant PAR-1 signalling. This mechanism is dependant on APC interacting with 
endothelial cells but interestingly, the EPCR is also expressed on monocytes and
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epithelial cells (Galligan et al, 2001, Scheffer et al, 2002), which may also prove 
important in understanding the beneficial effects of APC in this model.
One final important new observation regarding PARs, which warrants further 
discussion, is that PAR-2 can be transactivated by cleaved PAR-1, which implies that 
PAR-2 may also contribute to the cellular responses elicited by thrombin (O’Brien et 
al, 2001). Although very little is known about the role of PAR-2 in the fibrotic lung, 
this receptor is thought to play a role in lung inflammation and asthma in vivo (Knight 
et al, 2000). A recent study has shown that mice deficient in PAR-2 were protected in 
an adjuvant model of chronic monoarthritis (Ferrell et al, 2003) and also have delayed 
inflammatory responses (Lindner et al, 2000). These studies suggest that cellular 
effects mediated via PAR-2 may play a role in the pathogenesis of pulmonary fibrosis 
and experiments to examine this mechanism require further attention.
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Diagram 4.2: Coagulation Proteases and Protease Activated Receptor Activation
4.5 Summary
This thesis reports several novel in vitro and in vivo observations which support 
the hypothesis that thrombin and PAR-1 play a critical role in the pathogenesis of 
bleomycin-induced pulmonary fibrosis. More specifically the experiments conducted 
in this thesis have shown that:
(i) The direct thrombin inhibitor, UK-156406 abrogated thrombin-induced 
fibroblast proliferation, procollagen production and CTGF mRNA levels 
in in vitro studies.
(ii) Immunohistochemical studies performed to localise thrombin and PAR-1 
in the lung, following bleomycin instillation revealed that both thrombin 
and PAR-1 were predominantly localised to macrophages in interstitial 
inflammatory and fibroproliferative foci and also on spindle-shaped 
interstitial cells in these areas. This confirmed that thrombin and its major 
cellular receptor were localised to the cell types that are likely to mediate 
important pro-inflammatory and pro-fibrotic effects critical to the fibrotic 
response following bleomycin injury.
(iii) Modulation of the proteolytic activity of thrombin by direct thrombin 
inhibition, reduced lung collagen accumulation in the bleomycin-model of 
pulmonary fibrosis in rats. The attenuation in lung collagen accumulation 
in bleomycin-treated animals given UK-156406, was preceded by a 
reduction in ai(I) procollagen and CTGF mRNA levels, but not 
inflammatory cell recruitment. These mechanistic studies, combined with 
the recent observation that fibrinogen-null mice are not protected from
bleomycin-induced lung injury (Ploplis et al, 2000), suggest that abrogation 
of the direct pro-fibrotic effects of thrombin might be important in 
explaining the protective effects of UK-156406 on lung collagen 
accumulation following bleomycin instillation.
The effect of bleomycin instillation in PAR-1 'A and wild-type mice 
provided unequivocal evidence that this receptor plays a pivotal role in the 
pathogenesis of this condition. PAR-1 _/‘ mice were dramatically protected 
from bleomycin-induced pulmonary fibrosis since lung collagen 
accumulation was reduced when assessed both biochemically and 
histologically.
Experiments performed to examine mechanism(s) by which PAR-1 ~*m mice 
were protected following bleomycin injury showed that inflammatory cell 
recruitment, vascular leak and FISP12 mRNA levels were all reduced in 
bleomycin-treated PAR-1 "A mice, compared with wild-type mice receiving 
bleomycin. This suggests that abrogation of the PAR-1-mediated effects of 
thrombin on inflammatory cells, endothelial cells and fibroblasts may all 
have been important in explaining this observation. However, the recent 
finding that PAR-1 is a common signalling receptor for several 
coagulation proteases provides evidence that this receptor may play a vital 
role in orchestrating cellular effects that are important in promoting tissue 
fibrosis in vivo. Since other coagulant proteases are so abundant in the 
lung following bleomycin injury, this may explain why the level of 
protection of PAR-1 v’ mice from bleomycin-induced pulmonary fibrosis 
was so impressive and also why inflammatory cell recruitment was
reduced in these mice but not significantly altered in bleomycin-treated 
rats, given UK-156406.
4.6 Future Directions
4.6.1 Mechanism of Protection of PAR-1 ‘/_ Mice in Bleomycin-Induced 
Pulmonary Fibrosis
The mechanism of protection in PAR-1 ''' mice following bleomycin-induced 
lung injury could be elucidated further by performing the following experiments.
(i) To further assess the effect of PAR-1 deficiency on lung inflammation 
following bleomycin instillation in PAR-1 'A and wild-type mice, levels of 
serum and BALF pro-inflammatory cytokines, which are known to be 
induced following PAR-1 activation such as IL-1, IL-6 and IL-8, could be 
assayed.
(ii) The effect of bleomycin instillation on pulmonary vascular permeability in 
PAR-1 _/' and wild-type mice could be further evaluated by the technique 
of Evans blue extravasation.
(iii) Pro-angiogenic cytokines and growth factors, in BALF and homogenised 
lung tissue, such as VEGF, PDGF, IL-1/3 and angiopoietin-1, which are 
thought to be induced following PAR-1 activation, could be assayed to 
assess the role of angiogenesis in this model.
(iv) In order to dissect which pathways contribute to lung collagen 
accumulation in this model, the effect of a selective PAR-1 antagonist 
could be assessed by delivering this agent at different phases of the injury 
response following bleomycin instillation.
4.6.2 The Role of CTGF/FISP12 in Mediating Pro-fibrotic Effects Following 
PAR-1 Activation
Experiments performed in his thesis support the hypothesis that direct PAR-1 
mediated pro-fibrotic effects of thrombin may be important in the pathogenesis of 
bleomycin-induced pulmonary fibrosis and that they might, in part, be mediated via a 
CTGF/FISP 12-dependent mechanism. The following experiments could further assess 
if FISP12 expression is altered in bleomycin-treated PAR-1 *A mice and whether 
FISP12 mediates pro-fibrotic effects following PAR-1 activation.
(i) Quantitative immunohistochemistry for FISP12 expression in the lungs of 
PAR-1 'A and wild-type mice could be combined with in situ hybridisation 
studies for collagen to examine the cell types responsible FISP12 and 
collagen production in this model.
(ii) FISP12 could be transiently transfected using an adenoviral delivery 
system and reexpressed in the lungs of PAR-1 'A mice to assess if this 
restores susceptibility to lung collagen accumulation following bleomycin 
instillation.
4.6.3 The Role of PAR-2 in Pulmonary Fibrosis
The recent finding that PAR-2 is also activated by coagulation proteases and 
that PAR-2 mice have delayed inflammatory responses (Lindner et al, 2000) has 
lead to the hypothesis that this receptor may also play a role in lung inflammation and 
fibrosis. The following experiments could begin to assess the role of PAR-2 in this 
disease.
(i) Assess the effect of bleomycin-induced pulmonary fibrosis in PAR-2 
mice and wild-type controls.
(ii) The combined role of PAR-1 and PAR-2 deficiency could be investigated
by assessing the effect of bleomycin-induced pulmonary fibrosis in dual 
knockout (PAR-1/2 mice and wild-type controls.
These experiments should provide further understanding of the role of coagulation 
proteases and protease-activated receptors in pulmonary fibrosis. The ultimate aim of 
these studies would be to establish a successful therapeutic strategy for patients with 
fibrotic lung disease.
4.7 Therapeutic Implications and Relevance to Human Disease
Activation of the coagulation cascade is a feature of a number of lung 
disorders associated with inflammation and excessive deposition of extracellular 
matrix proteins such as idiopathic pulmonary fibrosis (Chapman et al, 1986, Ikeda et 
al, 1989, Kotani et al, 1995), pulmonary fibrosis associated with systemic sclerosis 
(Hemadez-Rodriguez et al, 1995, Ohba et al, 1994), ALI/ARDS (Bachofen et al, 
1982), chronic lung disease of prematurity (CLD), (Dik et al, 2002), cryptogenic 
organizing pneumonia (Peyrol et al, 1990) and airway remodeling in asthma (Gabazza 
et al, 1999).
The findings of this thesis suggest that inhibition of thrombin proteolytic 
activity, and more specifically the PAR-1-mediated cellular effects of thrombin and 
possibly other coagulation proteases, play an important role in lung collagen 
accumulation in experimental pulmonary fibrosis. An obvious question at this stage is, 
whether therapies aimed at blocking the coagulation cascade in general, or specifically 
targeting thrombin or PAR-1, warrant evaluation as potential therapeutic strategies for 
the treatment of fibrotic lung disease? Given the paucity of available treatments for 
pulmonary fibrosis, there may be some justification to begin clinical trials with such 
agents. The NHBLI workshop recently reviewed current therapeutic options for 
IPF/CFA and for the first time, anticoagulants appear on this list of potential agents that 
should be evaluated in clinical trials (Crystal et al, 2002). This opinion is also ratified 
by the most recent review of the pathogenesis of this condition (Strieter et al, 2003).
In terms of inhibiting the coagulation cascade, there are a number of classical 
pharmacological agents that are clinically well established, for the treatment of 
thromboembolic disease. Warfarin, which is orally bioavailable, acts by inhibiting
vitamin K epoxide reductase, thereby blocking the activity of a number of coagulation 
factors, including thrombin (Scully, 2002). However, warfarin has a number of 
unwanted side-effects and other pharmacological agents interact with this drug and 
affect its pharmacokinetic profile (Scully, 2002). Unfractionated heparin acts as a 
cofactor for endogenous antithrombin IE, which catalyses the inhibition of thrombin 
and factor Xa. However, since this drug has to be given parenterally and its 
bioavailability is extremely unpredictable, it would be an unattractive drug for chronic 
fibrotic lung diseases, but may be more appropriate for use in acute fibrotic conditions 
such as ALI/ARDS. Although use of these agents may not be justified in a clinical trial 
for fibrotic lung disease at present, since thromboembolic disease is common, a large 
proportion of the population have been prescribed these therapies. Given that there is 
now an extensive database generated from patient episodes in general practice, a study 
could be conducted to assess the incidence of pulmonary fibrosis in patients who have 
received anticoagulant therapy compared with the known incidence of the disease.
Warfarin and heparin have poor pharmacokinetic profiles so a number of more 
novel anticoagulant agents have been developed that target specific coagulation factors, 
predominantly for use in the field of vascular biology. Low molecular weight inhibitors 
of factor Xa and thrombin have been designed and are in clinical use. In addition, a 
number of novel factor Xa and thrombin inhibitors have also been commercially 
produced through peptidomimickry of natural anticoagulants from haematophagous 
animals (reviewed in Walker and Royston, 2002).
The use of low molecular weight factor Xa inhibitors has revolutionised the 
treatment of thromboembolic disease and their use in this setting is now standard in 
clinical practice since they can easily be administered by subcutaneous injection and 
have a more predictable pharmacokinetic profile than unfractionated heparin. Low
molecular weight direct thrombin inhibitors, such as UK-156046 represent a new class 
of anticoagulants that are emerging as antithrombotic drugs with a wide range of 
indications. These drugs produce predictable, stable and rapidly reversible 
anticoagulation, measurable by common coagulation assays. In addition, significant 
pharmacokinetic drug-drug interactions have not been reported. The best-known agent 
produced by peptidomimickry of a natural anticoagulant is hirudin. Recent studies in 
patients with acute coronary syndromes have suggested that recombinant hirudin may 
become routinely used clinically (Breddin, 2002).
Perhaps more directly relevant to the experiments of this thesis are studies using 
low molecular weight inhibitors of thrombin, factor Xa and recombinant anticoagulant 
proteins to treat restenosis after vascular injury. A number of studies have revealed that 
these agents reduce neointima formation and extracellular matrix production in vessel 
walls, in animal models of this condition (Chajara et al, 1994, Gallo et al, 1998). Since 
these agents are now so widely available and have a good safety profile in patients, it 
may be reasonable to use them in clinical trials for fibrotic lung disease.
A number of recent studies have modified the coagulation cascade with 
anticoagulant agents in severe sepsis. Of relevance to the results of this thesis, the 
underlying systemic inflammatory response in severe sepsis is similar to that seen in 
ALI/ARDS. A number of preclinical trials using AT-III in septic patients were 
successful e.g. (Fourrier et al, 1993), but the double-blind, placebo controlled phase 
III trial was not (Warren et al, 2001). Although A T -in  did not improve survival in the 
phase III trial, it did improve survival of patients in this study that did not heparin as a 
prophylactic agent. AT-III binds a cellular receptor, syndecan-4 that interferes with 
intracellular signals induced by inflammatory mediators, such as lipopolysaccharide 
(Roemisch et al, 2002). It has been suggested that the reason the phase IQ trial failed
to show a treatment benefit was because the AT-III-heparin complex was not able to 
functionally interact with syndecan-4, thus reducing any potential anti-inflammatory 
properties. AT-III supplementation in the absence of heparin may yet show beneficial 
effects for septic patients due to its direct cellular effects rather than an effect on 
coagulation per se.
A number of other anticoagulant agents such as TFPI, factor Vila and heparin 
have all shown promise in animal models of sepsis and ALI/ARDS (Creasey et al, 
1993, Miller et al, 2002, Abubakar et al, 1998). A phase El trial of TFPI in severe 
sepsis failed to show a survival benefit (Abraham et al, 2003), but clinical trials of 
these agents in patients with ALI/ARDS are ongoing (reviewed in Latterre et al,
2003). The only phase III trial to date, that has shown a mortality benefit in either 
sepsis or ALI/ARDS is the PROWESS trial (Bernard et al, 2001). In this study, 
recombinant APC significantly improved survival in septic patients, which is the first 
real advance in the pharmacotherapy of this condition since the introduction of 
antibiotics in the last century. Since the results of the PROWESS trial were so 
successful, and severe sepsis has so many pathophysiological similarities with 
ALI/ARDS, a trial of APC in this condition is now ongoing. Of note, intratracheal 
administration of APC has been shown to be protective in bleomycin-induced 
pulmonary fibrosis (Yasui et al, 2001), so the results of this study are eagerly awaited.
If this trial is successful and the effect of APC is subsequently evaluated in 
patients with IPF/UIP, an obvious problem with anticoagulant therapies in any of these 
conditions is the high risk of bleeding complications, which were observed in the 
PROWESS trial. For this reason, strategies aimed at blocking PAR-1 may provide a 
unique opportunity for selectively interfering with the pro-fibrotic and pro-
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inflammatory effects o f coagulation proteases, whilst avoiding potential haemostatic 
complications associated with direct proteolytic inhibition of these factors.
PAR-1 antagonists, blocking antibodies and antisense oligonucleotides are 
currently being developed as potential anti-thrombotic agents (Brass et al, 1997, 
Bematowicz et al, 1996). A PAR-1 antagonist peptide has recently been shown to be 
successful in preventing restenosis and neointima formation in an animal model 
(Andrade-Gordon et al, 2001). Furthermore, a recent study successfully used a PAR-1 
antagonist to attenuate a model of vascular thrombosis in primates (Derian et al, 2003), 
suggesting that a suitable agent for use in humans is on the horizon. Evaluating PAR-1 
blocking strategies in the context of acute and chronic forms o f fibrotic lung disease 
represents an exciting challenge for the future, the results o f which may generate a 
novel therapy for this currently incurable condition.
Appendix
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Fibroblast Proliferation
(% above media control)
Thrombin
(nM)
10
Expt 1 74±6 f t
Expt 2 m6 ft
Expt 3 81±4 f f
Thrombin (10 nM) 
+ UK-156406 (nM)
1 1 0 1 0 0
66±2 44±3 * 14±5 **
65±3 79±7 20±4 **
85±6 69±2 * 10±2 **
UK-156406
(nM)
1000
9±2
8±4
14±1
Table 3.1.1 Effect of UK-156406 on Thrombin-Induced 
Fibroblast Proliferation in vitro.
Table summarises the values obtained for HFL-1 proliferation in response to thrombin 
(10 nM) and in addition, the effect of varying concentrations of UK-156406 on thrombin- 
induced fibroproliferation. This data, which is expressed as % above media control 
values, is also shown in Results Section, Figure 3.1.1. ff/KO.Ol indicates significance of 
thrombin-treated fibroblast cultures compared with cells treated with media alone, 
*/7<0.05; **/k 0.01 denote the statistical significance of the indicated data compared with 
cells treated with thrombin alone (10 nM).
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Fibroblast Procollagen Production
(nmoles hyp/105 cells/48hours)
Expt
1
Expt
2
Expt
3
Media
Control
0.65±
0.09
1.21±
0.05
1.31±
0.12
Thrombin
(nM)
10
1.67±
0.12 f t
1.94±
0.09 f f
1.52±
o . i i f t
Thrombin (lOnM) + 
UK-156406 (nM)
1 1 0 1 0 0
1.54±
0.12
1.29±
0.08*
0.61±
0.13**
2.09±
0.12
1.89±
0.13
1.06±
0.09**
1.41±
0.06
1.49±
0.06
1.36±
0.04*
UK-
156406
JnM L
1000
0.71±
0.11
1.12±
0.08
1.21±
0.12
Table 3.1.2 Effect of UK-156406 on Thrombin-Induced 
Fibroblast Procollagen Production in vitro.
Table summarises the values obtained for HFL-1 procollagen production, in response to 
thrombin (10 nM) and varying concentrations of thrombin together with UK-156406. 
This data, which is expressed as nmoles hyp/105 cells/48hours, is also shown in Results, 
Figure 3.1.2, ff/7<0.01 indicates significance of thrombin-treated fibroblast cultures 
compared with cells treated with media alone, */K0.05; **/K0.01 denote the statistical 
significance of the indicated data compared with cells treated with thrombin alone (10 
nM).
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Optimisation of Thrombin Immunohistochemistry
Expt 1 
Expt 2 
Expt 3 
Expt 4 
Expt 5 
Expt 6  
Expt 7 
Expt 8  
Expt 9
Table 3.2.3 Dilution Table of Reagents for Thrombin Immunohistochemistry.
Table summarises the different concentrations of reagents used to localise active 
thrombin immunohistochemically in rat lung tissue sections. At higher concentrations, of 
both hirudin (panel a) and the anti-hirudin antibody complex (panel b), there was 
extensive non-specific brown background staining, making interpretation of results 
impossible. The optimal concentration of reagents used is in bold and results of these 
experiments are shown in Figure 3.2.4, plates 1-4, panels a-x.
Panel a Panel b
Hirudin Anti-Hirudin
Antibody
Secondary
Antibody
Streptavidin
1:10 1:50 1:300 1:300
1:10 1:100 1:300 1:300
1:10 1:200 1:300 1:300
1:25 1:100 1:300 1:300
1:25 1:200 1:300 1:300
1:50 1:200 1:300 1:300
1:50 1:500 1:300 1:300
1:50 1:1000 1:300 1:300
1:50 1 : 1 2 0 0 1:300 1:300
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Optimisation of PAR-1 Immunohistochemistry
Expt 1 
Expt 2 
Expt 3
Table 3.2.5 Dilution Table of Reagents for PAR-1 Immunohistochemistry.
Table summarises the different concentrations of reagents used to localise PAR-1 
immunohistochemically in rat lung tissue sections. Although a dilution series was 
performed, the optimal concentration of the primary antibody used (shown in bold) 
was similar to that of published studies. Results of these experiments are shown in 
Figure 3.2.5, plates 1 and 2, panels a-h.
PAR-1
Primary
Secondary
Antibody
Streptavidin
1:500 1:300 1:300
1:1250 1:300 1:300
1 : 1 0 0 0 1:300 1:300
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Fibroblast Proliferation
(% above media control)
Thrombin 
__________ (25nM)
Expt 1 62 ± 0 .1 * *
Expt 2 60 ±0.1 **
TFLLR
(50pM)
29 ± 0 .2 * *  
25 ± 0 .2  **
Table 3.2.10 Effect of Thrombin and PAR-1 Specific Agonist (TFLLR) on Primary 
Rat Lung Fibroblast Proliferation in vitro.
Table summarises the values obtained for rat lung fibroblast proliferation in response to 
thrombin (25 nM) and TFLLR (50 pM). This data, which is expressed as % above media 
control values, is also shown in Results Section, Figure 3.2.10. The p  values denote the 
statistical significance of the indicated data compared with media control cells **/K0.01.
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Mean Increase in Body Weight (%)
Day 4
Sal Sal 6.92 ± 2.05
Sal UK 6.33 ±2.21
Bleo Sal 0.26 ± 2.62
Bleo UK 0.73 ± 1.74
Day 5
14.7 ± 2.18 
13.9 ±2.65 
0.06 ±3.68 
0.04 ± 2.00
Day 7
20.1 ±2 .28  
18.1 ±3 .66  
2.96 ±4.25 
3.90 ± 2.20
Day 11
30.9 ± 1.82
29.0 ± 1.58
12.0 ±4 .46
15.5 ±2 .50
Day 14
38.7 ± 1.38
38.1 ± 1 .47
22.6 ±3.80 
25.4 ±2 .50
Table 3.3.2 Effect of UK-156406 on R at Body W eight in 
Bleomycin-Induced Pulm onary Fibrosis.
Table summarises the values obtained for the effect of UK-156406 (0.5 mg/kg/hr) on rat 
body weight following a single intratracheal injection of bleomycin (1.5 mg/kg body 
weight), or saline. Results are expressed as mean ± S.E.M increase in body weight (%) 
compared with day 0 values, (n=6) for all treatment groups. This data is also shown in 
Results Section, F igure 3.3.2. (Sal = Saline, Bleo = Bleomycin, UK = UK-156406).
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Total Lung Collagen (mg)
Expt 1 
Expt 2 
Expt 3 
Expt 4
Table 3.3.3 Effect of UK-156406 on Lung Collagen Accumulation in Bleomycin-
Induced Pulmonary Fibrosis.
Table summarises the effect of a continuous subcutaneous infusion of UK-156406 on 
lung collagen accumulation following a single intra-tracheal instillation of bleomycin (1.5 
mg/kg), obtained in four separate experiments. Data is expressed as mean total lung 
collagen (mg), ± S.E.M (n as indicated). In experiments 1-3, UK-156406 was delivered at 
0.5 mg/kg/hr, for 14 days. In experiment 4, UK-156406 was delivered at 0.33 mg/kg/hr 
for 21 days. **(/?<0.01) denotes the statistical difference in total lung collagen between 
bleomycin and saline-treated animals, whereas *(p<0.05) indicates the statistical 
difference in lung collagen accumulation in bleomycin-treated rats given UK-156406 
compared with rats given bleomycin alone. ff(/?<0.01) denotes the statistical difference 
in total lung collagen between bleomycin-treated rats given UK-156406 and saline-treated 
rats given UK-156046, in experiment 4. Statistical analysis was not performed on pilot 
experiment 1 since n= 3 per group. Data from experiment 3 is also represented in Results 
Section, Figure 3.3.3. (IT = intratracheal).
IT Saline Saline Bleomycin Bleomycin
Osmotic
Minipump
Saline UK-
156406
Saline UK-
156406
n = 3 26.7 ±0.9 21.4 ± 1.6 48.8 ±2.7 36.0 ±2.7
n = 6 21.5 ±0.9 22.2 ± 1.8 29.3 ± 1.5** 22.2 ± 2 .8 *
17 = 6 17.1 ±1.4 22.8 ±2.6 38.4 ±2.0** 31.3 ±2.3 *
n = 6 21.0 ±1.0 21.0 ± 1.3 33.5 ±1.8** 31.3 ± 1 .5ft
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Lung Weight (g)
Expt 2 
Expt 3 
Expt 4
IT Saline Saline Bleomycin Bleomycin
Osmotic
Minipump
Saline UK-
156406
Saline UK-
156406
n = 6 1.0 ±0.06 1.1 ±0.03 1.5 ± 0.13** 1.5 ±0.06**
n = 6 1.0 ±0.02 1.1 ±0.03 1.4 ±0.02** 1.4 ±0.07**
n = 6 1.2 ±0.05 1.3 ±0.05 1.6 ±0.09** 1.6 ±0.07**
Table 3.3.3a Effect of UK-156406 on Lung Weight in Bleomycin-Induced
Pulmonary Fibrosis.
Table summarises the effect o f a continuous subcutaneous infusion o f UK- 
156406 on lung weight following a single intra-tracheal instillation o f bleomycin 
(1.5 mg/kg). Data is expressed as mean total lung collagen (g), ± S.E.M (n as 
indicated). Lung weights for pilot experiment 1 are not shown. In experiments 2 
and 3, UK-156406 was delivered at 0.5 mg/kg/hr, for 14 days. In experiment 4, 
UK-156406 was delivered at 0.33 mg/kg/hr for 21 days. **(/?<0.01) denotes the 
statistical difference in lung weight between bleomycin-treated rats and 
respective saline-treated control animals. There was no significant difference in 
lung weight between bleomycin-treated animals given UK-156406 and animals 
given bleomycin alone. This data is also represented in Results Section, Figure 
3.3.3. (IT = intratracheal).
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BALF Total Inflammatory Cell Number (xlO4) and Differential Cell Proportions
Day 3 ___
IT Mini- 
Pump
Sal
Sal
Bleo
Bleo
Sal
Sal
Bleo
Bleo
Sal
UK
Sal
UK
Total Cell 
Count (xlO4)
Macrophages
(%)
Lymphocytes
(%)
Neutrophils
(%)
61±14 96.9±0.5 3.010.6 0.210.2
52±13 98.4±0.4 1.110.6 0.510.2
155±15 ** 60.211.4 f f 2.011.0 f t 37.810.8 f f
159±10 ** 56.5±0.5 f t 1.710.5 f t 4 1 .8 i0 .7 f f
Day 6  
IT Mini- 
pump
Sal
UK
Sal
UK
Total Cell 
Count (xlO4)
Macrophages
(%)
Lymphocytes
(%)
Neutrophils
(%)
3313 97.711.0 0.610.3 1.710.8
2817 96.912.0 0.410.2 2.711.8
219122 ** 62.312.3 f f 4.612.7 f f 33.111.8 f f
181110** 62.311.9 f t 4.110.8 f t 33.712.3 f f
Table 3.3.7 Effect of UK-156406 on BALF Inflammatory Cell Number and 
Differential Proportions in Bleomycin-Induced Pulmonary Fibrosis
at 3 and 6  Days.
Table shows data for the effect o f UK-156406 (0.5mg/kg/hr) on BALF total 
inflammatory cell number and differential cell proportions following intratracheal 
bleomycin (1.5 mg/kg), or saline after 3 and 6 days. ** (^kO.OI) denotes the statistical 
difference in BALF total inflammatory cell number between bleomycin-treated 
animals and saline-treated controls. There was no significant difference in BALF total 
inflammatory cell number in bleomycin-treated animals given UK-156406 compared 
with animals given bleomycin alone, at either time point, n=6. In all bleomycin-treated 
animals there was a characteristic significant increase in the proportion o f  both 
neutrophils and lymphocytes and a corresponding reduction in the proportion of 
macrophages, compared with saline-treated controls f f  (/KO.Ol). However, UK- 
156406 had no effect on the relative proportion o f inflammatory cells in bleomycin or 
in saline-treated control animals. Data is also represented in Results, Figure 3.3.7, (IT
= intratracheal,, Sal = Saline, Bleo = Bleomycin, UK = UK-156406).
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PAR-1 7 Mice
Breeding
Pair
A
Breeding
Pair
B
Breeding
Pair
C
Breeding
Pair
D
Breeding
Pair
E
Breeding
Pair
F
Litter 8 8 8 ? 8 V 8 8 ?
1 3 3 3 4 4 2 2 3 5 1 3 2
2 2 5 1 4 1 3 2
3 1 2 3 2 2 6 2 2
4 3 2 4 4 4 2
5 2
6 2 3
7 1 1
Total 1 2 1 1 1 1 9 14 13 9 9 5 1 3 2
WT Mice
Breeding
Pair
A
Bree
Pa
I
ding
lir
1
Breeding
Pair
C
Breeding
Pair
D
Breeding
Pair
E
Breeding
Pair
F
Litter 8 8 ? 8 ? 8 ? 8 ? 8 ?
1 5 3 5 4 6 3 5 5 3 3 6 4
2 5 4 5 1 2 4 5 2 3 6
3 4 5 2 8 4 1 4 3 5 5
4
5
6
7
Total 14 1 2 1 2 13 1 2 8 14 1 0 1 1 14 6 4
Table 3.4.1 PAR-1 */_and WT Mice Breeding Data.
Table shows breeding data for PAR-1 _/' and wild-type (WT) mice. The homozygous 
PAR-1 ''' breeding pairs (A -  F) produced 20 litters in total and the average litter size 
was 5 ± 2 live bom mice. WT breeding pairs (A -  F) produced 11 litters in total and 
the average litter size was 9 ± 2 live bom mice. The number o f live bom male and 
female mice varied in each individual litter but the cumulative sum o f male and female 
mice bom from each breeding pair showed that there was no disparity in male/female 
ratio. Data is also shown in Results Section, Figure 3.4.1.
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Mean Increase in Body Weight (%)
Day 3 Day 6
WT Sal -3.07 ±2.41 3.10 ± 2.38
KO Sal -3.50 ±1.32 0.39 ±1.87
WT Bleo -3.84 ± 1.51 -3.22 ±1 .86
KO Bleo -5.84 ±2 .37 -2.45 ±1 .39
Day 14
7.57 ±1 .34
7.38 ±1.32
4.49 ± 1.21
4.62 ± 1.02
Table 3.4.3 Effect of Bleomycin Instillation on Body Weight in PAR-1
and Wild-Type Mice.
Table summarises the values obtained for the effect of a single intratracheal 
injection of bleomycin (1 mg/kg body weight) or saline, on body weight for 
PAR-1 A and wild-type mice. Results are expressed as mean ± S.E.M increase 
in body weight (%) compared with day 0 values, (n=6) for all treatment groups. 
This data is also shown in Results Section, Figure 3.4.3.
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Lung Collagen (mg)
Expt 1 
Expt 2
n = 9 
n = 6
WT Sal
1.46 ±0.07 
1.35 ±0.06
KO Sal
1.42 ± 0.11 
1.56 ± 0.14
WT Bleo
2.42 ±0.08** 
2.32 ±0.12**
KO Bleo
1.80 ± 0.17 f f  
1.70 ±0.21 f
Table 3.4.4 Effect of Bleomycin Instillation on Lung Collagen in PAR-1 ''' and
Wild-Type Mice at 14 Days.
Table summarises the effect of a single intra-tracheal instillation o f bleomycin (1 
g/kg) or saline on total lung collagen for PAR-1 ''' and wild-type mice. Data is 
expressed as mean total lung collagen (mg), ± S.E.M (n as indicated). **(/K0.01) 
denotes the statistical difference in total lung collagen between bleomycin-treated 
wild-type mice and saline-treated control animals. ff(^<0.01) indicates the statistical 
difference in lung collagen accumulation in PAR-1 _/' mice given bleomycin 
compared with wild-type mice given bleomycin for experiment 1, whereas, 
f(p<0.05), indicates the significance of this data for experiment 2. Data is also 
represented in Results Section, Figure 3.4.4.
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Lung Weight (g)
Expt 1 
Expt 2
n = 9
WT Sal
0.12 ± 0 .01
KO Sal
0.13 ±0.01
WT Bleo
0.25 ±0.01**
KO Bleo
0.19 ±0.01 f t  tt
n-  6 0.14 ±0.01 0.13 ±0.01 0.23 ±0.01** 0.18 ±0.01 f f  tt
Table 3.4.4a Effect of Bleomycin Instillation on Lung Weight in PAR-1 
and Wild-Type Mice at 14 Days.
Table summarises the effect o f a single intra-tracheal instillation of bleomycin 
(1 mg/kg) or saline on lung weight for PAR-1 A and wild-type mice at 14 Days. 
**(/K0.01) denotes the statistical difference in lung weight between 
bleomycin-treated wild-type mice and saline-treated control animals and £}( 
p<0.01) denotes the statistical difference in lung weight between bleomycin- 
treated PAR-1 'A mice and PAR-1 A mice given saline. ttG^O .Ol) denotes the 
statistical difference in lung weight which was observed between bleomycin- 
treated PAR-1 mice and wild-type mice given bleomycin.
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BALF Total Inflammatory Cell Number (xlO5) and 
Differential Cell Proportions (%)
WT Sal 
KO Sal 
WT Bleo 
KO Bleo
Table 3.4.6 Effect of Bleomycin Instillation on BALF Inflammatory Cell 
Number and Relative Proportions in PAR-1 and Wild-Type Mice at 6  Days.
Table shows data for the effect o f intratracheal injection o f bleomycin (1 mg/kg), or 
saline on BALF total inflammatory cell number and differential cell proportions for 
PAR-1 A and wild-type mice after 6 days, n=8. BALF total inflammatory cell 
number was significantly increased in wild-type and PAR-1 "A mice given 
bleomycin, compared with saline-treated controls **(/?<0.01) and *(/k0.05), 
respectively. There was no significant difference in BALF total inflammatory cell 
number in bleomycin-treated wild-type and PAR-1 "A mice. In bleomycin-treated 
wild-type and PAR-1 *A mice, there was a characteristic significant increase in the 
proportion o f both neutrophils and lymphocytes and a corresponding reduction in 
the proportion of macrophages, compared with saline-treated controls ff(/K 0.01). 
However, the relative proportion o f inflammatory cells was unaffected when 
bleomycin-treated wild-type and PAR-1 *A mice were compared. This data is also 
shown in Results, Figure 3.4.6,
Total Cell Macrophages Lymphocytes Neutrophils 
Count (xlO5) (%) (%) (%)
1.32±0.3 97.811.1 0.310.2 1.911.0
1.02±0.2 96.511.3 1.610.6 1.911.1
7.74±1.2 ** 69.113.2 t t 24.413.3 f f 6.512.0 t t
3.4210.7 * 67.115.4 f t 28.915.6 t t 4.114.1 t t
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Lung Weight (g)
WT Sal KO Sal WT Bleo KO Bleo
Expt n — 6 0.12 ±0.01 0.13 ±0.01 0.24 ± 0.02** 0.19 ±0.02 f t  t t
Table 3.4.7 Effect of Bleomycin Instillation on Lung Weight in PAR-1'/_ 
and Wild-Type Mice at 6 Days.
Table summarises the effect of a single intra-tracheal instillation of 
bleomycin (1 mg/kg) or saline on lung weight for PAR-1 "A and wild-type 
mice at 6 Days. In wild-type animals, receiving bleomycin, total lung weight 
was increased by 94.7 ± 6.4% compared with control animals given 
intratracheal saline **(/K0.01). Lung weight in PAR-1 A mice given 
bleomycin was increased by 49.8 ± 6.4% compared with PAR-1 _/" animals 
given saline ftC^O.Ol). Lung weight was therefore reduced by 43.7 ± 4.2% 
in bleomycin-treated PAR-1 "A mice compared with bleomycin-treated wild- 
type controls ^(/kO.OI). Data shown is derived from a single experiment 
where n=6.
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